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ABSTRACT 
 
Molecular Mechanisms of Immunosuppressive Effects of Dietary n-3 PUFA, Curcumin 
and Limonin on Murine CD4
+
 T Cells. (December 2008) 
Wooki Kim, B.S., Yonsei University, Seoul, Korea 
Co-Chairs of Advisory Committee: Dr. Robert S. Chapkin 
Dr. David N. McMurray 
 
 The molecular mechanisms of putative anti-inflammatory nutrients, i.e., fish oil, 
curcumin and limonin, were investgated with respect to CD4
+
 T cell function. Initially, 
using a DO11.10 mouse model which exhibits a transgenic T cell receptor specific to 
OVA 323-339 peptide, we demonstrated that dietary fish oil suppresses antigen-specific 
Th1 clonal expansion in vivo. Following immunization, the accumulation of adoptively 
transferred transgenic cells in wild type recipient mouse lymph nodes was suppressed. In 
addition, cell division analysis by carboxyfluorescein succinimidyl ester (CFSE) 
revealed that both total cell number in lymph nodes as well as cell division were 
decreased by fish oil. 
Since n-3 polyunsaturated fatty acids (PUFA), active long chain fatty acids in 
fish oil, elicit favorable effects on a variety of cell types, e.g., anti-tumor effect on 
colonocytes, amelioration of coronary heart disease and anti-inflammatory effects 
involving T cells, B cells, dendritic cells and macrophages, we postulated that a 
fundamental mechanism of action may explain the multiple effects observed. In a series 
of experiments described herein, we demonstrated that n-3 PUFA alters the 
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formation/location of membrane subdomains, referenced to as lipid rafts. Specifically, 
lipid raft formation at the immunological synapse (IS) in CD4
+
 T cells was suppressed 
following membrane enrichment with n-3 PUFA. The alteration of lipid rafts down-
regulated the localization of select signaling proteins, including F-actin, PKC and 
PLC-1, and phosphorylation of PLC-1 at the IS. Consequently, CD4+ T cell 
proliferation was suppressed as assessed by CFSE analysis and radioactive thymidine 
incorporation. 
Phytochemicals have been used for chemopreventive and chemotherapeutic 
purposes. We examined the putative anti-inflammatory effects of curcumin (1%) and 
limonin (0.02%) with respect to CD4
+
 T cell function. Dietary curcumin and limonin 
suppressed NF-B activation in CD4+ T cells. In addition, CD4+ T cell proliferation was 
modulated by 2% curcumin. We further investigated the combined therapeutic potential 
of phytochemicals and fish oil, containing n-3 PUFA. Interestingly, fish oil and limonin 
together significantly (P<0.05) suppressed T cell proliferation, whereas feeding either 
fish oil or limonin alone showed little effect. 
In summary, our data indicated that dietary fish oil alters proximal signaling of T 
cells by perturbing lipid raft formation. Curcumin and limoin are capable of suppressing 
NF-B in T cells, thereby exhibiting a synergistic effect when combined with fish oil. 
Further studies are required to elucidate the relationship of dietary dose of active 
compoments with respect to mechanism of actions. 
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GM-CSF, granulocyte macrophage colony stimulating factor 
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IL, interleukin 
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PGE, prostaglandin E 
PKC, protein kinase C 
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PPAR, peroxisome proliferator-activated receptor 
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CHAPTER I 
INTRODUCTION AND LITERATURE REVIEW 
 
Function of CD4
+
 T cells in immune diseases 
CD4
+
 helper T (Th) cells are essential regulators of the immune response. Upon 
activation, naïve Th cells differentiate into effector cells (Fig. 1). For example, classical 
Th1 and Th2 lineages are characterized by their cytokine secretion and immune 
regulation function (1, 2). IL-2 and IFN-γ are signature cytokines produced by Th1 cells 
which regulate cell-mediated immune response, whereas Th2 cells regulate humoral 
immune response in part by secreting IL-4, IL-5, IL-10 and IL-13 (3).  
Most autoimmune diseases and/or chronic inflammation involve an overactive, 
self-destructive immune response toward a particular tissue, for example, the pancreas in 
type 1 diabetes, the central nervous system in multiple sclerosis (MS), various joints in 
rheumatoid arthritis and the small and large intestine in inflammatory bowel disease 
(IBD; Crohn’s disease and ulcerative colitis). The pathogenesis of immune diseases is 
made up of a complex network involving a variety of cell types. For example, IBD 
involves intestinal epithelial cells, lymphocytes, dendritic cells and macrophages (4, 5). 
Th1 cells are of pivotal importance for the pathogenesis of IBD (6). A growing 
body of evidence indicates that IL-23 and TNF-α, as well as Th1-inducing cytokines, 
drive Th1-induced IBD. Furthermore, an IL-17 producing Th cell lineage activated by 
IL-23 was recently identified. These cells are classified as distinct pro-inflammatory 
____________ 
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Th17 (Thi) cells (7-9). Hence, autoreactive Th1 cells, as well as Th17 cells, are major 
players in chronic inflammatory diseases (10-13), and inhibition of the expansion of Th1 
cells can be one of the mechanisms by which anti-inflammatory agents exert their effect. 
 
 
Figure 1. Subpopulations of Th cells. Following stimulation, naïve CD4
+
 T cells 
differentiate into either Th1, Th2 or Th17 cells, determined in part by antigen, APC and 
cytokine interaction. Th1 and Th17 lineages are reported to be pro-inflammatory T cells. 
Image was reprinted with permission from “Diversification of T-helper-cell lineages: 
finding the family root of IL-17-producing cells” by Dong, C., 2006, Nat. Rev. Immunol. 
(9). Copyright 2006 by Nature Publishing Group. 
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T cell activation and lipid rafts 
For T cell activation to occur, only cognate peptide-major histocompatibility 
complexes (MHC), among a total pool of peptide presenting MHC molecules expressed 
on antigen presenting cells (APC), are recognized by receptors on the T cell to generate 
an immune response (14). At the contact zone between the T cell and APC (e.g., B cells, 
macrophages and dendritic cells), the immunological synapse (IS) is formed to facilitate 
T cell receptor (TCR) binding to antigen (Ag) peptide. Interestingly, during the 
formation of the IS, T cells polarize their cytoskeleton, including actin and microtubule 
networks. Furthermore, Thauland et al. (15) reported that polarized Th1 and Th2 cells 
form morphologically distinct IS. Specifically, IS formation of Th1 cells is unique in that 
a compact central cluster of MHC/TCR surrounded by adhesion molecules is formed. In 
contrast, Th2 polarized cells exhibit a multifocal IS by forming multiple MHC/TCR 
accumulations at high Ag concentrations. 
The plasma membrane is involved in almost all aspects of cell biology, including 
morphogenesis, proliferation, migration, invasion, transformation, differentiation, 
secretion and apoptosis. The classical concept of the cell membrane, i.e., Singer-
Nicholson fluid mosaic model of the lipid bilayers, had little influence on membrane 
protein function (16). However, in the past two decades, a growing body of data indicate 
that lipids exist in gel, liquid-ordered or liquid-disordered states, depending on the 
complex environment of the cell. Subsequently, a lipid raft theory has evolved in which 
liquid-ordered microdomains, i.e. lipid rafts, are floating over the “sea” of bulk 
membrane, which is in a liquid-disordered state (17). It is postulated that the 
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preponderance of saturated hydrocarbon chains in sphingolipids allows for cholesterol to 
be tightly interacted, forming the “packed” liquid-ordered phase. Hence, historically, 
lipid rafts have been characterized by two operational definitions; the insolubility in cold 
nonionic detergents, for which lipid rafts are also called detergent-resistant membrane 
fractions (DRM), and a loss of function associated with cholesterol depletion (18). 
Among a variety of functions, lipid rafts are now believed to modulate 
intracellular signaling cascades, endocytosis, protein trafficking and cell-cell 
communication in part by altering the lipid-protein composition of the bulk membrane 
via specialized lipid microdomains (17, 19-21). In terms of immune cell related 
signaling, lipid rafts are known to be involved in the signal transduction-related 
processes involving FcεRI receptor (22), T cell receptor (TCR) (23), B cell receptor 
(BCR) (24), epidermal growth factor (EGF) receptor (25, 26), insulin receptor (27), 
integrins (28) and endothelial nitric oxide synthase (eNOS) (29). These data indicate that 
the composition and formation/dissociation status of lipid rafts is likely critical for T cell 
activation. 
 
Effect of n-3 PUFA on the immune response 
With respect to the dietary manipulation of immune function, long chain n-3 
polyunsaturated fatty acids (n-3 PUFA), which are enriched in dietary fish oil, have been 
studied in relation to their anti-inflammatory properties (30-34). With respect to 
molecular structure, n-3 PUFA have their first double bond at the third carbon from the 
methyl end. α-linolenic acid (ALA; 18:3n-3), eicosapentaenoic acid (EPA; 20:5n-3) and 
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docosahexaenoic acid (DHA; 22:6n-3) are examples of n-3 PUFA. Interestingly, DHA is 
unique in that it is the longest and most unsaturated fatty acid commonly found in 
membranes (35). In contrast, n-6 PUFA (i.e, linoleic acid (LA; 18:2n-6) and arachidonic 
acid (AA; 20:4n-6)), which have the first double bond at the sixth carbon from the 
methyl end, generally exhibit pro-inflammatory properties. Due to the degree of 
unsaturation and the low activation energy for rotation about the single C-C bonds that 
separate the unsaturated carbon atoms in the recurring =CH-CH2-CH= pattern, DHA is 
thought to form a liquid-disordered structure in biological membrane (36-38). Our 
proposed anti-inflammatory actions of n-3 PUFA are summarized in Fig. 2. The 
summary of beneficial clinical effects of n-3 PUFA on the immune system has been well 
documented by other investigators in humans and animal models (39-43). 
 
Alteration of cytokine production 
A growing body of data indicate that n-3 PUFA alter cytokine production, which 
in turn influences the function of a variety of cell types mediating both the induction and 
resolution of inflammation. Zhao et al. reported that ALA inhibits pro-inflammatory 
cytokine production, such as IL-2, IL-1β, and TNF-α, in peripheral blood mononuclear 
cells from hypercholesterolemic subjects (44). A reduction in IFN- production by FO 
feeding in multiple sclerosis (MS) patients and a rat model has also been reported by 
several investigators (45-47). Petursdottir et al. demonstrated that dietary FO (18% 
FO+2% corn oil (CO, contains n-6 PUFA)) decreased the production of both pro-
inflammatory TNF-α and anti-inflammatory IL-10 in Concanavalin A (ConA) stimulated  
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Figure 2. Proposed molecular model by which EPA and DHA modulate immune cell 
function and inflammation. n-3 PUFA suppress nuclear receptor activation, e.g., NF-kB, 
arachidonic acid-cyclooxygenase derived eicosanoids, and alter plasma membrane 
micro-organization (lipid rafts). We propose that lipid rafts may be targets for the 
development of n-3 PUFA-containing dietary bioactive agents to down-modulate 
chronic inflammatory responses. AA, arachidonic acid (20:4
∆5,8,11,14
, an n-6 PUFA); 
DHA, docosahexaenoic acid (22:6
∆4,7,10,13,16,19
); (EPA, eicosapentaenoic acid 
(20:5
∆5,8,11,14,17
); NF-kB, nuclear factor kB; IkB, inhibitor of NF-kB; IL, interleukin; 
PPAR, peroxisome proliferator-activated receptor; PUFA, polyunsaturated fatty acids; 
TLR, Toll-like receptors are a member of the pattern recognition receptor family.  These 
receptors recognize highly conserved pathogen-associated molecular patterns (PAMPs) 
to generate an immune response; TNF, tumor necrosis factor-alpha. 
 
mouse splenocytes (48), emphasizing the complexity of cytokine biology in 
inflammation. In addition, Kim et al. delineated the effect of n-3 PUFA in inflammation 
by demonstrating that dietary FO elicited anti-inflammatory effects via increases in lipid 
peroxidation and superoxide generation in the murine kidney (49).  
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Effect on CD4
+
 T cell function 
In terms of n-3 PUFA effects on CD4
+
 T cells, Arrington et al. from our 
laboratory reported that IL-2 secretion by mitogenic anti-CD3/anti-CD28 stimulation of 
murine splenic T cells was suppressed by dietary DHA (34). In a parallel experiment, 
they further demonstrated that IL-2 production by Jurkat T cells was suppressed by 50 
μM AA or DHA, compared to LA. Interestingly, DHA treatment suppressed IL-2 
secretion compared to AA treatment only when CD28 was engaged in T cell activation, 
indicating that n-3 PUFA also affect the function of co-stimulatory CD28 signaling (33). 
Since IL-2 production is critical for T cell proliferation, Switzer et al. from our 
laboratory examined the effect of n-3 PUFA on activation-induced cell death (AICD) of 
mouse splenic CD4
+
 T cells. They showed that dietary FO enhanced Th1 polarization 
and AICD ex vivo. They also reported that the n-3 PUFA enriched FA composition of T 
cell membranes was maintained in long-term culture in the presence of homologous 
mouse serum (HMS). In contrast, cell culture with FBS displaced n-3 PUFA derived 
from FO feeding, resulting in the loss of dietary effect (50). Other investigators have 
demonstrated that apoptosis is enhanced by DHA in murine CD4
+
 T cells as well as T 
cell lines (51). The induction of apoptosis by n-3 PUFA might explain why fewer cells 
entered the cell cycle after long-term culture (52).  
Zhang et al. from our laboratory also investigated the effect of n-3 PUFA on 
antigen-induced CD4
+
 T cell proliferation. They confirmed that n-3 PUFA are capable of 
suppressing proliferation of mouse antigen-specific (DO11.10) CD4
+
 T cells in the 
presence of HMS (52). The effects of serum on antigen-specific T cell activation was in 
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accordance with previous observations indicating that HMS is required in long-term 
culture to preserve n-3 PUFA-induced changes in plasma membrane microdomain fatty 
acyl composition and cell functionality (50). They further reported that dietary FO 
modulates the Th1/Th2 balance toward the Th2 pole in the presence of HMS. In 
subsequent experiments, it was demonstrated that Th2 proliferation was not affected by 
FO, indicating that FO selectively suppressed Th1 development (30). 
Overall, these findings suggest that n-3 PUFA suppress CD4
+
 T cell proliferation 
and function. CD4
+
 T cells are one of the major immunoregulators and therefore a target 
cell type for immunosuppressive dietary agents including n-3 PUFA. 
 
Eicosanoids, protectins and resolvins 
It was shown that dietary intake of AA is correlated with plasma levels of AA-
derived pro-inflammatory eicosanoids, prostaglandin (PGE2) and leukotriene (LTE4) 
(53). This is noteworthy because dietary EPA competes for the key enzymes, i.e. 
cyclooxygenase (COX)-2 and 5-lipoxygenase (LOX) to be converted to PGE3 and LTE5, 
respectively (54). Furthermore, FO also suppressed the expression of iNOS and COX-2, 
thereby ameliorating inflammatory markers, for example, PGE2 and LTB4 (49, 55, 56).  
Of interest, resolvins (RvE1 and RvE2), docosatrienes and neutroprotectins 
derived from DHA and EPA were recently classified as anti-inflammatory mediators 
(57). For example, it was reported that RvE1 displayed potent ability to regulate 
leukocyte/dendritic cell trafficking, block IL-12 production, counter-regulate TNF- 
induced NF-B signaling, and protect against murine colitis (58). Others have further 
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demonstrated that these n-3 PUFA derived metabolites can counter-regulate and 
terminate inflammation (59, 60), which may explain why the biosynthesis of these 
metabolites seem to be defective in patients with chronic inflammation (59, 61).  
It is noteworthy that the AA pool size is large and conversion of metabolic 
precursors to AA is relatively slow, whereas the DHA pool is relatively small and 
therefore susceptible to dietary alteration (62).  
 
PPAR agonist 
Hontecillas et al. reported that the loss of peroxisome proliferator-activated 
receptor (PPAR)-γ enhanced Ag-specific proliferation and overproduction of pro-
inflammatory IFN-γ in response to IL-12 using effector CD4+ T cells from PPAR-γ 
knockout mice (63), indicating the anti-inflammatory role of PPAR-γ. Furthermore, 
PPAR-γ knockout resulted in the loss of anti-inflammatory regulatory T cells (Treg) 
required to prevent effector T cell-induced colitis (63). This is noteworthy, because 
micromolar levels of n-3 PUFA can activate PPAR-γ (64, 65), which in turn is capable 
of antagonizing a “life signaling” transcription factor, i.e. nuclear factor NF-κB (66). 
 
Protein lipidation and intracellular targeting 
For TCR initiated T cell activation, it is critical that co-receptors and signaling 
proteins are palmitoylated. Palmitate, a 16-carbon saturated fatty acid (16:0), is known to 
be essential for the targeting of many proteins into lipid rafts. For example, localization 
of CD4 into lipid rafts requires palmitoylation of CD4 molecules (67). Src family 
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kinases (SFK), Lck and Fyn, are dual-acylated by myristate (14:0) and palmitate in order 
to localize into lipid rafts. Interestingly, Webb et al. showed that inhibition of 
palmitoylation resulted not only in dislocation of SFK from rafts but also the failure of 
TCR signaling and T cell activation (68, 69). 
Zeyda et al. reported that EPA treated Jurkat T cells exhibited a displaced linker 
for activation of T cell (LAT) from lipid rafts compared to the saturated stearic acid 
(18:0) treated control group, as assessed by biochemical separation of DRM and Western 
blot of LAT using specific antibodies (70). In the same experiment, they showed that not 
only the location of LAT but also the phosphorylation status of LAT and phospholipase 
C (PLC)-γ1 was suppressed, indicating suppressed activation of signaling proteins by n-
3 PUFA (70). This observation is relevant because LAT is palmitoylated at two cysteine 
residues, which might drive the migration of LAT into lipid rafts. However, the 
biological impact of LAT localization into rafts has been recently challenged. Zhu et al. 
demonstrated that mutated LAT, which locates out of lipid rafts, functioned comparably 
to the wild-type LAT, suggesting that LAT palmitoylation and/or raft targeting is not 
necessary for LAT function (71). Therefore, further studies are required to determine the 
effect of n-3 PUFA on LAT localization in T cell activation. 
 
Dietary alteration of lipid rafts 
Since lipid rafts are thought to regulate many cell functions, a number of studies 
have examined the effects of fatty acid manipulation on T cell lipid rafts. Stulnig et al. 
reported the enrichment of n-3 PUFA in plasma membranes of Jurkat T cells by addition 
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of fatty acids into the culture media (70, 72-76). These manipulations were associated 
with a marked displacement of Src family kinases, e.g., Lck and Fyn, from DRM 
indicating that the alteration of lipid rafts affects the intracellular localization of 
signaling proteins. Interestingly, the displacement of Lck correlated with diminished 
calcium signaling indicating the functional role of lipid rafts in T cell activation (72). 
Our laboratory also previously showed that highly purified dietary DHA ethyl ester and 
FO, in which n-3 PUFA are highly enriched, were incorporated into murine splenic T 
cell lipid rafts and soluble membrane phospholipids, resulting in a 30% reduction in raft 
sphingomyelin content (32, 77). 
Recently, using immunogold electron microscopy of plasma membrane sheets 
coupled with spatial point analysis which enabled visualization of morphologically 
featureless microdomains, our laboratory has shown that DHA altered the size and 
distribution of lipid rafts in HeLa cells. Specifically, DHA treatment significantly 
reduced the interparticle distance of lipid raft marker proteins. In contrast, distance of 
marker proteins of bulk membrane was not affected by DHA treatment indicating that n-
3 PUFA can selectively increase clustering of proteins in cholesterol-dependent 
microdomains, i.e. lipid rafts (78, 79). These observations can be explained in part by the 
fact that n-3 PUFA, specifically DHA, has a low affinity for cholesterol, providing a 
lipid-driven mechanism for lateral phase separation of cholesterol/sphingolipid-rich lipid 
microdomains from the surrounding liquid-disordered (ld) phase (80-84). Similarly, Patra 
et al. has demonstrated that enrichment of ceramide, derived from the hydrolysis of 
sphingomyelin in the outer leaflet of the plasma membrane, resulted in coalescence of 
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lipid raft sub-domains into large-membrane macrodomains, in part by excluding 
cholesterol from bulk membrane. In addition, the displacement of cholesterol from lipid 
rafts suppressed the association of the raft-binding and cholesterol binding proteins (85).  
 
Anti-inflammatory phytogenic polyphenols 
Curcumin 
Curcumin [(E,E)-1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dion 
or diferuloymethane, Fig. 3A] is a food-derived yellow pigment extracted from Curcuma 
longa (Linn). Curcumin has been shown to have chemopreventive and chemotherapeutic 
properties in animal models (86) and humans (87, 88). In addition, numerous studies 
indicate that curcumin has anti-inflammatory properties (89) by inhibiting the activation 
of nuclear transcription factors including NF-B (90, 91) and activated protein 1 (AP-1) 
(92, 93). Milacic et al. (94) recently reported that curcumin directly binds to and inhibits 
proteasomes, by which NF-B activity was suppressed in a human colon cancer cell line. 
Fujiyama et al. have shown that 3.5% dietary curcumin feeding to mice prevented the 
development of  dextran sulphate sodium (DSS)-induced colitis in part by blocking NF-
B activity (86, 95). In addition, clinical data from ulcerative colitis patients treated with 
curcumin indicated the suppressive effect on relapse (95). Another recent clinical pilot 
study also supports the contention that dietary curcumin intake reduces the Crohn’s 
Disease Activity Index (CDAI) (96). Sharma et al. also reported that curcumin 
suppressed NF-B and COX-2 expression in human oral premalignant and cancer cells 
(97). 
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A. Curcumin B. Limonin 
 
 
M.W. 368.38 g/mol M.W. 470.52 g/mol 
Figure 3. Chemical structures of curcumin and limonin. 
 
Curcumin has been shown to down-regulate a variety of cell growth related 
genes. For example, Gertsch et al. reported that mRNA levels of granulocyte 
macrophage colony stimulating factor (GM-CSF), cyclin D1 and IFN- were down-
regulated in Jurkat T cells and human peripheral blood mononuclear cells (PBMC) 
following addition of curcumin into the culture media. Furthermore, IL-2 and IL-6 
mRNAs levels were suppressed in Jurkat T cells (89). 
Zhang et al. studied the effect of curcumin on Th1/Th2 balance in a chronic 
colitis mouse model. Interestingly, intraperitoneal injection of curcumin decreased the 
expression of IL-12, IFN-, TNF- and IL-2 (Th1 cytokines) and increased the 
expression of IL-4 and IL-10 (Th2 cytokines) in colon mucosa. In addition, the IFN-
/IL-4 ratio in splenocytes and blood circulation was suppressed by curcumin, indicating 
that curcumin shifts the Th1/Th2 balance to the Th2 pole  (98). In accordance, Kang et 
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al. reported that curcumin suppressed IL-2 production in macrophages, which in turn 
inhibited the Th1 cytokine profile in murine CD4
+
 T cells (99). 
 
Limonin 
Limonin (7,16-dioxo-7,16-dideoxylimondiol, Fig. 3B) is derived from citrus fruit. 
It has been demonstrated that dietary limonin reduced colon cancer development in part 
by suppressing COX-2 and iNOS expression in rats (100, 101). It is noteworthy that both 
COX-2 and iNOS are in part regulated by NF-B, which is generally a pro-inflammatory 
signal (102, 103). Hence, the putative anti-inflammatory properties of limonin merit 
study. Yu et al. reported that limonin suppressed production of superoxide radical 
formation and offered protection against LDL oxidation. These data suggest that limonin 
exhibits antioxidant-like properties (104). Furthermore, limonin improved vascular 
permeability, the decrease of paw edema and AA-induced ear swelling, suggesting that 
limonin is a bioactive molecule exhibiting anti-inflammatory properties. 
 
Advances in methodologies and mouse models 
Use of Laurdan to visualize lipid rafts in living cells 
There have been several methodologies developed to identify and visualize the 
lipid rafts. For instance, flotation of DRM fractions and immunofluorescence 
microscopy by antibody patching have been used to identify putative raft association and 
raft proteins (105, 106). In addition, immunoelectron microscopy and single fluorophore 
tracking microscopy were utilized to track the location of raft components (107). 
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Fluorescence resonance energy transfer (FRET) was also applied to determine whether 
two raft components are spatially impacted (108). However, due to their nano scale sizes 
(<50 nm in diameter) and highly dynamic formation and dissociation (up to 10
-8
 cm
-2
sec
-
1
) of larger domains (17, 109), microdomain morphology has been hard to visualize. 
Recently, it was demonstrated that the fluorescent probe Laurdan can align itself 
parallel with the hydrophobic tails of phospholipids in membranes (110-112). Owing to 
its ability to emit two different wavelengths according to the fluidity of the 
microenvironment, Laurdan can be used to measure membrane fluidity and visualize 
lipid rafts in living cells by two-photon microscopy (111). Since lipid raft formation was 
expected to be induced by the formation of the IS (110), non IS forming APC and /or 
non IS regions of plasma membrane in the CD4
+
 T cells can be used as negative controls. 
 
Fat-1 (n-3 desaturase) mouse 
Since mammals cannot produce n-3 PUFA from the major n-6 PUFA found in 
the diet due to the lack of ∆15-desaturase activity, it is necessary to enrich the diet with 
eicosapentaenoic acid (EPA, 20:5n-3) and/or DHA in order to assess their biological 
properties in vivo.  Recently, the fat-1 gene encoding an n-3 fatty acid desaturase was 
cloned from Caenorhabditis elegans and expressed in mammalian cells (113).  This 
enzyme can catalyze the conversion of n-6 PUFA to n-3 PUFA by introducing a double 
bond into fatty acyl chains. Hence, transgenic mice expressing fat-1 allow us to 
investigate the biological properties of n-3 PUFA without having to incorporate these 
fatty acids into the diet. 
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Jia et al. from our laboratory previously reported that fat-1 transgenic mice 
exhibit a reduction in colitis-induced colon cancer (114). In a parallel experiment, they 
also demonstrated that transgenic mice recovered better from chronic vs acute dextran 
sodium sulphate (DSS) exposure, indicating that n-3 PUFA differently modulate the 
acute vs chronic phases of inflammation. 
 
DO11.10 TCR transgenic mouse 
The DO11.10 Rag 2
-/- 
transgenic mouse model has been used to study antigen-
specific T cell activation and differentiation. The DO11.10 mouse expresses a transgenic 
T cell receptor (TCR), which recognizes only an ovalbumin (OVA) 323-339 peptide, 
(115). The transgenic TCR also can be identified using the clonotypic monoclonal 
antibody (mAb) KJ1–26 (116). The deletion of rag2 gene enabled virtually all peripheral 
CD4
+
 T cells from these mice to be TCR transgenic, compared to ~25% TCR positive 
CD4
+
 T cells in the periphery of the conventional DO11.10 mouse (117). This mouse 
model is advantageous in that one can induce an antigen-specific T cell response 
excluding the effect of non-specifically responding lymphocytes. Pompos et al. have 
shown that dietary n-3 PUFA suppressed OVA peptide stimulated proliferation of 
splenocytes and IL-2 secretion in DO11.10 TCR transgenic mice (117). To extend this 
observation, our laboratory previously revealed that purified CD4
+
 T cells from the 
DO11.10 Rag2
-/-
 mice fed FO had significantly decreased proliferation in response to 
OVA peptide, when cultured in the presence of HMS (52). These data conclusively 
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demonstrate that dietary n-3 PUFA suppress antigen-specific CD4
+
 T cell functions ex 
vivo. 
The genetic background determines the default Th1/Th2 development of naïve 
Th cells under neutral conditions and the DO11.10 mouse is on a Th1-prone B10.D2 
background (118, 119). In fact, more than 90% of the CD4
+
 cells were shown to be Th1 
cells after Th1 polarization in culture (52). Zhang et al. from our laboratory revealed that 
FO feeding did not alter the percentage of Th1 cells generated under stringent Th1 
polarizing conditions, suggesting that dietary FO does not affect the Th1 differentiation 
process in mice. In contrast, FO feeding suppressed Th1 clonal expansion driven by IL-2 
(52). 
 
Summary 
 Data indicate that dietary n-3 PUFA have anti-inflammatory properties in both 
animal models and humans. However, the molecular/cellular mechanisms of action are 
not fully elucidated to date. Therefore, herein, we further studied the effect of n-3 PUFA 
on lipid raft formation in naïve CD4
+
 T cells and Ag-specific in vivo proliferation of Th1 
cells. With respect to phytochemicals, curcumin and limonin exert anti-inflammatory 
effects in part by affecting CD4
+
 T cell function. To date, no study has investigated the 
effect of dietary curcumin and limonin on CD4
+
 T cells. Therefore, we determined how 
dietary curcumin and limonin with or without n-3 PUFA supplementation alter murine 
CD4
+
 T cell function. 
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Hypotheses and specific aims 
Hypothesis 1. Dietary n-3 PUFA inhibit antigen-stimulated Th1 development in vivo 
Aim 1. Determine the effect of n-3 PUFA on recipient mouse lymph nodes. 
Aim 2. Determine the effect of n-3 PUFA on the proliferation of donor cells in 
recipient mouse organs. 
Hypothesis 2. n-3 PUFA promote lipid raft formation at the immune synapse, thereby 
altering signaling molecule recruitment and activation in CD4
+
 T cells 
Aim 1. Visualize and measure lipid rafts at the IS. 
Aim 2. Determine the localization of select signaling proteins at the IS. 
Aim 3. Determine the activation status of key signaling proteins at the IS. 
Aim 4. Measure the proliferation of CD4
+ 
T cells in response to various stimuli. 
Hypothesis 3. Dietary curcumin and/or limonin suppress antigenic CD4
+ 
T cell 
proliferation via down-regulation of NF-kB activation 
Aim 1. Quantify NF-kB activation. 
Aim 2. Measure IL-2 production. 
Aim 3. Measure CD4
+
 T cell proliferation. 
Aim 4. Determine if FO supplementation with or without curcumin/limonin elicit 
maximal anti-inflammatory properties by “combination chemotherapy”. 
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CHAPTER II 
DIETARY n-3 PUFA SUPPRESS Th1 CLONAL EXPANSION OF CD4
+
 T CELLS IN 
VIVO* 
 
Introduction 
Our laboratory previously demonstrated that n-3 PUFA inhibit expansion of 
antigen-specific Th1 cells, ex vivo (52). In that study, DO11.10 Rag2
-/-
 TCR transgenic 
mice were fed either CO control diet or FO for 2 wk, followed by CD4
+
 T cell 
purification, Th1 polarization and long-term stimulation by antigenic or mitogenic 
stimuli in culture. In addition, 2.5% homologous mouse serum (HMS) was utilized to 
prevent culture-induced alteration of plasma membrane fatty acids. It is important to 
note that the use of HMS, along with an ex vivo culture system, complicates the 
physiological relevance of the study. 
DO11.10 TCR transgenic mice cannot be directly immunized with cognate 
OVA323-339 peptide in order to investigate in vivo immune response, due to the 
abnormal immune response to direct in vivo antigen challenge at the artificially high 
frequency of OVA peptide-specific T cells (120). Therefore, Kearney et al. (120) 
developed an adoptive transfer model in which TCR transgenic T cells were injected into 
a non-transgenic recipient, and transgenic  T cells could be reliably detected using KJ1-
26 mAb, which is specific to transgenic TCR.  
____________ 
* Reprinted with permission from “Dietary fish oil inhibits antigen-specific murine Th1 
cell development by suppression of clonal expansion” by Zhang, P. et al., 2006. J Nutr. 
136, 2391-2398. Copyright 2006 by American Society of Nutritional Sciences. 
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Complete Freuds’ adjuvant (CFA) is known to induce Th1 differentiation (121). 
The resultant immune response following subcutaneous injection induces the 
accumulation of antigen-specific transgenic T cells only in the draining lymph nodes, 
allowing one to harvest and investigate Th1 polarized cells in vivo. Interestingly, rounds 
of T cell division can be assessed by CFSE profile analysis as previously reported (122). 
Taking advantage of the adoptive transfer system, Th1 polarized immunization and 
CFSE profile analysis, here we show that antigen-driven Th1 clonal expansion was 
suppressed by n-3 PUFA in vivo, in accordance with previous ex vivo observations. 
 
Materials and Methods 
Animals and diets 
All experimental procedures using laboratory animals were approved by the 
Texas A&M University Laboratory Animal Care Committee. Pathogen-free B10.D2 and 
syngeneic TCR transgenic DO11.10 Rag2
-/-
 mice were purchased from Taconic Farms, 
bred, and maintained at Texas A&M University. Representative results of DO11.10 
genotyping is avalible in Appendix A-1. At the onset of the study, B10.D2 and DO11.10 
Rag2
-/- 
mice (8–10 wk of age) were fed a control semi-purified diet containing 5% CO 
by weight during the 7 d acclimation period, followed by a 2 wk feeding period with the 
same control diet or a FO diet (1% CO + 4% FO). B10.D2 mice were maintained on the 
same diets following adoptive transfer and immunization. All diets met the NRC 
nutrition requirements and varied only in lipid content (32). The basic diet composition, 
expressed as g/100 g was as follows: casein, 20; sucrose, 42; cornstarch, 22; cellulose, 6; 
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AIN-76 mineral mix, 3.5; AIN-76 vitamin mix, 1; DL-methionine, 0.3; choline chloride, 
0.2; Tenox 20A, 0.1; and oil, 5 (32).  
 
CD4
+
 T cell purification 
After feeding, mice were killed by CO2 asphyxiation. Spleens and lymph nodes 
(brachial and mesenteric) were removed from DO11.10 Rag2
-/-
 mice and placed in 
RPMI complete medium (RPMI 1640 medium with 25 mmol/L HEPES (Irvine 
Scientific), supplemented with 5% fetal bovine serum (FBS) or homologous mouse 
serum (HMS 2.5% + 2.5% FBS), 10
5
 U/L penicillin and 100 mg/L streptomycin (Irvine 
Scientific), 2 mmol/L L-glutamine, and 10 µmol/L 2-mercaptoethanol). T cells were 
purified by a negative selection column method as previously described (34). The 
detailed protocol is included in Appendix B-2. HMS was collected according to the 
method of Pompos et al. (117). In general, spleens from DO11.10 Rag2
-/-
 mice were 
smaller than from conventional mice in accordance with a previous report (123), and the 
number of lymphocytes obtained was much lower compared to conventional C57BL/6 
mice (1.7  106 vs. 20  106, n=5-6, P<0.05).  
 
Adoptive transfer and immunization 
CD4
+
 T cells were purified from spleens and lymph nodes (brachial, axillary and 
mesenteric) of DO11.10 donor mice as described above and labeled using CFSE. Briefly, 
purified CD4
+
 T cells were mixed with 10 µM CFSE in PBS containing 0.1% bovine 
serum albumin and incubated at 37°C.  After 10 min, 10% FBS RPMI was added and the 
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cells were placed on ice for 5 min to quench excessive CFSE in media. Following 3 
successive washes with PBS, cells were adjusted to 3x10
7
cells/ml, loaded into 30-guage 
insulin syringes, and injected (100 µl) via tail vein into B10.D2 recipient mice 
maintained on the same diet as donor mice.  One day after adoptive transfer, recipient 
mice were immunized with OVA peptide (300 µg/mouse) and CFA via subcutaneous 
injection at two dorsal sites on the back according to the protocol of Lee et al (124). Full 
details can be found in Appendix B-2. 
 
Immune cell collection and flow cytometry  
Three days after immunization, mice were sacrificed by CO2 asphyxiation. 
Draining (axillary, brachial, and inguinal) lymph nodes were collected from individual 
recipient mice. Viable lymphocytes were counted by trypan blue exclusion. 
Approximately 2x10
6
 cells were collected and labeled using KJ1-26 monoclonal 
antibody specific for detection of DO11.10 transgenic TCR as described in Appendix B-
2. Briefly, cells were incubated with Fc block (5 µg/ml) at 4°C for 15 min, washed with 
buffer (PBS with 1% heat-inactivated FBS and 0.09% sodium azide, pH 7.4), stained 
using 2 µg/ml KJ-126 mAb at 4°C for 30 min, and analyzed using flow cytometry. 
Green fluorescence from CFSE was collected through a 530/30-nm bandpass filter and 
red fluorescence from phycoerythrin-cyanine 5 (PE-Cy5) through a 670-nm longpass 
filter. List mode data were acquired on at least 20,000 KJ1-26-positive events or until 
the sample was consumed.  Data analysis was performed using ModFitLT (Verity 
Software House, Topsham, ME). A lymphocyte region was established using forward 
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and side light scattering properties, and a region for KJ1-26-positive events within the 
lymphocyte region was defined.  Using the Proliferation Wizard, KJ1-26-positive 
lymphocytes from unimmunized mice were used to establish the position of non-
dividing cells, and the data for cells from immunized mice were modeled using that 
point for the parent generation. Parent generations were established independently for 
each set of CFSE-stained, adoptively transferred lymphocytes (52). Donor CD4
+
 T cells 
and recipient cells from lymph nodes served as KJ1-26 staining controls (Appendix A-2). 
 
Statistics  
To elucidate the effects of diet, average proliferation percentages of antigen-
specific T cells were determined as described elsewhere (125).  Each sub-dataset of 
every four consecutive generations was analyzed using a quadratic random effect model 
that incorporated the correlation structure and random effects of individual samples 
(126).  It was determined that the quadratic model performed well for data from four 
consecutive generations. Individual samples were preserved as the experimental units 
through the correlation structure of the data. The model was fit using REML (restricted 
maximum likelihood) (127).  Wald tests were performed for any main effects or 
interactions. Analyses on the sub-datasets were performed using R (version 1.9.1, R 
Foundation for Statistical Computing). 
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Results 
Dietary fish oil suppressed Ag-specific Th1 proliferation of CD4
+ 
T cells 
DO11.10 Rag2
-/-
 donor mice and B10.D2 recipient mice were fed either a control 
diet (CO) or a FO diet for 2 wks.  CD4
+
 T cells from lymph nodes of donors were 
labeled with CFSE to follow cell division.  Cells were adoptively transferred into 
recipient mice fed the same diet as the donor.  B10.D2 mice were immunized 1 d after 
adoptive transfer, and 3 d after immunization, lymph nodes were harvested. The absolute 
number of viable lymphocytes recovered from lymph nodes of FO-fed recipient mice 
was significantly reduced (p=0.014) (2.40.6x106) compared to CO-fed recipients 
(1.00.2x107, n=3) (Fig. 4). In addition, KJ-126 stained cells were analyzed by flow 
cytometry indicating that the percentage of transgenic donor cells among the total 
lymphocytes in recipient lymph nodes was suppressed in FO fed group. (Fig. 5) 
To determine the ability of n-3 PUFA to modulate antigen-induced T cell 
activation in vivo, flow cytometric gating was used to detect cellular division (Fig. 6). 
Consistent with previous studies using peptide-stimulated DO11.10 T cells, flow 
cytometric analysis showed that the transferred cells of both groups underwent 9 cell 
divisions in vivo following immunization (125, 128).  Interestingly, FO-fed mice 
exhibited a reduction (p=0.078) in the percentage of transgenic CD4
+
 T cells in lymph 
nodes (FO 1.35±0.34 vs CO 2.12±0.37, n=6).  Determination of the average number of 
cell divisions (expressed as average generation number) of antigen-specific T cells 
revealed that FO fed animals exhibited a higher percentage of early generation cells 
(Fig. 7).  Specifically, percentages of cells in generations 3 (p=0.047) and 6 (p=0.006) 
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were elevated in cells following FO treatment.  In contrast, percentages of cells in 
generations 8 (p<0.001) and 9 (p<0.001) were reduced in the FO vs CO fed animals.  
We conclude that antigen-specific CD4
+
 daughter cells were arrested in their progression 
through the proliferation cycle in FO-fed mice. 
 
Discussion 
In order to extend our ex vivo observations on clonal expansion to antigen-
stimulated T cells in a whole animal, we utilized the vital dye CFSE within the context 
of an adoptive transfer model to examine antigen-specific T cell activation and Th1 
proliferation in vivo. In agreement with our in vitro findings (52), we observed fewer 
antigen-specific CD4
+
 T cells in FO-fed recipient mice following immunization with 
OVA peptide mixed with a Th1 polarizing adjuvant. This, combined with a reduction in 
daughter cell accumulation (Fig. 6), conclusively demonstrates that dietary FO 
suppresses Th1 development in vivo. The lower number of transgenic T cells in the 
lymph nodes of FO-fed recipient mice may also be explained by an effect of (n-3) PUFA 
on T cell trafficking into and out of the nodes and/or on the extent of local 
lymphoproliferation or AICD. We hypothesize that the suppressive effects (described 
above) are due to modifications in lipid raft composition, which may subsequently alter 
IL-2 receptor downstream signaling. The exact mechanisms of involvement of lipid rafts 
in inducing these changes will be the subject of further investigation and will provide 
insight into how dietary (n-3) PUFA can favorably modulate Th1-mediated autoimmune 
diseases. 
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Figure 4. FO decreased (P<0.05) recipient lymph node viable cell number. Three days 
after immunization, recipient mice were sacrificed and total viable cells in draining 
lymph nodes were counted. Data represent mean ± SEM from 4 mice per group. 
 
 
 
Figure 5. FO decreased (P<0.05) the percentage of transgenic CD4
+
 donor cells. The 
number of KJ1-26
+ 
cells were divided by the total lymph node cell number. Data 
represent mean ± SEM from 7 mice per group. 
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Figure 6. Determination of cell division number and daughter cell profiles. (A) and (C) 
are representative analyses from CO and FO fed mice, respectively. Computer modeling 
was performed (B and D) to identify each generation and cell division number using 
MOdFitLT
TM
. (E) Unimmunized control. 
 
 
Figure 7. Dietary n-3 PUFA modulate T cell clonal expansion in vivo. Values represent 
data sets derived from consecutive generations and were plotted by expressing the 
generation number against the difference of the averages between the estimated FO% 
and CO% at the generation. The data shown were compiled from a total of 6 mice for 
each diet group from 3 separate experiments. Values greater than 0 indicated that in the 
FO group, the % of cells in a specific generation exceeds the CO group. The P-value was 
calculated using the Wald test (*P<0.05). 
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CHAPTER III 
n-3 POLYUNSATURATED FATTY ACIDS SUPPRESS THE LOCALIZATION AND 
ACTIVATION OF SIGNALING PROTEINS AT THE IMMUNOLOGICAL 
SYNAPSE IN CD4
+
 T CELLS BY AFFECTING LIPID RAFT FORMATION* 
 
Introduction 
The Singer and Nicholson lipid bilayer model of the plasma membrane (16) has 
evolved significantly to include specialized microdomains, i.e., lipid rafts. Lipid rafts 
can be classified as morphologically featureless, detergent-resistant membranes (DRM)
3
 
due to their insolubility in cold nonionic detergents (129).  Their highly enriched 
cholesterol and sphingolipid content suggests that they are in a liquid ordered (lo) state, 
whereas the bulk membrane is in a liquid disordered (ld) state (17). The biochemical 
characterization of lipid rafts has provided new insight into the regulation and function 
of plasma membrane proteins. For example, it is now known that T cell intracellular 
signaling cascades, endocytosis, protein trafficking and cell-cell communication are 
modulated in part by altering the lipid-protein composition of the bulk membrane and 
specialized lipid microdomains (17, 19-21). 
Dietary fish oil, rich in n-3 polyunsaturated fatty acids (PUFA), can alter  
immune cell function and aid in the resolution of chronic inflammation, e.g., arthritis,  
____________ 
* Reprinted with permission from “n-3 polyunsaturated fatty acids suppress the 
localization and activation of signaling proteins at the immunological synapse in CD4
+
 T 
cells by affecting lipid raft formation” by Kim, W. et al., 2008, J Immunol, 181, 6236-
6243. Copyright 2008 by The American Association of Immunologists. 
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Crohn’s disease, dermatitis, psoriasis and ulcerative colitis (35, 130-132). To further 
investigate the anti-inflammatory properties of fish oil, we have demonstrated that n-3 
PUFA modulate CD4
+
 T cell immune responses in part via reduction in Th1 clonal 
expansion (52), IL-2 secretion and IL-2 receptor α-chain mRNA transcription (77). 
However, the molecular mechanisms by which n-3 PUFA suppress CD4
+
 T cell function 
are not fully understood. 
It has been reported that the fatty acid composition of lipid rafts and the bulk 
membrane in Jurkat T cells was altered by addition of n-3 PUFA to the culture media 
(133). Our laboratory also demonstrated the modulation of T cell lipid rafts by dietary n-
3 PUFA in a mouse model (32). In the latter study, it was demonstrated that dietary fish 
oil as well as purified docosahexaenoic acid (DHA, 22:6n-3), a major bioactive n-3 
PUFA, altered CD4
+
 T cell plasma membrane fatty acid composition, specifically in 
phosphatidylserine and phosphatidylethanolamine, which are abundant in the cytofacial 
leaflet of the cell membrane (134). In contrast, fatty acid profiles in sphingomyelin, 
phosphatidylinositol, and phosphatidylcholine, which are major lipids in the exofacial 
leaflet (134) in which TCR is linked, were not altered. These observations may partially 
explain why n-3 PUFA alter signaling pathways without affecting expression and/or 
affinity of the TCR/CD3 complex (135, 136). Furthermore, in complementary studies, 
changes in lipid raft fatty acid composition were associated with a decrease in the 
translocation of protein kinase C (PKC)θ, a key molecule regulating CD4+ T cell 
activation, into lipid rafts in mitogen stimulated T cells (77). In contrast, n-3 PUFA 
incubation displaced F-actin, talin, LFA-1α, but not PKCθ from the IS, where T cells 
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and APC form a conjunction (74). In terms of cell signaling triggered by TCR, it was 
reported that a scaffold protein, caspase recruitment domain-containing protein 11 
(CARD11, CARMA1) is recruited into the IS and plays an essential role in linking Ag 
recognition, PKCθ activation via translocation into lipid rafts and NF-kB nuclear 
translocation (137).  From these studies, it is apparent that n-3 PUFA may modulate T 
cell function via alteration of lipid raft structure and the translocation of signaling 
molecules. 
We have recently reported that long chain PUFA alter the size and distribution of 
lipid rafts in HeLa cells, as determined by immuno-gold electron microscopy (78). These 
data suggest that plasma membrane organization of inner leaflets is fundamentally 
altered by n-3 PUFA enrichment. However, to date, the direct visualization of T cell 
lipid rafts at the IS following n-3 PUFA membrane enrichment has not been reported. 
Recently, it was demonstrated that the fluorescent probe Laurdan can align itself parallel 
with the hydrophobic tails of phospholipids in membranes (110-112). Owing to its 
ability to emit two different wavelengths according to the fluidity of the 
microenvironment, Laurdan can be used to measure membrane fluidity and visualize 
lipid rafts in living cells by two-photon microscopy (111).  
Since mammals cannot produce n-3 PUFA from the major n-6 PUFA found in 
the diet due to the lack of ∆15-desaturase activity, it is necessary to enrich the diet with 
eicosapentaenoic acid (EPA, 20:5n-3) and/or DHA in order to assess their biological 
properties in vivo.  Recently, the fat-1 gene encoding an n-3 fatty acid desaturase was 
cloned from Caenorhabditis elegans and expressed in mammalian cells (113).  This 
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enzyme can catalyze the conversion of n-6 PUFA to n-3 PUFA by introducing a double 
bond into fatty acyl chains. Hence, transgenic mice expressing fat-1 allow us to 
investigate the biological properties of n-3 PUFA without having to incorporate these 
fatty acids in the diet. Using the fat-1 mouse model, we report for the first time the effect 
of n-3 PUFA on (a) the formation of lipid rafts in living CD4
+
 T cells at the 
immunological synapse, (b) membrane translocation of signaling molecules, (c) 
phosphorylation (activation status) of key signaling proteins and (d) the proliferation of 
CD4
+
 T cells. 
 
Materials and Methods 
Animals, diets, and CD4
+
 T cell purification 
  Fat-1 transgenic mice were generated and backcrossed onto a C57BL/6 
background by breeding heterozygous mice (113, 114). Littermates were used in all 
experiments as previously described (114). All procedures followed guidelines approved 
by Public Health Service and the Institutional Animal Care and Use Committee at Texas 
A&M University. Mice were genotyped using tail DNA. To confirm the phenotype, total 
lipids were isolated from splenic CD4
+  
T cells and the fatty acid profile was 
characterized by gas chromatography as previously described (32). The detailed 
protocols for fat-1 phenotyping and genotyping are described in Appendix B-3 and 4, 
respectively. Representative chromatograms and RT-PCR results from fat-1 and WT 
mice are available in Appendix A-3 and 4, respectively. Animals were fed a 10% 
safflower oil diet (n-6 PUFA rich, Research Diets) ad libitum with a 12 h light/ dark 
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cycle. The diet contained 40 (g/100 g diet) sucrose, 20 casein, 15 corn starch, 0.3 DL-
methionine, 3.5 AIN 76A salt mix, 1.0 AIN 76A mineral mix, 0.2 choline chloride, 5 
fiber (cellulose), 10 safflower oil. CD4
+
 T cells from fat-1 or WT mice were isolated 
from spleens by a magnetic microbead positive selection method (Miltenyi Biotec) 
according to the manufacturer’s recommendation.  
 
Laurdan labeling 
Purified (91.0 ± 1.0% determined by flow cytometry, n=3) CD4
+
 T cells were 
stained with Laurdan (Invitrogen) for lipid raft visualization. The detailed protocol for 
positive CD4
+
 T cell purification is available in Appendix B-5. Briefly, 5 μmol/L 
Laurdan was prepared in serum-free RPMI medium and incubated with 2x10
6
 cells/ml 
for 30 min at 37°C (110) (Full details are provided in Appendix B-7). Cells were 
subsequently washed and resuspended in serum-free Leibovitz’s medium. To evaluate 
the effect of cholesterol depletion on lipid raft formation, cells were pretreated with 10 
mmol/L methyl-β-cyclodextrin (MβCD, Sigma) in fatty acid-free RPMI media 
containing 0.1% BSA for 3 min prior to Laurdan labeling (138) The detailed protocol is 
provided in Appendix B-7. 
 
CD4
+
 T cell activation and two-photon microscopy 
For mitogenic activation, CD4
+
 T cells were cocultured with CD3-specific Ab 
expressing hybridoma cells (clone 145-2C11, ATCC, anti-CD3 hybridoma) in complete 
medium [RPMI 1640 medium with 25 mmol/L HEPES (Irvine Scientific), supplemented 
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with 5% heat-inactivated FBS (Invitrogen), 10
5
 U/L penicillin and 100 mg/L 
streptomycin (Gibco), 2 mmol/L L-glutamine (Glutamax® , Gibco), and 10 µmol/L 2-
ME (Sigma)]. To validate immune synapse formation, T cells were also incubated with 
an irrelevant DNP-specific Ab expressing hybridoma cells (clone UC8-1B9, anti-DNP 
hybridoma) (139). In select experiments, hybridoma cells were prelabeled with Cell 
Tracker orange-fluorescent tetramethylrhodamine (CMTMR, Invitrogen, full protocol is 
provided in Appendix B-7). Laurdan labeled CD4
+
 T cells were coincubated with 
hybridoma cells at a ratio of 5:1. Cell mixtures were seeded onto poly-L-lysine (Sigma) 
precoated chambered coverglass slides (2x10
6
 CD4
+
 T cells/chamber). After a 30 min 
incubation period at 37°C, Laurdan was measured by two-photon microscopy (Zeiss 
LSM 510 META NLO, 40x objective 1.3 NA oil) at 400-460 nm and 470-530 nm (Fig. 
A-D) to calculate generalized polarization (GP)-values, which indicate lo and ld states of 
the membrane, respectively (111). A representative calculation of GP-value is available 
in Appendix A-5. The Coherent Chameleon femtosecond pulsed Ti:Sapphire laser was 
set at an excitation of 770 nm. 
 
GP-value calculation 
All images were converted to 8-bit/channel TIFF format and were processed 
using Adobe Photoshop CS3® . The mean intensities of each color channel were 
measured in either whole cells or contact regions of the synapse by drawing a polygon 
around each cell boundary (whole cell) (Fig. 8F) or by drawing an oval at the T cell 
membrane proximal to the hybridoma cell (Fig. 8E). GP-values were obtained by the 
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formula, GP=(I400-460-I470-530)÷( I400-460+I470-530), where I stands for intensities of each 
region of interest for the blue and green channels, respectively (110, 111) Full details are 
described in Appendix B-8. A representative calculation of GP-value is available in 
Appendix A-5. 
 
 
Figure 8. Two-photon microscopy images of Laurdan labeled T cells. 8-bit TIFF format 
captured images were analyzed in (A) RGB, (B) red (CMTMR), (C) green (I470-530) or 
(D) blue (I400-460) channels, respectively. Regions of interest (ROI) at (E) T cell immune 
synapse, (F) contact whole cell and non-contact whole cell were selected by drawing an 
oval or polygon as shown in white dotted lines. Mean intensities from blue and green 
channels were recorded to calculate GP-values as described in the Methods. Scale bar, 5 
µm. 
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Quantification of protein localization, activation and GM1 relocation 
To assess the relocalization of signaling proteins or cytoskeletal F-actin, isolated 
CD4
+
 T cells were mixed with hybridoma cells (5:1) and seeded onto poly-L-lysine 
precoated coverglass slides. After a 30 min incubation period, cells were fixed in 4% 
formaldehyde for 20 min, rinsed with PBS, and incubated with 10 mmol/L glycine in 
PBS for 10 min at room temperature to quench aldehyde groups. Cell membranes were 
permeabilized by exposure to 0.2% Triton X-100 in PBS for 5 min at room temperature, 
followed by PBS washing. Cells were subsequently covered with blocking solution (1% 
BSA/0.1% NaN3 in PBS) and incubated at 4°C overnight with primary Abs, rabbit Abs 
specific to either PKCθ (Santa Cruz Biotechnology), linker for activation of T cells 
(LAT), phospho-LAT (Upstate Biotechnology), CARMA1, phospholipase C (PLC)γ-1, 
phospho-PLCγ-1 (Cell Signaling Technology) as previously reported (77) (Detailed 
protocol is provided in Appendix B-9). After PBS washing, cells were incubated with 
secondary Alexa Fluor®  568 goat Ab to rabbit IgG (Molecular Probes). In order to 
visualize F-actin and ganglioside GM1 localization, cells were incubated with F-actin-
specific phallotoxin-Alexa Fluor 568®  (Molecular Probes) or GM1-specific cholera 
toxin B subunit-fluorescein isothiocyanate (CTx-FITC, Sigma), respectively. Following 
serial ethanol dehydration steps, samples were mounted onto glass slides with ProLong 
Antifade reagent (Molecular Probes) (77). Fluorescence images were acquired by 
confocal microscopy to determine both the translocation and phosphorylation status 
(activation) of signaling proteins in CD4
+
 T cells. Either a BioRad Radiance 2000MP 
(argon laser excitation at 568 nm and emission at 590 nm, 63x objective 1.4 NA water) 
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or Zeiss LSM 510 META NLO (argon laser excitation at 543 nm and emission with a 
LP 560 nm, 63x objective 1.4 NA oil) system was used for image acquisition. Cell 
images were captured in 8-bit TIFF format and the percentage of cells with protein 
patching at the IS was counted to assess the relocalization of signaling proteins or F-
actin (raw data can be found in Appendix A-6). GM1 recruitment into the IS was 
quantified by relative relocation index (RRI) (140). Briefly, polygons were drawn to 
designate the IS, the contact whole cell and background area. RRI was calculated by the 
formula, RRI=[mean fluorescence intensity (MFI) at the IS-background]÷(MFI at the 
contact whole cell-background). Raw data are included in Appendix A-7. Quantitative 
analysis of MFI was performed using Adobe Photoshop®  CS3 for Windows. 
 
CD4
+
 T cell proliferation assay 
The effect of n-3 PUFA on T cell proliferation was evaluated by the [
3
H]-
thymidine incorporation and CFSE labeling as previously described (52, 141). Briefly, 
2x10
5
 purified CD4
+
 T cells were stimulated using either control RPMI complete 
medium, 5x10
5
 anti-CD3 hybridoma cells which were pretreated with 10 µmol/L 
mitomycin C (Sigma) for 30 min to block cell division, plate bound CD3-specific mAb 
(1 mg/L) and soluble CD28-specific mAb (10 mg/L, BD Pharmingen) (anti-CD3/28 
mAbs) or PMA (1 pg/L) and Ionomycin (500 nmol/L) (PMA/Ionomycin). Cells were 
cultured for 72 h in round-bottom 96-well multiplates. For CFSE profile analysis, CD4
+
 
T cells were pretreated with 5 µmol/L CFSE in PBS supplemented with 5% FBS for 10 
min (141). After 72 h in culture as described above, CFSE was analyzed by flow 
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cytometry (FACSCalibur, BD) as previously reported (52). Briefly, cells were harvested 
by centrifugation and resuspended in PBS. To determine viability, propidium iodide (PI, 
Sigma) was added to each sample prior to analysis. CFSE fluorescence was detected 
using a 530/30 band pass filter and PI fluorescence through a 650LP filter. CFSE 
fluorescence was sufficiently intense to be detected through a 650LP filter. Viable cells 
were determined using a plot of CFSE vs PI fluorescence, based on the fluorescence 
patterns of a sample with CFSE but no PI. This gate also excluded most of the 
hybridoma cells because of their higher level of autofluorescence. An additional 
lymphocyte gate was set based on forward and side light scattering properties. CFSE 
profiles were analyzed by ModFit LT 3.0 (Verity Software House). Data were expressed 
as difference of percentage (Δpercentage, fat-1 - WT) at each daughter cell generation. 
Raw data and calculation can be found in Appendix A-8. For the [
3
H]-thymidine 
incorporation, 4 µCi [
3
H]-thymidine/well (New England Nuclear) was added to the 
cultures for the final 6 h.  Cells were harvested using a 96-well cell harvester (Packard 
Instrument) and thymidine uptake was measured using liquid scintillation counting 
(Beckman Coulter). Results are expressed as proliferation index, which is derived by 
dividing disintegrations per minute (DPM) of stimulated wells by DPM of basal control. 
Raw data are included in Appendix A-9. 
 
Statistics 
Data were analyzed using Student’s t-test to compare fat-1 and WT cells. The 
Kolmogorov-Smirnov method was applied to test the normality of the data distribution. 
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Statistical interaction of the variables (genotype and ROI) was tested by two-way 
ANOVA. To compare multiple treatment means, one-way ANOVA and LSD multiple 
post-hoc tests were used (SPSS 15.0 for Windows). Data are expressed as mean ± SEM 
and differences of P<0.05 were considered statistically significant. 
 
Results 
n-3 PUFA enhances the formation of lipid rafts at the immune synapse 
Both fat-1 transgenic and wild type (WT) control offspring were fed a 10% 
safflower oil diet enriched in n-6 PUFA throughout the duration of study as described in 
Materials and Methods. Splenic CD4
+
 T cell total lipid fatty acid compositional analyses 
revealed an increase in n-3 PUFA [EPA (P=0.010), docosapentaenoic acid (DPA 22:5n-
3, P=0.007) and DHA (P=0.015)] and a decrease in n-6 PUFA, specifically arachidonic 
acid (20:4n-6, P=0.053), adrenic acid (22:4n-6, P=0.041) and DPA (22:5n-6, P=0.008) in 
fat-1 transgenic mice (Fig. 9). In addition, the ratio of n-6 to n-3 PUFA was significantly 
(P=0.003) suppressed in fat-1 (5.13 ± 1.18), compared to WT T cells (35.71 ± 6.38). 
These data indicate that an appropriate activity of n-3 fatty acid desaturase was present 
and that T cells from fat-1 mice were enriched in n-3 PUFA. 
To investigate the effect of endogenous n-3 PUFA on lipid raft formation at the 
IS, Laurdan labeled CD4
+
 T cells were cocultured with anti-CD3 hybridoma cells at 
37°C in 5% CO2 for 30 min. Images of conjugate CD4
+
 T cells and hybridomas were 
captured, while non-contact CD4
+
 T cells served as a negative control. Two-way 
ANOVA of generalized polarization (GP)-values revealed that there was no statistical 
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interaction between genotype and regions of interest (ROI) (P=0.430). GP-values were 
significantly (P<0.001, LSD post-hoc test) increased at the IS (0.412 ± 0.017 WT vs 
0.452 ± 0.014 fat-1) compared to non-contact T cells (0.329 ± 0.008 WT vs 0.372 ± 
0.008 fat-1) or contact whole cells (0.363 ± 0.010 WT vs 0.377 ± 0.008 fat-1) (Fig. 
10A). Overall, raft formation was enhanced in fat-1 vs WT cells in both resting 
(P=0.016) and stimulated (P=0.022) CD4
+
 T cells. The DNP-specific Ab expressing 
hybridoma was used as a negative control, and failed to exhibit an increase in the GP 
index at the IS (Fig. 10B and C). These data demonstrate that the n-3 PUFA-dependent 
increase in the GP index is IS dependent. 
In independent experiments, CD4
+
 T cells were pretreated with 10 mmol/L 
MβCD for 3 min to specifically deplete cholesterol from lipid rafts as described 
 
Figure 9. Fatty acid composition of CD4
+
 T cell total lipids in WT and fat-1 mice. 
Splenic CD4
+
 T cells were isolated from wild type (WT) or fat-1 transgenic mice. Total 
phospholipids were isolated and fatty acid composition was analyzed by gas 
chromatography, n=5. 
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previously (138). Laurdan analysis revealed that the elevated GP values associated 
withIS formation (ΔGP=0.195 ± 0.030, fat-1 and 0.139 ± 0.015, WT, n=6-14 cells per 
mouse from 1-2 mice per genotype) was diminished following MβCD treatment 
(ΔGP=0.053 ± 0.022, fat-1 and ΔGP=0.059 ± 0.033, WT), indicating that changes in the 
GP index at the IS are cholesterol dependent. 
In complementary experiments, GM1-specific microcluster recruitment was 
assessed using CTx-FITC. CTx has been used to mark membrane microdomains in the 
exofacial leaflet, although a significant fraction of GM1 is found outside lo regions 
(142). Interestingly, in contrast to the enhanced lo domain formation at the IS (Fig. 10B), 
GM1 recruitment was not altered in fat-1 CD4
+
 T cells (Fig. 10D and E). 
 
n-3 PUFA suppress the localization of signaling proteins into the IS 
Following Ag recognition by the TCR, signaling cascades proximal to the IS are 
initiated by relocalization of a complex of molecules, i.e., protein kinases (Fyn, Lck, 
ZAP-70, PLCγ-1), scaffolding proteins (LAT, Grb-2, SLP-76, CARMA1) and 
cytoskeletal proteins (F-actin) into the IS (20, 137, 143). In this study, the effect of n-3 
PUFA on the localization of select signaling molecules in the plasma membrane at the IS  
was quantified. Fig. 11A shows representative cell images obtained following incubation 
with rabbit mAb specific to mouse LAT and the secondary Alexa Fluor®  568 Ab 
specific to rabbit IgG. Relocalization of PKCθ, PLCγ-1 and F-actin into the IS, 
expressed as the percentage conjugate with patching, were suppressed in fat-1 transgenic 
cells by 30% (P=0.050), 32% (P=0.081) and 36% (P=0.020), respectively (Fig. 11B). In 
  
 
41
contrast, the intracellular localization of LAT and CARMA1 at the IS was not altered by 
n-3 PUFA. 
 
n-3 PUFA down-regulate PLCγ-1 phosphorylation at the IS 
Since phosphorylation of LAT and PLCγ-1 occurs at the very early stages of T 
cell activation, either phospho-LAT or phospho-PLCγ-1 specific Ab was used to 
visualize the effect of n-3 PUFA on T cell activation. Specifically, the percentage 
conjugate patching of phospho-Y195 (LAT) (144) and phospho-Y783 (PLCγ-1) (145) 
was examined and showed that PLCγ-1 phosphorylation was suppressed by 29% 
(P=0.034) in n-3 PUFA enriched cells at the IS, whereas LAT phosphorylation was not 
altered (P=0.464) (Fig. 12A and B). 
 
n-3 PUFA suppress CD4
+ 
T cell proliferation 
CD4
+
 T cells were labeled with CFSE and cultured for 72 h for the purpose of 
determining whether the effect of n-3 PUFA on lipid rafts and signaling protein 
recruitment/activation was associated with an alteration in T cell proliferation. Using 
flow cytometry analysis, non-viable cells were gated out based on their uptake of PI 
(Fig. 13A, D and G) and lymphocytes were identified by forward and side scatter plot 
analysis (Fig. 13B, E and H). The parental peak was obtained by examining 
unstimulated control cells, which did not divide (Fig. 13C), whereas cell division was 
visualized by the shift of CFSE peak to the left (52, 141). To identify each daughter 
generation, computer-aided modeling was performed (Fig. 13F and I). Examination of 
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Figure 10. Lipid raft formation and GM1 relocalization at the IS of CD4
+
 T cells. (A) 
GP-values, which indicate microenvironment fluidity in the plasma membrane, were 
quantified in CD4
+
 T cells obtained from either fat-1 or WT mice  (8-14 cells per mouse 
from 3-4 mice per genotype were examined to obtain a total of n=27-51 observations).  
Bars with different letters indicate significant differences at P<0.05 across all treatment 
groups within panel A. (B) IS-dependent increase of GP-values was confirmed by anti-
DNP hybridoma cells (negative control, n=6-9 cells from one mouse per genotype). Bars 
with different letters indicate significant differences at P<0.05 across all treatment 
groups within panel B. (C) Schematic of IS formation  (top) and non-IS contact 
(bottom), respectively. (D and E) Immunofluorescence analysis of GM1 recruitment into 
the IS. Purified CD4
+
 T cells and anti-CD3 hybridomas were coincubated, fixed, 
permeabilized, labeled with CTx-FITC. Confocal microscopic images were captured and 
MFI was measured at the IS relative to the whole cell to calculate RRI, as described in 
the Methods. (D) Representative image of GM1 localization. Scale bar, 5 µm. (E) The 
relocation of GM1 at the IS was assessed by RRI of CTx-FITC (n=31-32 cells from 3 
mice per genotype). 
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Figure 11. Immunofluorescence analysis and localization of signaling molecules into the 
IS. Purified CD4
+
 T cells and anti-CD3 hybridomas were coincubated, fixed, 
permeablized, and labeled with Abs specific to either PKCθ, CARMA1, LAT, PLCγ-1 
or F-actin, as described in the Methods. (A) Representative images of LAT localization 
to the IS in fat-1 cells. Image contrast was adjusted. Scale bar, 5 µm. (B) Protein 
localization was assessed by percent patching (the number of patching cells divided by 
the number of total cells examined, n=37-101 cells from 2-5 mice per genotype for each 
protein). 
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Figure 12. Phosphorylation status of signaling proteins at the IS. Purified CD4
+
 T cells 
and anti-CD3 hybridomas were coincubated, fixed, permeablized, and labeled with Abs 
specific to either phospho-LAT or phospho-PLCγ-1, as described in the Methods. (A) 
Representative image of LAT phosphorylation at the IS in fat-1 cells. Image contrast 
was adjusted. Scale bar, 5 µm. (B) Protein activation was assessed by percent patching 
(n=37-59 cells from 3-4 mice per genotype for each protein). 
 
the percentage of each daughter cell generation revealed that fat-1 CD4
+
 T cell 
proliferation was suppressed in response to anti-CD3 hybridoma stimulation. 
Specifically, a higher percentage of non-divided parental cells (Δpercentage=5.87, 
P=0.028) and lower percentage of daughter cells at generation 4 (Δpercentage=-0.98, 
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P=0.037), 5 (Δpercentage=-1.73, P=0.042) and 6 (Δpercentage=-1.38, P=0.065) were 
obtained (Fig. 14A). In addition, CD4
+
 T cells stimulated by either anti-CD3/28 mAbs 
or PMA/Ionomycin exhibited a similar trend; larger fraction at generation 1 
(Δpercentage=4.30, P=0.085 anti-CD3/28 mAbs, Δpercentage=3.58, P=0.001 
PMA/Ionomycin) and a reduced number of cells at generation 4 (Δpercentage=-3.34, 
P=0.081 anti-CD3/28 mAbs), suggesting a suppression of cell division in the fat-1 group 
(Fig. 14B and C). 
In a complementary experiment, CD4
+
 T cell proliferation was assessed by the 
incorporation of [
3
H]-thymidine. In accordance with the CFSE profile data, thymidine 
uptake expressed as the proliferation index revealed that fat-1 CD4
+
 T cell division was 
significantly suppressed by 52% (P<0.001), 45% (P=0.002) and 56% (P=0.001) in anti-
CD3 hybridoma, anti-CD3/28 mAbs and PMA/Ionomycin stimulated cells, respectively 
(Fig. 15). 
 
Discussion 
It has been postulated that n-3 PUFA, because of their perceived broad acting 
effects on mammalian physiology, act at a fundamental level common to all cells, i.e., by 
altering the physical properties of biological membranes (74, 80-84, 131, 132). More 
specifically, we hypothesized that the anti-inflammatory effects of n-3 PUFA on CD4
+
 T 
cells would be explained, in part, by suppressing/disrupting lipid raft formation at the IS. 
To elucidate the membrane bioactive properties of n-3 PUFA in T cells, the fat-1 
transgenic mouse model was utilized because it is uniquely capable of converting n-6 
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PUFA to n-3 PUFA endogenously by introducing a cis double bond into fatty acyl 
chains (113, 146). Data from initial experiments showed that the fat-1 gene was 
functionally expressed in splenic CD4
+
 T cells and that the plasma membrane was 
enriched in n-3 PUFA (Fig. 9). 
 
 
Figure 13. Representative CFSE profiles. Data from either basal WT T cells (A-C), anti-
CD3 hybridoma stimulated WT (D-F) or fat-1 (G-I) CD4
+ 
T cells were shown. Regions 
for viable cells (A, D and G) and lymphocytes (B, E and H) were set based on propidium 
iodide incorporation and forward/side scatter plots, respectively. Viable lymphocytes 
were defined as those events falling within both the viability and lymphocyte regions. 
Computer-aided modeling of each daughter generation (C, F and I) was performed as 
described in the Methods. The non-divided parental peak was obtained from the 
unstimulated control group (C). The left shift of peaks (F and G) indicated successive 
rounds of cell division. 
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Figure 14. The difference in the percentage of T cells (Δpercentage) at each generation. 
The difference was obtained by subtracting the percentage of the WT group from the 
percentage of fat-1. Positive bars show that fat-1 cultures had more cells in those 
generations, whereas negative bars show fewer fat-1cells. (A) anti-CD3 hybridoma, (B) 
anti-CD3/28 mAbs and (C) PMA/Ionomycin stimulated (n=6-10 cultures from 3-5 mice 
per genotype for each stimulus) (
*
P<0.05, 
**
P<0.10). 
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Figure 15. Proliferation of CD4
+
 T cells expressed as proliferation index. Proliferation 
index was calculated by DPM stimulated ÷ DPM unstimulated in response to either anti-
CD3 hybridoma, anti-CD3/28 mAbs or PMA/Ionomycin (n=6-10 cultures from 3-5 mice 
per genotype for each stimulus). 
 
We have demonstrated previously that n-3 PUFA suppress murine CD4
+
 T cell 
proliferation by remodeling lipid raft fatty acid composition and by altering PKCθ 
colocalization (77). In that study, CD4
+
 T cells were stimulated by culture plate-bound 
mAb to CD3 (anti-CD3 mAb) to induce the colocalization of PKCθ with GM1, a marker 
of lipid rafts. However, the direct visualization of lipid rafts at the IS is necessary in 
order to investigate microdomain assembly and localization at the plasma membrane. 
Hence, in the present study, we incubated CD4
+
 T cells with Laurdan to directly measure 
membrane fluidity and visualize lipid rafts by two-photon microscopy.  For this purpose, 
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anti-CD3 hybridoma cells were used as Ag presenting cells to form an IS, since they 
express cell surface costimulatory B7 and intercellular adhesion molecule (ICAM-1) 
(139). In a major step toward developing a unifying mechanistic hypothesis addressing 
how dietary PUFA modulate cell membrane microdomains, we demonstrate for the first 
time that n-3 PUFA actually promote lipid raft formation at the IS (Fig. 10A-C). These 
results can be explained in part by the fact that n-3 PUFA, specifically DHA, has a low 
affinity for cholesterol, providing a lipid-driven mechanism for lateral phase separation 
of cholesterol/sphingolipid-rich lipid microdomains from the surrounding ld phase (80-
84).  Hence, the insertion of DHA into the bulk membrane should enhance the 
coalescence of cholesterol-rich lipid raft-like domains in living cells.  These findings are 
consistent with previous observations using immuno-gold electron microscopy of plasma 
membrane sheets coupled with spatial point analysis of validated microdomain markers 
(78).  In that study, we demonstrated that DHA increased lipid raft clustering in HeLa 
cells, indicating that plasma membrane organization of inner leaflets is fundamentally 
altered by n-3 PUFA-enrichment. 
With regard to the role of lipid rafts in T cell activation, T cells from patients 
suffering from autoimmune disease synthesized more GM1 following TCR activation 
(20), suggesting that GM1 enriched domains play a critical role in the activation of 
immune responses. However, cholesterol overloading in healthy T cells reduced the 
lateral mobility of receptors and signaling molecules providing a link between plasma 
membrane cholesterol content and immunosenescence (20). These observations are 
controversial because GM1 and cholesterol, which are both thought to be lipid raft 
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building blocks (17), play different roles in T cell activation and regulation. Therefore, 
we measured the recruitment of GM1 into the IS by labeling with CTx-FITC in order to 
evaluate the effect of n-3 PUFA on GM1-specific lipid rafts. Of interest, GM1 relocation 
as assessed by RRI was not altered by n-3 PUFA (Fig. 10E). This observation is 
consistent with a previous report, where GM1 localization as assessed by biochemical 
isolation of DRM was not affected by PUFA treatment (72). Interestingly, the fatty acid 
composition of phospholipids in the exofacial leaflet of T cells, where GM1 is enriched, 
was not altered by n-3 PUFA (32). In addition, long chain PUFA are predominantly 
enriched in phospholipids localized to the cytofacial leaflet (32, 147). Based on these 
findings, the data suggest that the incorporation of n-3 PUFA into cytofacial leaflet 
phospholipids alters the lateral composition of lipid rafts in the plasma membrane, 
thereby altering the IS microenvironment to impact thresholds for the activation TCR 
mediated cell signaling. 
The proximal events of cell signaling following Ag recognition by the TCR are 
initiated by the localization of signaling molecules into the IS (20). To evaluate the 
effect of n-3 PUFA on the localization of select signaling proteins, the percentage of 
cells with multi-protein signaling complexes relocalized to the IS was enumerated by 
immunofluorescence microscopy. Consistent with a perturbation in lipid raft structure, 
n-3 PUFA enriched CD4
+
 T cells exhibited a suppressed localization of PKCθ, PLCγ-1 
and F-actin into the IS (Fig. 11). We also reported that PKCθ colocalization with GM1 
in anti-CD3 mAb stimulated T cells was suppressed by dietary fish oil and purified DHA 
ethyl ester administration (77). Although a significant fraction of GM1 can be found 
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outside lo regions (142, 148), the dislocation of PKCθ from GM1 enriched domains may 
explain in part why PKCθ accumulation at the IS was suppressed by n-3 PUFA, while 
lipid raft formation was enhanced. In addition, we also show that the localization of 
PLCγ-1 and F-actin was selectively suppressed by n-3 PUFA, whereas LAT and 
CARMA1 localization was not altered. In contrast, in a previous study, F-actin, LAT and 
PKCθ localization into the IS was not altered by n-3 PUFA (EPA) treatment compared 
to n-6 PUFA (arachidonic acid) (74). Indeed, both n-3 and n-6 PUFA treatment equally 
suppressed the localization of F-actin, talin, leukocyte function-associated molecule-1α, 
LAT and CD3ε into the IS, compared to the saturated stearic acid (18:0) treated control 
group. The apparent differences between these studies may be attributed to the fact that 
Jurkat human T cells were directly incubated with 50 µmol/L fatty acid followed by 
antigenic stimulation (74). 
Since not only the spatial migration but also the phosphorylation status of LAT 
and PLCγ-1 is critical for T cell activation (144, 145) and dietary FO has been shown to 
modulate PLCγ-1 phosphorylation in rat lymphocytes (149), we counted cells with 
phospho-specific immunofluorescent patching in order to assess the activation status of 
those proteins. In accordance with the localization results, LAT phosphorylation was not 
affected by n-3 PUFA, however PLCγ-1 phosphorylation was suppressed in fat-1 
transgenic T cells (Fig. 12). These data indicate that n-3 PUFA selectively modulate the 
localization and/or activation status of signaling proteins in TCR-mediated T cell 
activation. 
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The understanding of the function of the IS is still evolving. For example, 
membrane condensation and signaling protein translocation to the IS has been shown to 
be critical for TCR triggered T cell activation (110). In contrast, compelling data suggest 
central supramolecular activation cluster (cSMAC) of mature IS may promote TCR/CD3 
internalization and recycling (124). In addition, TCR microclusters initiate T cell 
signaling in seconds (150) following binding to peptide-MHC complex but the signal 
becomes weaker when cSMAC is formed in minutes (151, 152). These observations 
suggest that the dynamic nature of the IS and perhaps rapid formation/dissolution of rafts 
promote TCR signaling. It is possible, therefore, that n-3 PUFA by stabilizing lipid rafts 
at the IS disrupt lipid-protein interactions and perturb membrane structure/function. 
Alteration of CD4
+
 T cell lipid raft microdomains and proximal T cell signaling 
by n-3 PUFA in fat-1 cells resulted in the suppression of proliferation (Fig. 14A and 
15), indicating the critical importance of lipid raft localization of proteins such as PKCθ, 
PLCγ-1 and F-actin to TCR signaling. To test if the mechanism of suppression by n-3 
PUFA was limited to the IS or proximal signaling cascades, T cells were stimulated with 
either anti-CD3/28 mAbs or PMA/Ionomycin to bypass IS formation and TCR mediated 
signaling, respectively. T cell proliferation by anti-CD3/28 mAbs and PMA/Ionomycin 
was suppressed as assessed by CFSE profiles and thymidine uptake, indicating that the 
down-regulation of T cell proliferation by n-3 PUFA is not limited to TCR-mediated 
activation. Indeed, CFSE profile analysis revealed that the largest Δpercentage was 
associated with the non-dividing parental generation when T cells were stimulated with 
the IS forming anti-CD3 hybridoma cell model (Fig. 14), consistent with a very strong 
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suppression of T cell proliferation. These data are consistent with previous reports that 
n-3 PUFA are anti-inflammatory and immunomodulatory in vivo (77, 153). 
In general, hyperactivation of CD4
+
 T cells is associated with enhanced susceptibility to 
autoimmune disorders and chronic inflammatory diseases (131, 132). Recently, our 
laboratory reported that fat-1 mice exhibited an enhanced ability to resolve dextran 
sodium sulphate-induced intestinal inflammation and injury (114). Since subsets of 
CD4
+
 T cells are known to be critical mediators of chronic inflammation, results from 
our study may partially explain why n-3 PUFA favorably modulate the inflammation-
dysplasia-carcinoma axis. 
In conclusion, we have shown that n-3 PUFA promote the formation of lipid rafts 
and perturb the reorganization of signaling machinery which is critical to T cell 
activation. These results provide a critical new paradigm in understanding the molecular 
mechanisms through which dietary n-3 PUFA modulate T cell activation. Additional 
studies are needed to further elucidate the effect of dietary n-3 PUFA on T cell signaling 
networks. 
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CHAPTER IV 
DIETARY CURCUMIN AND LIMONIN SUPPRESS MURINE CD4
+
 T CELL 
PROLIFERATION AND INTERLEUKIN-2 PRODUCTION IN PART BY 
SUPPRESSING NF-B ACTIVATION 
 
Introduction 
Inflammation is an imperative host defense response comprising both innate and 
adaptive immune systems. Interestingly, chronic inflammation is a disease state which is 
associated with a higher risk of cancer development (131, 154-156). With respect to the 
adaptive immune response, CD4
+
 T cells regulate inflammatory responses, in part, by 
clonal expansion into effector T helper cell subsets and cytokine production. The 
function of CD4
+
 T cells is affected by a variety of factors such as genetic background, 
antigen peptide, adjuvant, antigen presenting cell subset, as well as nutrients.  
Dietary fat, a major energy source, can modify membrane structure thereby 
playing an important role in cell signaling in a variety of cell types. The anti-
inflammatory properties of diets rich in n-3 PUFA, e.g., eicosapentaenoic acid (EPA, 
20:5
∆5,8,11,14,17
) and docosahexaenoic acid (DHA, 22:6
∆4,7,10,13,16,19
) which are highly 
enriched in cold water fish, on T cell function have been established in both humans and 
experimental animals (41, 42, 157-161).  In contrast, dietary lipids rich in n-6 PUFA, 
found in vegetable oils and animal fats, e.g., linoleic acid (18:2
∆9,12
) and arachidonic acid 
(20:4
∆5,8,11,14
), can be deleterious with respect to some inflammatory diseases (reviewed 
in (41)).  This is significant because the typical Western diet contains 10 to 20 times 
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more n-6 than n-3 PUFA (162).  Though the molecular mechanisms of anti-
inflammatory n-3 PUFA are not fully elucidated to date, a growing body of data indicate 
that n-3 PUFA modulate CD4
+
 T cell function, in part, by altering plasma membrane 
microenvironment , thereby modulating intracellular localization of signaling molecules 
(32, 77). This may aid in the resolution of a series of chronic inflammatory diseases, 
such as arthritis, Crohn’s disease, dermatitis, psoriasis and ulcerative colitis (35, 130-
132).  
The molecular mechanisms of T cell activation have been well documented. 
Antigenic T cell activation through the T cell receptor (TCR)/CD3 complex requires 
antigen peptide (Ag) in the context of major histocompatibility complex class II of 
antigen presenting cells (APC), directing the subsets of adaptive immune responses, i.e. 
cell-mediated or humoral immunity. With respect to the heterogeneous plasma 
membrane phospholipid bilayer, cholesterol/sphingomyelin rich microdomains, i.e., lipid 
rafts (17, 129, 163) are thought to be platforms for receptor residence and signaling 
molecule migration (20). In addition, signaling molecules are recruited to the 
immunological synapse where T cells and APCs make physical contact after TCR/CD3 
ligation to Ag. Following the induction of signal cascades proximal to TCR initiated 
signaling, nuclear factors (NF) translocate from cytosol into the nucleus to elicit the 
expression of an array of cytokines. It is now appreciated that NF-kB delivers a “life 
signal” by stimulating pro-inflammatory cytokines such as interleukin (IL)-2 and 
interferon (INF)-γ in T cells (164, 165). IL-2 gene transcription is a hallmark feature of 
T cell activation, which is also regulated by AP-1 and NFAT nuclear factors (Fig. 16). 
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Interestingly, Fan et al. from our laboratory reported that dietary fish oil (FO), as well as 
purified DHA, suppressed the recruitment of signaling molecules into lipid rafts, NF-
kB/AP-1 activation and IL-2 production, linking alteration in lipid raft composition to 
reduced IL-2 production (77). In that study, CD4
+
 T cells were stimulated using 
mitogenic monoclonal antibodies to CD3 and CD28 (anti-CD3/28 mAbs), which 
avoided the engagement of an immunological synapse. 
 
 
 
Figure 16. Transcriptional regulation of IL-2 in T cells. Image was reprinted with 
permission from “Transcriptional repression of interleukin-2 in human systemic lupus 
erythematosus” by Katsiari, C.G. 2006, et al, Autoimmun. Rev. (166). Copyright 2005 by 
Elsevier B.V. 
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The experimental model system of T cell activation has evolved significantly to 
include DO11.10 Rag2
-/-
 TCR transgenic mouse models. T cells from these transgenic 
mice respond specifically to a peptide of ovalbumin (OVA323-339) to mimic 
physiological Ag selection by Ag-specific T cells (115). In addition, OVA peptide 
antigen presentation by APC forms an immunological synapse with T cells, following 
which T cells redistribute signaling molecules and organelles such as mitochondria (167). 
Phytochemicals have been investigated for decades as chemotherapeutic agents 
for cancer and chronic inflammatory diseases. Of interest, it has been reported that 
curcumin (diferuloylmethane, Cur), a major active component of turmeric (Curcuma 
longa Linn), exhibited anti-inflammatory effects by suppression of the NF-κB signaling 
pathway in ovarian and pancreatic cancer cell-line models (168-170). In addition, 
Vanamala et al. from our laboratory has shown that limonin (7,16-Dioxo-7,16-
dideoxylimondiol, Lim), a citrus fruit extract compound, down-regulates iNOS and 
COX-2, which are regulated in part by NF-kB, in a rat mucosal cancer model (100). 
These data suggest that limonin may also be a putative NF-kB inhibitor and therefore 
capable of modulating CD4
+
 T cell function. However, the function of curcumin and 
limonin with regard to CD4
+
 T cell activation has not been elucidated to date.  
Hence, in this study, using antigen-specific or mitogenic stimulation, we 
hypothesized that (a) dietary curcumin and limonin suppress CD4
+
 T cell function by 
modulating NF-kB activity and (b) dietary “combination chemotherapy”, using n-3 
PUFA plus either curcumin or limonin, will maximally suppress IL-2 secretion and cell 
proliferation. 
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Materials and Methods 
Animals, diets, and cell purification 
All procedures followed guidelines approved by Public Health Service and the 
Institutional Animal Care and Use Committee at Texas A&M University. TCR 
transgenic DO11.10 Rag2
-/-
 mice were purchased from Taconic Farms, Inc. 
(Germantown, NY), bred and maintained at Texas A&M University.  The composition 
of experimental diets is shown in Table 1 and met the NRC nutrition requirements. 
Briefly, diets differed with respect to  fat source and the addition of Cur or Lim. The FO 
diet contained 4% FO+1% corn oil (CO) to meet essential fatty acids requirement, while 
the 5% CO diet served as a control. 1% Cur or 0.02% Lim was added to both CO and FO 
diets at the expense of cellulose. Mice were fed (1 wk) a wash-out CO diet followed by 
(2 wk) experimental diet feeding. CD4
+
 T cells from mice were isolated from spleens by 
a magnetic microbead positive selection method (Miltenyi Biotec) according to the 
manufacturer’s recommendation (Working protocol can be found in Appendix B-5). For 
antigenic stimulation, splenic lymphocytes from chow-fed BALB/c mice were used as 
APCs. Briefly, lymphocytes were isolated by density gradient centrifugation using 
Lympholyte-M®  (Cedarlane Labs) and incubated in 25 µg/ml Mitomicin C (Sigma) for 
30 min, followed by a washing step to remove excessive Mitomicin C (refer to Appendix 
B-10 for details). 
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Table 1. Experimental diet composition of curcumin and limonin supplement. 
  Composition (g/100g) 
Ingredients CO* CC CL FO FC FL 
Casein (Bio-serv) 20.0 20.0 20.0 20.0 20.0 20.0 
Sucrose (Bio-serv) 42.0 42.0 42.0 42.0 42.0 42.0 
Corn starch (Bio-serv) 22.0 22.0 22.0 22.0 22.0 22.0 
Cellulose (Bio-serv) 6.0 5.0 5.98 6.0 5.0 5.98 
AIN-76 mineral mix (Bio-serv) 3.5 3.5 3.5 3.5 3.5 3.5 
AIN-76 vitamin mix (Bio-serv) 1.0 1.0 1.0 1.0 1.0 1.0 
DL-Methionine (Bio-serv) 0.3 0.3 0.3 0.3 0.3 0.3 
Choline chloride (Bio-serv) 0.2 0.2 0.2 0.2 0.2 0.2 
CO (Dyets, Inc.) 5.0 5.0 5.0 1.0 1.0 1.0 
FO (Omega protein) - - - 4.0 4.0 4.0 
Curcumin (Sabinsa Co.) - 1.0 - - 1.0 - 
Limonin** - - 0.02 - - 0.02 
Total 100.0 100.0 100.0 100.0 100.0 100.0 
 
*CO, corn oil; CC, corn oil+curcumin; CL, curcumin+limonin; FO, fish oil; FC, fish 
oil+curcumin; FL, fish oil+limonin 
 
**Limonin was purified and provided by Dr. Patil, Vegetable and Fruit Improvement 
Center, Texas A&M University 
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T cell activation using antigen or mitogen 
In order to test either cell proliferation or IL-2 production/nuclear factor 
activation, 2x10
5
 DO11.10 CD4
+
 T cells/ml were cultured in 200 µl medium in an U-
bottomed 96-well culture plate or in 2 ml medium in a flat bottom 24-well culture plate, 
respectively, in a 5% CO2 incubator at 37 
o
C for 72 hr in the presence of the following 
stimuli. For antigen-specific stimulation, CD4
+
 T cells were co-cultured with 5x10
5
 
APC/ml in the presence of 0.1 µmol/L OVA323-339 peptide (Biosource) in complete 
medium [RPMI 1640 medium with 25 mmol/L HEPES (Irvine Scientific), supplemented 
with 5% heat-inactivated FBS (Invitrogen), 10
5
 U/L penicillin and 100 mg/L 
streptomycin (Gibco), 2 mmol/L L-glutamine (Glutamax® , Gibco), and 10 µmol/L 2-
ME (Sigma)]. Plate bound CD3-specific mAb (1 ng/L) and soluble CD28-specific mAb 
(5 ng/L, BD Pharmingen) (anti-CD3/28 mAbs) were used for mitogenic stimulation.  
 
Nuclear extraction and quantification of NF-κB, NFAT and AP-1 activation 
Following a 72 hr incubation of CD4
+
 T cells as described above, nuclei were 
pelleted and extracted using a Nuclear Extraction kit (Active Motif). The levels of 
activated NF-κB, NFAT and AP-1 were measured using an ELISA-based Trans AM NF-
κB p65, NFATc1 and AP-1 c-Jun Transcription Factor Assay kits (Active Motif), 
respectively, as previously described (77). Briefly, induction of NF-κB, NFAT or AP-1 
in the nuclear extracts was quantified by nucleotide (5’-GGGACTTTCC-3’ for NF-κB, 
5’-T/AGGAAA-3’ for NFAT or 5’-TGA(C/G)TCA-3’ for AP-1) binding using specific 
Abs to NF-κBp65, NFATc1 or c-Jun followed by secondary HRP conjugated Abs and 
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chromogenic substrate. A sensitive colorimetric readout was quantified by either 
chemiluminescence (NF-κB) or spectrophotometry at 450 nm with a reference 
wavelength of 655 nm (NFAT and AP-1). Competition experiments were performed by 
incubating the extracts with the labeled probe in the presence of excess (20 pmol/L) of 
unlabeled wild-type NF-κB, NFAT or AP-1 oligonucleotide. TPA and calcium 
ionophore-stimulated Jurkat T cell extracts were used as a positive control, resulting in a 
18-fold activation of NF-κB in comparison to the negative control (Jurkat T cell extract 
plus NF-κB wildtype oligonucleotide competitor). Similarly, a 4-fold (NFAT) and a 9-
fold (AP-1) level of activation were observed in the positive controls (PHA-stimulated 
Jurkat T cell nuclear extract and TPA-stimulated K-562 nuclear extract, respectively) 
relative to the negative controls (Jurkat nuclear extract plus NFAT wild-type 
oligonucleotide competitor and K-562 nuclear extract plus AP-1 wild-type 
oligonucleotide competitor). Serial dilution of control nuclear extract revealed a dose 
dependent sensitivity of the kits (Appendix A-19). The induction of nuclear factors was 
expressed as fold increase, which was derived by (colorimetric readout of stimulated 
cells) ÷ (colorimetric readout of unstimulated cells). 
 
IL-2 quantification 
IL-2 secretion was measured in cell culture supernatants. Following a 72 hr cell 
stimulation period, culture media was harvested and stored at -80°C until analysis by 
Quantikine mouse IL-2 ELISA kit (R&D Systems) as previously described (77). The 
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amount of IL-2 in the media was calibrated by linear regression of serially diluted 
standards provided in the kit (Appendix A-20). 
 
Cell proliferation assay 
For CFSE profile analysis, CD4
+
 T cells were pretreated with 5 µmol/L CFSE 
(Molecular Probes) in PBS supplemented with 5% FBS for 10 min (141). After 72 h in 
culture as described above, CFSE was analyzed by flow cytometry (FACSCalibur, BD) 
as previously reported (52). Briefly, cells were harvested by centrifugation (200x g for 
10 min at RT) and resuspended in PBS. To determine viability, propidium iodide (1 
µg/ml) (PI, Sigma) was added to each sample prior to analysis. CFSE fluorescence was 
detected using a 530/30 band pass filter and PI fluorescence through a 650LP filter. 
CFSE fluorescence was sufficiently intense to be detected through a 650LP filter. Viable 
cells were determined using a plot of CFSE vs PI fluorescence, based on the 
fluorescence patterns of a sample with CFSE but no PI. This gate also excluded most of 
the APC because of their higher level of autofluorescence (Appendix A-21). An 
additional lymphocyte gate was set based on forward and side light scattering properties 
(Appendix A-22). CFSE profiles were analyzed by FlowJo (Tree Star). Data were 
expressed as difference of percentage compared to CO control (Δpercentage) at each 
daughter cell generation. For the [
3
H]-thymidine incorporation, 4 µCi [
3
H]-
thymidine/well (New England Nuclear) was added to the cultures for the final 6 h.  Cells 
were harvested using a 96-well cell harvester (Packard Instrument) and thymidine uptake 
was measured using liquid scintillation counting (Beckman Coulter). 
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Statistics 
To compare multiple treatment means, one-way ANOVA and Duncan’s multiple 
comparison or Least Significant Difference (LSD) were used (SPSS 15.0 for Windows). 
Kolmogorov-Smirnov method was applied to test the normality of the data distribution. 
Statistical interaction of the two dietary variables (fat source and phytochemicals) was 
tested by two-way ANOVA. Data are expressed as mean ± SEM and differences of 
P<0.05 were considered statistically significant. 
 
Results 
Dietary curcumin and limonin suppress NF-κB activation 
With respect to the physiological relevance of the diets used in this study, fish oil 
(4%), limonin (0.02%), and curcumin (1.0%) diets are within the estimated range 
consumed by humans (52, 88, 171, 172). Body weight gains of mice were not affected 
by the experimental diets following a 2 wk feeding period (data in Appendix A-10).  
In order to investigate the effect of Cur and Lim on nuclear transcription factor 
activation, nuclei were extracted from CD4
+
 T cells following a 72 h stimulation period 
with OVA peptide or mAbs. NF-kB translocation analysis revealed that both Cur and 
Lim suppressed NF-kB activation in both antigen- and mitogen-stimulated cells 
(P<0.001, one-way ANOVA) (Fig. 17). Two-way ANOVA analysis was performed to 
determine whether the Cur and Lim effect differed depending on the fat source. The 
statistical outcome indicated that there was no interaction of the two variables, fat source 
and phytochemical (P=0.610, anti-CD3/28 mAbs; P=0.712, OVA/APC). These data 
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indicate that FO did not influence NF-B activation, as opposed to Cur and Lim which 
suppressed activation (Fig. 17). Since the promoter region of a key T cell growth 
promoting cytokine, IL-2, also contains NFAT and AP-1 response elements (Fig. 16), 
we measured the effect of Cur and Lim on NFAT and AP-1 activation. The results 
demonstrate that NFAT activation was not affected by the experimental diets compared 
to CO control diet as shown in Fig. 18. Of interest, FO diet promoted (P<0.05) AP-1 
activation by 1.38 fold and 3.46 fold in the response to either anti-CD3/28 or APC+OVA 
peptide, respectively (Fig. 19). 
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Figure 17. Activation of NF-κB in CD4+ T cells. Cells were stimulated by either (A) 
anti-CD3/28 mAbs or (B) APC+OVA peptide as described in the Methods. Fold increase 
of chemiluminescence was expressed relative to unstimulated controls. Bars with 
different letters indicate significant differences (P<0.05) within the panel (CO, corn oil 
control; CC, CO+1% curcumin; CL, CO+0.02% limonin; FO, 4% fish oil+1% CO; FC, 
FO+1% curcumin; FL, FO+0.02% limonin, n=6-7 mice per diet). 
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Figure 18. Activation of NFAT in CD4
+
 T cells. Purified CD4
+
 T cells were stimulated 
by either (A) anti-CD3/28 mAbs or (B) APC+OVA peptide as described in the Methods. 
Fold increase of fluorescence absorbance at 450 nm was expressed relative to 
unstimulated controls. Bars with different letters indicate significant difference (P<0.05) 
within the panel. (CO, corn oil control; CC, CO+1% curcumin; CL, CO+0.02% limonin; 
FO, 4% fish oil+1% CO; FC, FO+1% curcumin; FL, FO+0.02% limonin, n=6-7 mice 
per diet). 
 
 (A) (B) 
A
P
-1
 (
fo
ld
 i
n
cr
ea
se
, 
n
=
5
-7
) 
  
Figure 19. Activation of AP-1 in CD4
+
 T cells. Purified CD4
+
 T cells were stimulated 
by either (A) anti-CD3/28 mAbs or (B) APC+OVA peptide as described in the Methods. 
Fold increase of fluorescence absorbance at 450 nm was expressed relative to 
unstimulated controls. Bars with different letters indicate significant difference (P<0.05) 
within the panel. (CO, corn oil control; CC, CO+1% curcumin; CL, CO+0.02% limonin; 
FO, 4% fish oil+1% CO; FC, FO+1% curcumin; FL, FO+0.02% limonin, n=5-7 mice 
per diet). 
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Dietary curcumin and limonin reduce IL-2 production 
In order to link suppression of NF-kB to T cell function, IL-2 secretion into the 
culture medium was measured. Interestingly, IL-2 production was not altered by the 
experimental diets in mitogen-stimulated cultures (Fig. 20A). In contrast, IL-2 
production was suppressed (P<0.05) by Cur and Lim supplementation, as well as FO, 
compared to CO control by 56-71% when CD4
+
 T cells were stimulated by OVA323-
339 peptide. However, Cur and Lim supplementation with FO did not further suppress 
IL-2 secretion (Fig. 20B).  
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Figure 20. IL-2 production by CD4
+
 T cells. Cells were stimulated by either (A) anti-
CD3/28 mAbs or (B) APC+OVA peptide as described in the Methods. Bars with 
different letters indicate significant differences (P<0.05) within the panel (CO, corn oil 
control; CC, CO+1% curcumin; CL, CO+0.02% limonin; FO, 4% fish oil+1% CO; FC, 
FO+1% curcumin; FL, FO+0.02% limonin, n=6-7 mice per diet). 
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Dietary curcumin and limonin suppress CD4
+ 
cell proliferation 
In order to investigate the effect of suppressed NF-κB activation and IL-2 on 
CD4
+
 T cell function, cell proliferation was measured using two independent methods. 
Analysis of CFSE profiles (Fig. 21) indicated that CD4
+
 T cell division was suppressed 
by dietary Cur and Lim added to CO. Specifically, compared to CO control diet group, 
Cur fed animals had significantly (P<0.05) more cells following anti-CD3/28 stimulation 
at generations 1, 2 and 3 (Δ percentage= 2.83, 2.89, 6.45, respectively) and fewer cells at 
generation 5 (Δ percentage=-7.69, Fig. 22A). Similarly, Cur supplementation in 
combination with FO (Fig. 22D) reduced the percentage of cells at generations 4 and 5 
(Δ percentage=-9.58 and -4.02, respectively). In contrast, Lim supplement did not alter 
the proliferation of CD4
+
 T cells (Fig. 22B) and the FO diet had little effect, except in 
generation 1 (Δ percentage=2.65, Fig. 22C). Of interest, the Lim and FO combination 
(Fig. 22E) exhibited a synergistic suppressive effect on CD4
+
 T cell proliferation with 
significantly more cells in generations 1 and 2 (Δ percentage=2.88 and 2.61, 
rescpectively) and fewer cells in generation 5 (Δ percentage=-4.70, P=0.066). Similarly, 
with an Ag-specific stimulation by OVA peptide+APC, Cur supplementation to the CO 
diet (Fig. 23A) resulted in more cells at generations 3 and 4 (Δ percentage= 5.46 and 
5.40, respectively) whereas fewer cells were observed at generations 5 and 6 (Δ 
percentage=-5.71 and -4.94, respectively). Cur+FO treatment resulted in more cells at 
generations 1 (Δ percentage=3.79, P=0.059) and 2 (Δ percentage=1.73, P=0.072) and 
fewer cells at generations 4 and 5 (Δ percentage=-7.67 and -8.31, respectively, Fig. 23D).  
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 CFSE vs PI FSC vs SSC CFSE modeling 
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Figure 21. Representative flow cytometry plots and CFSE modeling. Data from a CO-
fed control mouse were shown. Unstimulated (A-C), anti-CD3/28 stimulated (D-F) or 
OVA+APC stimulated (G-I) CD4
+
 T cell cultures were analyzed by flow cytometry. 
Propidium iodide negative cells were gated (A, D, G) which excluded non-viable 
parental CD4
+
 T cells (A) and auto-fluorescent APC (G), followed by lymphocyte gating 
by FSC vs SSC plot (B, E, H). Computer-aided modeling of CFSE plot indicated that the 
peak of unstimulated cells (C) shifts to left (F and I) as cells divide. 
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(C) FO-CO (D) FC-CO 
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Figure 22. Suppression of CD4
+
 T cell division in mitogen-stimulated cultures as 
assessed by CFSE anlalysis. Δ Percentages of each generation in anti-CD3/28 stimulated 
CD4
+
 T cells. Purified CD4
+
 T cells were labled by CFSE. Following a 72 hr stimulation 
period ex vivo, CFSE profile was analyzed by flow cytometry as described in the 
Methods. Data are presented as the difference of percentage of cells in each daughter 
generation compared to the corn oil control diet group (CO, corn oil control; CC, CO+1% 
curcumin; CL, CO+0.02% limonin; FO, 4% fish oil+1% CO; FC, FO+1% curcumin; FL, 
FO+0.02% limonin, n=10-12 cultures from 5-6 mice, *P<0.05, 
#
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However, Lim and/or FO supplement did not alter Ag-specific CD4
+
 T cell proliferation 
(Fig. 23B,C,E). 
In parallel experiments, cell proliferation was quantified by uptake of radioactive 
[
3
H] thymidine (Fig. 24). In contrast to the CFSE analysis, thymidine uptake was not 
significantly altered in the response to mitogenic anti-CD3/28 mAbs. Ag-specific OVA 
peptide+APC-induced [
3
H] thymidine uptake was suppressed (P<0.05) by Cur 
supplementation to both CO and FO based diets by 30.82% and 43.40%, respectively. 
 
Discussion 
In order to investigate the anti-inflammatory properties of dietary curcumin and 
limonin, we assessed NF-B activity in mitogenic anti-CD3/28 mAbs or antigenic OVA 
peptide+APC stimulated murine CD4
+
 T cells. NF-B p65 nuclear translocation was 
suppressed by both 1% curcumin and 0.02% limonin. Since NFAT and AP-1 nuclear 
factors are reported to regulate not only IL-2 gene expression but also T cell 
proliferation/function (166, 173-175), NFATc1 and AP-1 c-Jun nuclear translocation 
were measured. Of interest, dietary curcumin and limonin did not suppress NFATc1 and 
c-Jun activation in response to either mitogen or antigen. The selective suppression of 
NF-B by dietary curcumin and limonin can be explained in part by the mechanism of 
protein activation. In a resting state, NF-B family proteins, i.e., c-Rel, p50 (NF-B1), 
p52 (NF-B2), p65 (RelA) and RelB, form homo- or heterodimers which are bound to 
the inhibitor of NF-B (IB). Once T cells are activated, IB is phosphorylated by IB  
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(A) CC-CO (B)CL-CO 
  
(C) FO-CO (D) FC-CO 
  
(E) FL-CO   
 
 
 
Figure 23. Suppression of CD4
+
 T cell division in antigen-stimulated cultures as 
assessed by CFSE anlalysis. Δ Percentages of each generation in OVA peptide+APC 
stimulated CD4
+
 T cells. Purified CD4
+
 T cells were labled by CFSE. Following a 72 hr 
stimulation period ex vivo, CFSE profile was analyzed by flow cytometry as described in 
the Methods. Data are presented as the difference of percentage of cells in each daughter 
generation compared to the CO control diet group (CO, corn oil control; CC, CO+1% 
curcumin; CL, CO+0.02% limonin; FO, 4% fish oil+1% CO; FC, FO+1% curcumin; FL, 
FO+0.02% limonin, n=10-12 cultures from 5-6 mice, *P<0.05, 
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Figure 24. T cell proliferation assessed by thymidine incorporation. Purified CD4
+
 T 
cells from each diet group were labeled with CFSE and cultured for 72 hr with either 
mitogenic or antigenic stimuli. Radioactive [
3
H]-thymidine uptake was counted using a 
liquid scintillation counter..DPM, disintegrations per minute; CO, corn oil control; CC, 
CO+1% curcumin; CL, CO+0.02% limonin; FO, 4% fish oil+1% CO; FC, FO+1% 
curcumin; FL, FO+0.02% limonin, n=10-12 cultures from 5-6 mice. 
 
 
kinases (IKK) and detaches from the NF-B dimer. Phospho-IB is further degraded by 
the proteasomal pathway in an ubiquitin-dependent manner (176). 
NF-B dimer migrates into the nucleus to bind to the response element of target 
genes including IL-2. In contrast, NFAT activation requires direct dephosphorylation of 
the nuclear factor by calcineurin (166), and AP-1 c-Jun is up-regulated by 
phosphorylation and formation of a heterodimer with newly synthesized c-Fos. This is 
noteworthy, because Milacic et al. (94) recently reported that curcumin directly binds to 
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and inhibits proteasomes, resulting in suppressed dissociation of IB  from NF-B and 
therefore NF-B suppression in a human colon cancer cell line. In addition, Aggarwal et 
al. (88) demonstrated that curcumin also inhibits IKK activity. With respect to dietary 
FO, our laboratory has previously reported that DHA, a major active fatty acid in FO, 
suppresses PKC, which also has IKK activity. Hence, we hypothesized that FO, 
curcumin and limonin affect different molecular targets; FO alters proximal signaling 
whereas the phytochemicals antagonize NF-B. In order to test this hypothesis, FO was 
combined with either curcumin or limonin.  
We further examined the consequence of the suppression of NF-B p65 by 
curcumin and limonin with respect to T cell function. IL-2 production was suppressed in 
antigen stimulated cultures, whereas mitogen stimulated cells produced the same 
amounts of IL-2 across the dietary treatments. The function of NF-B subunits in regard 
to T cell activation has been well studied (173). Liou et al. reported that c-Rel is required 
for lymphocyte proliferation (177). Rao et al. observed that IL-2 gene transcription in 
CD4
+
 T cells is dependent on c-Rel, but not p65 (178). In contrast, Lederer et al. 
reported that the p65-p50 heterodimer accounts for the NF-B-mediated IL-2 
upregulation (179). IL-2 secretion data from this study suggest that NF-B p65 does not 
directly regulate IL-2 production in CD4
+
 T cells. In addition to transcriptional 
regulation of IL-2, mRNA degradation in activated T cells was also reported (180). 
These previous findings suggest further studies are required to elucidate the mechanism 
by which diet influences IL-2 production and NF-B inhibition. 
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The functional result of dietary modulation was assessed by examining CD4
+
 T 
cell proliferation using two different methods. Purified CD4
+ 
T cells were labeled by 
CFSE and stimulated for 72 hr. Cells were either analyzed by flow cytometry or 
radioactive [
3
H]-thymidine incorporation. The advantage of CFSE analysis compared to 
the traditional thymidine incorporation assay was reported by others. Specifically, CFSE 
analysis has been shown to be more sensitive than the [
3
H]-thymidine assay to quantify 
cell division (181-183). The thymidine incorporation analysis demonstrated that cell 
proliferation was significantly suppressed by curcumin supplementation to either corn 
oil or fish oil based diets when T cells were stimulated by antigen peptide. Interestingly, 
T cell proliferation by mitogenic stimulation was not affected by dietary intervention. In 
contrast, CFSE data revealed that dietary curcumin supplementation to corn oil and fish 
oil diets suppressed T cell proliferation following both mitogenic- and antigenic 
stimulation compared to the CO control diet. To our knowledge, this is the first study to 
investigate the anti-inflammatory effects of FO with either curcumin or limonin on CD4
+
 
T cells. 
We next tested the hypothesis that dietary “combination therapy” by curcumin 
and limonin supplementation to fish oil maximally suppresses CD4
+
 T cell function. 
Interestingly, fish oil control diet (4% FO+1% CO) did not suppress NF-B activation. 
In contrast, our laboratory has previously demonstrated that dietary FO, as well as 
purified DHA, suppressed NF-B nuclear translocation in part by affecting fatty acid 
composition of plasma membrane including lipid rafts (77). These apparent disparate 
outcomes may be explained by the different mouse strain and stimuli used. In addition, 
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the use of homologous mouse serum during the long-term 72 h culture in the previous 
study may have augmented the lipid effect by maintaining an n-3 PUFA enriched 
membrane microenvironment (77).  
Fish oil diet suppressed IL-2 secretion, which was not further suppressed by 
curcumin or limonin supplementation. We further investigated the combination effect on 
T cell proliferation. In accordance with the NF-B data, CD4+ T cell proliferation was 
modestly affected in the FO control diet. This is likely explained in part by the loss of n-
3 PUFA from the plasma membrane in a long-term culture (30, 50). Limonin 
supplementation to the CO control diet did not suppress T cell proliferation either. Of 
interest, FO+Lim supplementation significantly suppressed T cell proliferation in anti-
CD3/28 stimulated cultures. Taken together, these data suggest that n-3 PUFA indirectly 
affect NF-κB activation by altering membrane composition, but curcumin and limonin 
directly suppress NF-κB translocation. The combination treatments were shown to 
augment the anti-inflammatory effects. 
In summary, the anti-inflammatory effects of dietary curcumin and limonin on 
CD4
+
 T cell proliferation are attributed in part to the suppression of NF-B. Interestingly, 
there was no obvious association between NF-B status and IL-2 secretion. We further 
show that the combination of fish oil and curcumin or limonin elicits a maximal 
suppressive effect with respect to CD4
+
 T cell activation.  
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CHAPTER V 
SUMMARY AND CONCLUSIONS 
 
Humans have an adaptive immune system consisting of cell-mediated and 
humoral immune responses. It is well known that CD4
+
 T cells control the balance 
between these two immune responses. Upon infection, the immune system differentiates 
into one of those two immune responses, or both, depending on the type of pathogen and 
the individual’s age, genetic background and environment such as diet. Interestingly, it 
has been reported that prolonged activation of CD4
+
 T cell-mediated immune responses 
contributes to many chronic inflammatory and autoimmune diseases . 
A growing  body of  epidemiological and clinical studies show that dietary fish 
oil, which is enriched in n-3 PUFA, attenuates immune-mediated inflammatory diseases 
(39-43).  The major bioactive constituents of fish oil are eicosapentaenoic acid (EPA) 
and docosahexaenoic acid (DHA). Inuit in Greenland, whose diets are rich in EPA and 
DHA from fish, exhibit a very low incidence of certain chronic inflammatory diseases 
(43, 184). Subsequently, many clinical trials also demonstrated that FO supplementation 
results in clinical improvement in patients with rheumatoid arthritis (40, 41), 
inflammatory bowel diseases (42, 43, 185), psoriasis (186-188), lupus (189), and 
multiple sclerosis (190-193). However, to date, detailed molecular mechanisms related 
to this beneficial effect have not been elucidated. 
CD4
+
 T cells can be further categorized into at least 4 subpopulations, Th1, Th2, 
Th17 and Treg cells, determined by cytokine secretion and transcriptional factor 
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activation (1-3, 7-9). Interestingly, Th1 and Th17 subsets have been thought to be 
responsible for chronic inflammation and autoimmune diseases (10-13). Our lab as well 
as others previously demonstrated that n-3 PUFA suppress Th1 clonal expansion ex vivo 
(30, 52), which may explain in part the beneficial effect of dietary fish oil. To extend 
these observations, we used an in vivo model by adoptively transferring OVA323-339 
peptide-specific DO11.10 CD4
+
 T cells into WT recipient mice. Following 
immunization by OVA peptide with complete Freunds’ Adjuvant, the accumulation of 
donor cells in recipient mouse draining lymph nodes were suppressed in fish oil fed 
animals (Fig.4 and 5). In addition, this lower number of cells can be explained by 
suppressed cell proliferation, determined by CFSE profile analysis (Fig. 6 and 7). 
To identify a unifying mechanism of pleiotropic n-3 PUFA on a variety of cell 
types, we examined the alteration of plasma membrane composition/function and 
consequent cell signaling by n-3 PUFA in CD4
+
 T cells. Using an endogenously n-3 
PUFA producing transgenic mouse model, i.e., the fat-1 mouse, we show that the 
accumulation of cholesterol/sphingolipid-enriched microsubdomain of plasma 
membrane, i.e., lipid rafts, at the immunological synapse was enhanced by n-3 PUFA as 
assessed by labeling with the fluorescent dye Laurdan which reflects the fluidity of the T 
cell membrane microenvironment (Fig. 10). Interestingly, the suppression of 
intracellular localization of signaling proteins (F-actin, PKC and PLC-1) into the IS 
was associated with enhanced lipid raft formation (Fig. 11). In addition, the 
phosphorylation status of PLC-1 at the IS was also down-regulated (Fig. 12). As a 
consequence, CD4
+
 T cells derived from fat-1 transgenic mice exhibited a suppressed 
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ability to proliferate as assessed by two independent methods, CFSE labeling (Fig. 14) 
and radioactive thymidine incorporation (Fig. 15). These findings are novel because 
lipid rafts are generally considered as platforms for T cell signaling and disruption of 
these subdomains has been postulated to be associated with suppressed T cell function. 
However, our data emphasize that not only the quantity of lipid rafts but also the 
quality/diversity of lipid rafts should be addressed in further studies. 
Phytochemicals are also proposed to prevent or treat chronic inflammation and 
cancers. Among several bioactive phytochemicals, curcumin and limonin have been 
suggested to suppress cellular “life signals” in part by suppressing the NF-B pathway in 
various cell types (100, 168-170). Curcumin is a yellow pigment found in curry and 
limonin is a byproduct of citrus fruit juice production. By feeding DO11.10 mice with 1% 
curcumin or 0.02% limonin diets, which were previously reported to represent 
physiologically relevant doses in humans (52, 88, 171, 172), we show that both 
curcumin and limonin suppress NF-B p65 nuclear translocation in CD4+ T cells (Fig. 
17). Further analysis of AP-1 c-Jun and NFATc1 revealed that these agents selectively 
suppressed NF-B (Fig. 18 and 19). CD4+ T cell proliferation was also suppressed by 
curcumin in response to either mitogenic or antigenic stimulation, as assessed by CFSE 
analysis (Fig. 22 and 23). In contrast, IL-2 production was not directly associated with 
the NF-B pathway (Fig. 21). Collectively, these data demonstrate that n-3 PUFA 
modulate proximal T cell signaling by enhancing lipid raft formation at the IS. In 
contrast, curcumin and limonin suppress NF-B activation. Interestingly, dietary 
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combination of fish oil with limonin further suppressed CD4
+
 T cell proliferation in 
response to anti-CD3/28 stimulation (Fig. 22).  
In summary, dietary n-3 PUFA, curcumin and limonin attenuate CD4
+
 T cell-
mediated immune responses in well-established mouse models. We propose that n-3 
PUFA modulate different molecular targets relative to curcumin and/or limonin. Hence, 
the combination of n-3 PUFA and curcumin or limonin may be capable of synergizing to 
suppress chronic inflammatory diseases. 
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A-1. DO11.10 Genotyping Results 
 
 
 
Objective: To test the genotype of DO11.10 breeders. 
Methods: Detailed protocol is available in Appendix B-1. 
Results: All five mice tested were identified as DO11.10 transgenic mice. 
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A-2. KJ1-26 staining controls 
 
          (A)    
 
            (B)    
 
           (C) 
 
           (D) 
 
 
 
 
Objective: To test the DO11.10 specific staining of KJ1-26. 
Methods: Single cell suspensions from lymph nodes of (A) KJ1-26 stained B10.D2 cells, 
(B) non-stained DO11.10 cells, (C) double stained DO11.10 cells without stimulation or 
(D) double stained DO11.10 cells with PMA/Ionomycin stimulation were analyzed by 
flow cytometry. Refer to Appendix B-2 for experimental details. 
Results: KJ1-26 stains DO11.10 cells specifically (A vs B). In addition, KJ1-26 and 
CFSE are detected in different channels (B vs C). 
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A-3. Representative GC profiles of Fat-1 phenotyping 
 
(A)  Representative chromatogram of a WT mouse 
 
 
(B) Representative chromatogram of a fat-1 mouse 
 
 
The protocol for fat-1 phenotyping can be found in Appendix B-3. 
 
 
18:2n-6 20:4n-6 
22:4n-6 
22:5n-6 
18:3n-3 
20:5n-3 
22:5n-3 
22:6n-3 
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(C) Examples of determining phenotypes by mol% of major tail snip fatty acids 
ID Sex 
n-6  (mol%) n-3 (mol%) 
n-6:n-3  
ratio* 
Phenotype** 18:2 20:4 22:4 22:5 Total 
n-6 
18:3 20:5 22:5 22:6 Total 
n-3 
835 F 19.7 1.2 0.4 0.3 21.6 2.1 1.7 1.2 1.3 6.3 3.4 Fat-1 
839 F 19.0 1.2 0.6 0.4 21.2 1.7 1.6 1.5 1.1 5.9 3.6 Fat-1 
841 F 19.2 1.7 0.7 0.6 22.2 1.5 1.5 1.4 1.3 5.7 3.9 Fat-1 
847 F 11.8 1.2 0 0 13.0 2.7 1.8 1.6 1.6 7.7 1.7 Fat-1 
822 M 15.8 6.6 1.5 1.3 25.2 0.0 0.0 0.0 0.0 0.0 
 
WT 
830 M 13.7 6.1 1.6 1.2 22.6 0.0 0.0 0.0 0.0 0.0 
 
WT 
820 F 17.3 1.3 1.0 0.6 20.2 1.7 1.8 1.3 1.0 5.8 3.5 Fat-1 
833 F 16.2 1.2 0.6 0.0 18.0 2.5 1.3 1.2 1.7 6.7 2.7 Fat-1 
843 F 19.9 1.1 0.5 0.4 21.9 1.6 1.5 1.1 1.1 5.3 4.1 Fat-1 
844 F 13.8 2.6 0 0 16.4 2.2 1.8 1.8 1.4 7.2 2.3 Fat-1 
818 M 19.6 1.2 0.6 0.4 21.8 1.3 1.4 1.1 1.0 4.8 4.5 Fat-1 
829 M 15.8 1.5 0.4 0.0 17.7 1.8 1.2 1.1 1.3 5.4 3.3 Fat-1 
832 M 16.3 1.3 0.5 0.0 18.1 2.1 1.1 1.0 1.2 5.4 3.4 Fat-1 
836 M 9.7 0.6 0.3 0.2 10.8 1.1 0.9 0.9 0.6 3.5 3.1 Fat-1 
837 M 18.9 1.5 0.5 0.4 21.3 1.4 1.4 1.5 1.3 5.6 3.8 Fat-1 
838 M 17.8 1.7 0.5 0.4 20.4 1.7 3.5 1.6 1.2 8.0 2.6 Fat-1 
845 M 12.6 1.3 0.6 0 14.5 2.7 2.3 1.6 1.4 8.0 1.8 Fat-1 
846 M 11.3 0 0.7 0.2 12.2 3.3 2.6 1.8 1.5 9.2 1.3 Fat-1 
819 F 19.1 5.4 1.5 1.2 27.2 0.2 0.0 0.0 0.0 0.2 136.0 WT 
826 F 18.7 0.6 1.5 1.3 22.1 0.5 0.0 0.0 0.3 0.8 27.6 WT 
828 F 22.1 6.3 1.3 1.0 30.7 0.3 0.0 0.0 0.3 0.6 51.2 WT 
840 F 20.2 5.6 1.4 1.3 28.5 0.2 0.0 0.0 0.0 0.2 142.5 WT 
848 F 18.3 6.8 1.6 1.7 28.4 0 0 0 0 0.0 
 
WT 
825 M 16.2 5.9 1.5 1.2 24.8 0.3 0.0 0.0 0.3 0.6 41.3 WT 
821 F 25.4 1.4 0.7 0.5 28.0 0.8 1.0 0.8 0.6 3.2 8.8 Fat-1 
827 F 16.2 1.1 0.5 0.0 17.8 1.9 1.4 1.2 1.6 6.1 2.9 Fat-1 
834 F 20.1 0.7 0.5 0.0 21.3 2.1 0.9 0.8 1.1 4.9 4.3 Fat-1 
823 M 8.5 0.6 0.9 0.0 10.0 3.2 2.0 1.5 2.0 8.7 1.1 Fat-1 
824 M 12.8 1.8 0.7 0.4 15.7 1.8 1.4 1.2 1.3 5.7 2.8 Fat-1 
* Examplary calculation of n-6/n-3 ratio: 21.6 / 6.3 = 3.4 (Mouse ID 835) 
** Phenotype is determined by n-6/n-3 ratio. Generally, n-6/n-3> 10 were identified as 
WT, whereas n-6/n-3 < 10 were classified as fat-1. 
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A-4. Representative RT-PCR plots of Fat-1 genotyping 
 
(A) Representative amplification plot of fat-1 genotyping  
 
 
The detailed protocol of fat-1 genotyping can be found in Appendix B-4. 
 
 
Fat-1 
WT 
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(B) CT values 
ID Sex Ct (min)* Genotype 
835 F 25.814 Fat-1 
839 F 25.519 Fat-1 
841 F 24.200 Fat-1 
847 F 23.966 Fat-1 
822 M 38.180 WT 
830 M - WT 
820 F 23.491 Fat-1 
833 F 26.199 Fat-1 
843 F 24.550 Fat-1 
844 F 26.330 Fat-1 
818 M 23.931 Fat-1 
829 M 33.698 Fat-1 
832 M 26.494 Fat-1 
836 M 27.693 Fat-1 
837 M 25.153 Fat-1 
838 M 26.719 Fat-1 
845 M 22.910 Fat-1 
846 M 23.854 Fat-1 
819 F - WT 
826 F - WT 
828 F - WT 
840 F 39.315 WT 
848 F 35.729 WT 
825 M - WT 
831 M 36.570 WT 
815 
  
WT 
816 
  
WT 
821 F 34.798 Fat-1 
827 F 32.998 Fat-1 
834 F 28.700 Fat-1 
842 F 25.835 Fat-1 
823 M 29.992 Fat-1 
824 M 27.640 Fat-1 
 
*In general, mice with Ct<30.000 min were classified as Fat-1.  
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A-5. Examples of GP-value calculation 
 
The detailed protocol can be found in Appendix B-8. 
 
A) Animal ID: 730W 
IS     Contact whole cell Non-contact whole cell 
IBlue IGreen 
GP-
value IBlue IGreen 
GP-
value IBlue IGreen 
GP-
value 
205.89 107.48 0.31 172.10 104.86 0.24 193.46 140.44 0.16 
Ex) (205.89-107.48) =0.31 212.85 149.02 0.18 231.25 166.58 0.16 
    (205.89+107.48) 213.35 156.37 0.15 198.51 141.94 0.17 
211.53 107.84 0.32 157.78 81.92 0.32 223.29 159.90 0.17 
240.93 127.06 0.31 158.71 82.52 0.32 195.39 132.65 0.19 
177.72 59.56 0.50 183.08 122.51 0.20 186.15 116.11 0.23 
168.14 94.74 0.28 200.68 136.23 0.19 182.58 125.51 0.19 
235.22 134.63 0.27 191.54 117.14 0.24 186.19 130.28 0.18 
225.80 124.22 0.29 162.55 99.04 0.24 194.30 133.93 0.18 
218.85 112.44 0.32 190.58 110.59 0.27 191.54 138.68 0.16 
233.16 116.52 0.33 177.23 113.63 0.22 189.02 120.28 0.22 
224.20 120.02 0.30 164.79 94.51 0.27 211.60 176.78 0.09 
213.68 123.52 0.27 182.00 125.21 0.18 188.91 115.67 0.24 
241.68 144.41 0.25 182.79 122.86 0.20 202.74 141.64 0.18 
212.40 97.74 0.37 173.73 115.03 0.20 200.09 139.12 0.18 
244.27 101.93 0.41 201.83 131.76 0.21 207.31 153.61 0.15 
218.98 122.83 0.28 200.51 126.87 0.22 205.56 145.09 0.17 
183.43 90.99 0.34 179.62 130.63 0.16 180.95 115.27 0.22 
181.98 87.57 0.35 189.30 133.59 0.17 214.76 150.62 0.18 
207.66 112.49 0.30 177.73 120.91 0.19 203.60 134.70 0.20 
189.74 86.16 0.38   
 
  195.13 142.63 0.16 
234.90 110.56 0.36       196.95 138.54 0.17 
 
B) Animal ID: 705F 
IS     Contact whole cell Non-contact whole cell 
IBlue IGreen 
GP-
value IBlue IGreen 
GP-
value IBlue IGreen 
GP-
value 
89.93 40.37 0.38 82.50 35.40 0.40 85.14 36.12 0.40 
169.01 51.45 0.53 96.05 38.88 0.42 70.39 24.49 0.48 
100.59 50.02 0.34 83.84 36.34 0.40 83.23 30.22 0.47 
169.49 82.83 0.34 73.63 29.32 0.43 82.57 29.86 0.47 
65.24 17.83 0.57 58.55 19.17 0.51 79.57 33.02 0.41 
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56.54 25.53 0.38 61.60 24.38 0.43 56.80 22.05 0.44 
133.69 35.23 0.58 83.76 30.00 0.47 93.39 34.47 0.46 
171.27 43.87 0.59 73.68 29.48 0.43 110.63 42.85 0.44 
109.11 41.49 0.45 50.67 19.36 0.45 79.22 30.92 0.44 
154.13 52.45 0.49 74.76 28.73 0.44 65.10 21.60 0.50 
124.75 26.99 0.64 52.63 18.72 0.48 53.85 25.91 0.35 
137.26 41.25 0.54 55.24 21.03 0.45 68.24 26.51 0.44 
122.38 28.33 0.62 62.08 22.70 0.46 82.49 31.96 0.44 
74.12 23.49 0.52 47.74 14.60 0.53 77.60 28.70 0.46 
   
  
 
  91.91 35.36 0.44 
            76.15 27.79 0.47 
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A-6. Calculation of % patching of signaling proteins 
 
 
Protein Phenotype # patching # nonpatching # total % patching SEM p-value 
F-actin Fat-1 35 66 101 34.653 4.735 0.020 
   
Ex) 35 / 101 × 100 = 34.653 % 
  
 
WT 20 17 37 54.054 8.193 
 
LAT Fat-1 27 47 74 36.486 5.596 0.193 
  WT 23 29 52 44.231 6.887   
p-LAT Fat-1 19 26 45 42.222 7.363 0.464 
 
WT 16 21 37 43.243 8.145 
 
PLCg1 Fat-1 24 68 92 26.087 4.578 0.081 
  WT 16 26 42 38.095 7.493   
p-PLCg1 Fat-1 27 32 59 45.763 6.486 0.034 
 
WT 27 15 42 64.286 7.394 
 
CARMA1 Fat-1 17 32 49 34.694 6.800 0.399 
  WT 25 52 77 32.468 5.336   
PKCθ Fat-1 28 71 99 28.283 4.526 0.055 
  WT 24 35 59 40.678 6.395   
 
The details of the microscope setting are described in Materials and Methods of Chapter 
III.  
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A-7. GM1 relative relocaliztion index (RRI) calculation 
 
 
Mouse ID Genotype Intensity  
at 
synapse 
Intensity  
in whole 
cell 
RRI Mouse ID Genotype Intensity  
at 
synapse 
Intensity  
in whole 
cell 
RRI 
818F Fat-1 99.97 45.99 2.173733 838F Fat-1 37.68 43.78 0.860667 
  Ex) 99.97 / 45.99 = 2.173733 828W WT 61.29 52.59 1.165431 
818F Fat-1 74.83 76.42 0.979194 828W WT 43.86 36.8 1.191848 
818F Fat-1 33.89 35.42 0.956804 828W WT 74.74 39.33 1.900331 
818F Fat-1 71.03 46.91 1.514176 828W WT 48.53 32.33 1.501083 
818F Fat-1 86.16 55.32 1.557484 828W WT 74.06 34.4 2.152907 
818F Fat-1 79.93 63.49 1.258938 828W WT 32.14 32.79 0.980177 
818F Fat-1 75.22 38.15 1.971691 828W WT 56.49 51.91 1.08823 
818F Fat-1 94.46 62.3 1.516212 828W WT 47.06 37.06 1.269833 
818F Fat-1 52.73 35.77 1.47414 828W WT 56.15 42.47 1.32211 
818F Fat-1 70.57 65.87 1.071353 828W WT 68.14 46.26 1.472979 
818F Fat-1 58.71 57.74 1.016799 828W WT 68.5 56.8 1.205986 
818F Fat-1 116.86 54.15 2.158079 828W WT 31.36 51.44 0.609642 
818F Fat-1 83.65 52.33 1.598509 848W WT 50.3 27.51 1.828426 
838F Fat-1 55.37 23.87 2.319648 848W WT 45.33 31.54 1.437223 
838F Fat-1 45.91 27.57 1.665216 848W WT 36.05 26.46 1.362434 
838F Fat-1 27.59 24.32 1.134457 848W WT 50.77 36.71 1.383002 
838F Fat-1 34.9 20.41 1.709946 848W WT 61.83 30.37 2.035891 
838F Fat-1 37.32 21.74 1.716651 848W WT 47.13 29.77 1.583137 
838F Fat-1 45.99 24.68 1.863452 848W WT 56.54 30.52 1.852556 
838F Fat-1 53.64 28.42 1.887403 848W WT 50.1 29.24 1.713406 
838F Fat-1 53.32 25.74 2.071484 848W WT 151.06 65.82 2.295047 
838F Fat-1 47.51 27.47 1.729523 848W WT 116.86 58.99 1.981014 
838F Fat-1 84.31 34.28 2.459452 848W WT 145.9 59.8 2.439799 
838F Fat-1 127.85 69.06 1.851289 848W WT 134.82 52.18 2.583749 
838F Fat-1 41.15 36.98 1.112764 848W WT 88.92 46.66 1.905701 
838F Fat-1 63.4 37.01 1.713051 848W WT 94.43 52 1.815962 
838F Fat-1 65.71 45.46 1.445447 848W WT 83.82 68.16 1.229754 
838F Fat-1 103.93 75.43 1.377834 848W WT 109.86 52.2 2.104598 
838F Fat-1 133.43 76.07 1.754042 848W WT 123.12 68.09 1.808195 
838F Fat-1 91.79 62.55 1.467466 848W WT 91.51 52.04 1.758455 
838F Fat-1 185.76 102.41 1.813885 848W WT 103.91 53.96 1.925686 
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A-8. Analysis of CFSE profiles using ModFit
LT
 
Animal  
ID Phenotype Stimulation 
% of cells 
Gen1 Gen2 Gen3 Gen4 Gen5 Gen6 Gen7 Gen8 Sum 
843F Fat-1 
anti-
CD3/28 
26.53 11.13 21.64 23.23 14.24 3.07 0.15 0.00 
99.99 
843F Fat-1 
anti-
CD3/28 
31.00 11.66 20.41 21.13 13.34 2.35 0.10 0.00 
99.99 
844F Fat-1 
anti-
CD3/28 
17.93 11.09 21.39 29.35 16.42 3.39 0.42 0.00 
99.99 
844F Fat-1 
anti-
CD3/28 
26.56 11.68 20.58 24.48 13.79 2.43 0.48 0.00 
100.00 
845F Fat-1 
anti-
CD3/28 
19.45 5.96 9.42 16.62 25.51 17.47 4.65 0.92 
100.00 
845F Fat-1 
anti-
CD3/28 
21.71 8.23 10.54 17.51 23.13 14.83 3.95 0.09 
99.99 
846F Fat-1 
anti-
CD3/28 
39.05 6.44 10.41 14.68 16.74 9.11 3.12 0.43 
99.98 
846F Fat-1 
anti-
CD3/28 
37.69 6.44 10.02 15.27 16.88 10.23 3.41 0.07 
100.01 
829F Fat-1 
anti-
CD3/28 
48.72 6.49 10.25 13.40 14.22 6.66 0.26 0.00 
100.00 
829F Fat-1 
anti-
CD3/28 
52.60 7.25 9.28 12.11 12.37 5.67 0.58 0.15 
100.01 
832F Fat-1 
anti-
CD3/28 
46.04 6.53 10.93 14.47 14.64 6.79 0.60 0.00 
100.00 
832F Fat-1 
anti-
CD3/28 
54.52 6.40 8.84 11.37 11.97 6.21 0.69 0.00 
100.00 
Mean 
  
35.15 8.28 13.64 17.80 16.10 7.35 1.53 0.14 100.00 
SEM 
  
3.79 0.63 1.45 1.48 1.11 1.29 0.45 0.07 0.00 
825W WT 
anti-
CD3/28 
21.42 12.23 25.16 27.30 12.77 1.09 0.00 0.00 
99.97 
825W WT 
anti-
CD3/28 
18.47 12.24 25.26 28.96 13.38 1.51 0.18 0.00 
100.00 
840W WT 
anti-
CD3/28 
22.63 9.17 18.77 26.01 18.82 4.16 0.43 0.00 
99.99 
840W WT 
anti-
CD3/28 
27.60 10.27 18.98 24.90 17.03 1.22 0.00 0.00 
100.00 
815W WT 
anti-
CD3/28 
24.36 8.90 14.76 22.62 19.75 7.39 2.09 0.10 
99.97 
815W WT 
anti-
CD3/28 
23.70 10.92 16.33 20.77 19.47 6.93 1.79 0.10 
100.01 
816W WT 
anti-
CD3/28 
23.14 11.27 15.17 20.34 19.15 8.41 2.52 0.00 
100.00 
816W WT 
anti-
CD3/28 
27.53 12.13 15.79 19.00 16.59 6.92 1.67 0.37 
100.00 
819W WT 
anti-
CD3/28 
37.29 6.91 10.81 14.55 16.55 10.62 3.09 0.17 
99.99 
831W WT 
anti-
CD3/28 
45.24 6.68 10.29 14.90 14.65 6.96 1.29 0.00 
100.01 
831W WT 
anti-
CD3/28 
52.40 6.00 9.16 11.94 12.31 6.39 1.76 0.04 
100.00 
Mean 
  
29.43 9.70 16.41 21.03 16.41 5.60 1.35 0.07 99.99 
SEM     3.27 0.70 1.63 1.68 0.83 0.96 0.32 0.03 0.00 
843F Fat-1 Hybridoma 66.49 16.29 10.71 5.12 1.11 0.28 0.00 0.00 100.00 
843F Fat-1 Hybridoma 56.27 20.08 13.12 6.87 3.30 0.36 0.00 0.00 100.00 
844F Fat-1 Hybridoma 60.32 17.14 12.86 6.49 3.19 0.00 0.00 0.00 100.00 
844F Fat-1 Hybridoma 56.40 18.51 13.53 7.71 3.20 0.65 0.00 0.00 100.00 
845F Fat-1 Hybridoma 19.44 21.53 23.99 23.82 9.09 2.02 0.11 0.00 100.00 
845F Fat-1 Hybridoma 17.64 22.72 25.55 22.83 8.86 1.78 0.63 0.00 100.01 
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846F Fat-1 Hybridoma 16.15 20.01 24.84 24.25 11.74 2.63 0.39 0.00 100.01 
846F Fat-1 Hybridoma 17.30 20.35 25.75 23.09 10.62 2.37 0.53 0.00 100.01 
829F Fat-1 Hybridoma 50.76 29.66 13.07 4.17 1.80 0.45 0.08 0.00 99.99 
829F Fat-1 Hybridoma 50.77 27.52 9.81 6.14 4.27 1.21 0.30 0.00 100.02 
832F Fat-1 Hybridoma 40.51 29.91 21.36 5.99 1.81 0.38 0.05 0.00 100.01 
832F Fat-1 Hybridoma 40.86 31.08 21.15 5.01 1.21 0.60 0.09 0.00 100.00 
Mean 
  
41.08 22.90 17.98 11.79 5.02 1.06 0.18 0.00 100.00 
SEM 
  
5.42 1.52 1.82 2.51 1.13 0.26 0.06 0.00 0.00 
825W WT Hybridoma 75.44 13.18 7.15 2.45 1.65 0.13 0.00 0.00 100.00 
825W WT Hybridoma 82.42 9.49 1.83 4.67 1.59 0.00 0.00 0.00 100.00 
840W WT Hybridoma 57.04 20.93 6.12 6.57 6.76 2.58 0.00 0.00 100.00 
840W WT Hybridoma 49.81 20.52 1.15 13.61 10.55 4.35 0.00 0.00 99.99 
815W WT Hybridoma 26.86 23.26 23.54 17.52 7.03 1.63 0.15 0.00 99.99 
815W WT Hybridoma 24.99 25.61 23.21 18.03 6.54 1.34 0.28 0.00 100.00 
816W WT Hybridoma 27.51 23.23 21.70 16.97 7.66 2.40 0.53 0.00 100.00 
816W WT Hybridoma 30.21 24.22 22.24 15.23 5.89 1.74 0.47 0.00 100.00 
819W WT Hybridoma 40.85 29.82 20.19 6.03 1.96 0.84 0.30 0.00 99.99 
831W WT Hybridoma 47.34 28.36 17.47 4.60 1.59 0.51 0.14 0.00 100.01 
831W WT Hybridoma 43.12 30.91 17.97 5.86 1.77 0.35 0.04 0.00 100.02 
Mean 
  
45.96 22.68 14.78 10.14 4.82 1.44 0.17 0.00 100.00 
SEM     5.85 1.99 2.67 1.83 0.96 0.39 0.06 0.00 0.00 
843F Fat-1 PMA/Iono 2.60 8.35 33.65 40.88 13.65 0.88 0.00 0.00 100.01 
844F Fat-1 PMA/Iono 1.29 7.91 33.55 42.83 13.29 0.94 0.18 0.00 99.99 
845F Fat-1 PMA/Iono 1.35 6.16 16.94 32.77 32.75 8.98 1.05 0.00 100.00 
846F Fat-1 PMA/Iono 1.45 5.24 16.49 35.22 32.80 7.88 0.91 0.00 99.99 
829F Fat-1 PMA/Iono 1.81 5.59 16.19 33.60 31.33 9.73 1.75 0.00 100.00 
829F Fat-1 PMA/Iono 1.80 5.27 15.78 34.04 31.18 10.08 1.85 0.00 100.00 
832F Fat-1 PMA/Iono 2.22 6.98 19.47 35.04 27.34 7.94 1.02 0.00 100.01 
832F Fat-1 PMA/Iono 2.21 7.72 20.84 34.22 26.51 8.02 0.47 0.00 99.99 
Mean 
  
1.84 6.65 21.61 36.08 26.11 6.81 0.90 0.00 100.00 
SEM 
  
0.17 0.44 2.69 1.30 2.88 1.32 0.24 0.00 0.00 
825W WT PMA/Iono 1.97 6.92 29.85 47.05 13.29 0.93 0.00 0.00 100.01 
840W WT PMA/Iono 2.02 7.66 29.38 47.04 2.44 11.46 0.00 0.00 100.00 
815W WT PMA/Iono 0.84 4.69 19.20 39.67 27.69 6.83 1.07 0.00 99.99 
816W WT PMA/Iono 1.44 5.82 21.37 40.20 24.25 6.40 0.52 0.00 100.00 
819W WT PMA/Iono 1.62 5.58 19.10 32.23 29.18 9.89 1.40 0.00 99.00 
831W WT PMA/Iono 2.28 7.98 22.82 35.87 24.22 6.20 0.63 0.00 100.00 
831W WT PMA/Iono 2.65 8.64 24.66 34.67 22.38 6.15 0.85 0.00 100.00 
Mean 
  
1.83 6.76 23.77 39.53 20.49 6.84 0.64 0.00 99.86 
SEM     0.22 0.54 1.68 2.20 3.57 1.26 0.20 0.00 0.14 
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A-9. Calculation of proliferation index using [
3
H]-thymidine labeling 
 
Animal  
ID 
Pheno 
type 
Stimulation DPM 
Proliferation  
index 
Animal  
ID 
Pheno 
type 
Stimulation DPM 
Proliferation  
index 
820F Fat-1 Basal 300.89   837F Fat-1 Basal 437.08   
820F Fat-1 Basal 333.98 
 
837F Fat-1 Basal 528.47 
 
820F Fat-1 
anti-
CD3/28 22940.86 72.27 837F Fat-1 
anti-
CD3/28 17075.63 35.37 
Ex) 22940.86 / [(300.89+333.98)/2] = 72.27 837F Fat-1 
anti-
CD3/28 17263.07 35.76 
820F Fat-1 
anti-
CD3/28 23364.47 73.60 837F Fat-1 Hybridoma 924.66 1.92 
820F Fat-1 Hybridoma 1333.45 4.20 837F Fat-1 Hybridoma 992.24 2.06 
820F Fat-1 Hybridoma 1380.92 4.35 837F Fat-1 PMA/Iono 28419.30 58.87 
820F Fat-1 PMA/Iono 32469.71 102.29 837F Fat-1 PMA/Iono 35842.43 74.24 
820F Fat-1 PMA/Iono 33314.80 104.95 
     
836F Fat-1 Basal 452.23 
 
671W WT Basal 254.12 
 
836F Fat-1 Basal 281.70 
 
671W WT Basal 269.56 
 
836F Fat-1 
anti-
CD3/28 16431.50 44.78 671W WT 
anti-
CD3/28 19185.40 73.27 
836F Fat-1 
anti-
CD3/28 17455.79 47.57 671W WT 
anti-
CD3/28 19315.09 73.77 
836F Fat-1 Hybridoma 826.34 2.25 671W WT Hybridoma 1290.44 4.93 
836F Fat-1 Hybridoma 689.81 1.88 671W WT Hybridoma 1082.17 4.13 
836F Fat-1 PMA/Iono 28658.36 78.10 671W WT PMA/Iono 28383.79 108.40 
836F Fat-1 PMA/Iono 28043.95 76.42 671W WT PMA/Iono 32508.94 124.16 
826W WT Basal 180.96   614F Fat-1 Basal 409.99   
826W WT Basal 327.74 
 
614F Fat-1 Basal 573.26 
 
826W WT 
anti-
CD3/28 14433.01 56.74 614F Fat-1 
anti-
CD3/28 10166.86 20.68 
826W WT 
anti-
CD3/28 14907.45 58.61 614F Fat-1 
anti-
CD3/28 14552.08 29.60 
826W WT Hybridoma 1297.22 5.10 614F Fat-1 Hybridoma 681.57 1.39 
826W WT Hybridoma 1194.43 4.70 614F Fat-1 Hybridoma 712.15 1.45 
826W WT PMA/Iono 34598.12 136.03 614F Fat-1 PMA/Iono 25079.85 51.01 
826W WT PMA/Iono 30501.95 119.92 614F Fat-1 PMA/Iono 29053.75 59.10 
821F Fat-1 Basal 366.18   671W WT Basal 75.49   
821F Fat-1 Basal 443.66   671W WT Basal 175.88 
 
821F Fat-1 
anti-
CD3/28 11501.18 28.40 671W WT 
anti-
CD3/28 11928.80 94.91 
821F Fat-1 
anti-
CD3/28 11890.73 29.37 671W WT 
anti-
CD3/28 12752.29 101.46 
821F Fat-1 Hybridoma 1109.09 2.74 671W WT Hybridoma 871.90 6.94 
821F Fat-1 Hybridoma 1337.15 3.30 671W WT Hybridoma 805.28 6.41 
821F Fat-1 PMA/Iono 28729.87 70.95 671W WT PMA/Iono 31679.00 252.05 
821F Fat-1 PMA/Iono 29416.13 72.65 671W WT PMA/Iono 34437.94 274.00 
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A-10. Mouse body weight change during curcumin and limonin diet feeding 
 
 
(g/mouse, mean±SEM) 
 
Initial 
after 1wk control  
CO diet 
after 2wk 
experimental diets 
CO* (n=4) 23.5±1.7 23.6±1.6 24.6±1.4 
CC (n=5) 23.0±1.6 22.9±1.8 23.9±1.4 
CL (n=5) 22.5±1.5 22.5±1.7 23.6±1.7 
FO (n=5) 21.8±1.3 22.0±1.7 22.7±1.8 
FC (n=5) 21.2±0.8 20.4±0.8 21.8±0.8 
FL (n=5) 21.1±1.9 21.4±1.9 23.0±1.6 
 
*CO, corn oil; CC, corn oil+curcumin; CL, corn oil+limonin, FO, fish oil; FC, fish 
oil+curcumin, FL, fish oil+limonin 
 
Conclusion: Mouse body weight gain was not statiscally (P>0.05) altered by 
experimental diet feeding. 
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A-11. Comparison of CD4
+
 T cell isolation kits (Miltenyi vs R&D sytems) 
 
 
 
(x10
6 
cells*/mouse, mean±SEM) 
 Miltenyi** R&D systems 
 After column After CFSE staining After column 
DO11.10 5.11±0.90 (n=4) 2.19±0.33 (n=4) 0.44±0.215 (n=2) 
Balb/C 15.34 (n=1) 10.07 (n=1) 2.71 (n=1) 
 
 
* Viable CD4
+
 T cells were counted by Trypan Blue exclusion method using 
hemacytometer (Appendix B-2, Section I.5) 
 
** Detailed procedures of CD4
+
 T cell isolation using either R&D Systems 
or Miltenyi are described in Appendices B-2 and B-5, respectively. 
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A-12. Purity of CD4
+
 T cells isolated using Miltenyi system 
 
 
CD4
+
 T cell purity (C57BL/6, analyzed by BD FACSCalibur) 
  
 
Methods: CD4
+
 T cells were isolated as described in Appendix B-5. Purified cells were 
stained with 1 µg/ml rat anti-mouse CD4-FITC (Invitrogen, cat# MCD0401) at the cell 
density of 1×10
7
 cells/ml. 
Resultis: CD4
+
 T cell purity = 91.97 ± 1.05 % (n=3) 
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A-13. Optimization of antigenic stimulation of DO11.10 CD4
+
 T cells 
 
 
 
 
 
 
Objective: To set the optimum cell concentrations for antigenic DO11.10 CD4
+
 T cell 
proliferation. 
Methods: Purified CD4
+
 T cells were purified by Miltenyi beads (refer to Appendix B-5 
for details). APC were prepared from Balb/C spleens by lympholyte-M. Cells were co-
cultured in total 200µl complete RPMI medium in 96-well plates at different 
concentrations as indicated, in the presence of OVA peptide for 72 h at 37
o
C. (The 
detailed protocol for APC preparation and OVA stimulation can be found in Appendix 
B-10). For the last 6 h of culture, cells were pulsed with 4 µCi [
3
H]-thymidine/well. 
Following culture, cells were harvested and thymidine uptake was counted using liquid 
scintilation. 
Results: 1x10
5
 CD4
+
 T cell and 2x10
5
 CD4
+
 T cell exhibited the maximal stimulation. 
We decided to use 2.5x10
5
 CD4
+
 T cells in future studies. 
  
 
1x105 1x105 1x105 1x105 1x105 1x105 CD4+ cells 
1x105 
OVA 
V 
2x105 
- 
IV 
- 
P/I 
III VI II I  
2x105 - - APC 
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A-14. Test to evaluate the effect of CFSE labeling on CD4
+
 T cell proliferation 
 
 
 
 
Objective: To test the cytotoxicity of CFSE on CD4
+
 T cell proliferation. 
Methods: CD4
+
 T cells were purified from C57BL/6 by Miltenyi beads. Cells (at >10
7
 
cells/ml) were labeled with 5 µM CFSE in the presence of 5% FBS in PBS. Washed 
cells were stimulated for 72 hr by either control media, plate bound anti-CD3 
Ab+soluble anti-CD28 Ab or PMA+Ionomycin. Following stimulation, 4µCi [
3
H]-
thymidine was added in the culture for 6 hr. Cells were harvested and thymidine 
incorporation was measured by liquid scintilation counting. Data are expressed as 
disintegrations per minute (DPM). 
Results: CFSE labeled CD4
+
 T cells were responding to anti-CD3/28 mAbs and 
PMA/Ionomycin, indicationg that CFSE was not toxic to cells at this concentration in 
the presence of 5 % FBS in PBS. We decided to use FBS to protect cells from 
cytotoxicity of CFSE and the protocol was modified  as Appendix B-10. 
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A-15. Jurkat cell Laurdan labeling test 
 
 
  
 
Objective: 1) To set the Laurdan labeling protocol for Jurkat cells. 
2) To confirm Jurkat (clone E6-1, ATCC, cat# TIB-52) cells and Raji 
(ATCC, cat# CCL-86)+SEE (Toxin Technology, cat# ET404) form an 
immunological synapse (IS). 
Methods: Raji cells (10x10
6
 cells) were labled with 5µM CMTMR (Molecular Probe, 
cat# C2927) for 15 min and treated with 10 µM mitomycin C (Sigma, cat# M0503) in 
PBS for 20 min. Jurkat cells were washed and labeled by 10 µM Laurdan for 10 min. 
Excess Laurdan was washed out and Jurkat cells were cocultured with SEE pulsed Raji 
cells for 30 min at 37
o
C. Following incubation, 2-photon microscopy was performed. 
(The detailed Laurdan labeling protocol can be found in Appendix B-7). 
Results: Laurdan labeling was acceptable to measure GP-values. Jurkat and Raji cells 
formed an IS. 
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A-16. The effect of n-3 PUFA on GP-values at the IS of Jurkat-Raji co-culture 
    (GP-value, mean±SEM, n=12-22 cells) 
 Noncontact whole cell Immunological synapse 
AA 0.087±0.012 0.131±0.013 
DHA 0.089±0.009 0.163±0.023 
EPA 0.085±0.008 0.163±0.017 
 
Objective: To confirm the enhancement of lipid raft formation at the IS as shown in 
Chapter II using Jurkat-Raji co-culture system. 
Methods: Jurkat T cells (clone E6.1, ATCC) were treated with BSA complex of either 
control AA, DHA or EPA [50 µM] for 72 hr. 10 M Laurdan labeled cells (detailed 
protocol can be found in Appendix B-6) were washed and co-cultured with [5 µg/ml] 
superantigen Staphylococcal Enterotoxin E (SEE, Toxin Technology) pulsed Raji cells 
for 30 min. 2-Photon microscopy was applied to capture Laurdan images (n=12-19 cells). 
GP-values at the IS or noncontact whole cells were calculated as described in Appendix 
B-8. 
Results: The formation of IS resulted in an increase in lipid rafts consistent with 
previous observations (110). In accordance with the results in Chapter III, n-3 PUFA 
(DHA and EPA) tended to increase GP-values at the IS compared to control n-6 PUFA. 
Further studies are required to draw statistical conclusion. 
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A-17. Kinetics of GP-value increase following IS formation by Jurkat-Raji cells 
 
  
Objective: To test if the increase of the GP-value at the IS is dependent on IS formation 
and physiological cellular function. 
Methods: Laurdan labeled Jurkat T cells were co-cultured with Raji cells, which were 
either pulsed with SEE or a control medium. Mixed cells were incubated on the ice to 
block cellular function or 37 
o
C incubator for 15 or 30 min prior to imaging. Laurdan 
images were captured and GP-values were calculated as described in Appendix B-8. 
Results: GP-values at the IS increased only in the presence of SEE at 37 
o
C, indicating 
that the index is dependent on IS formation and cellular function. GP-values at the IS 
were not significantly (P>0.05) different at both time points (15 or 30 min).  
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A-18. Comparison of cell count by hemocytometer and Coulter counter  
 
 
 
 
Objective: To test if the Coulter counter can be used for T cell quantification. 
Methods: Purified CD4
+
 T cells by Miltenyi beads were resuspended in 1ml medium. 
Cells were subsequently counted by either Trypan Blue exclusion method using 
hemocytometer or Coulter counter (4 µm) as described in Appedice B-2 and  B-6 (n=3). 
Results: The cell numbers counted by the two different methods correlate at R
2
=0.9894. 
We concluded that Coulter counter can be used to count CD4
+
 T cells. 
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A-19. Controls for nuclear factor activation measurements 
(A) NF-B 
 
(B) NFAT 
 
(C) AP-1 
 
Objective: To confirm the sensitivity of nuclear factor detection ELISA kits (Active Motif, cat# 
40097, NF-B p65; 40296, NFATc1; 46096, AP-1 c-Jun). 
Methods: Standard nuclear extracts (provided in the kit) were quantified using kits as described 
in the Methods. Extracts were serially diluted in order to measure the dose-dependent 
colorimetric readouts. Wild-type or mutant oligonucleotides, which were included in the kits, 
were added into buffer to confirm the specificity of each kit. 
Results: The readouts were affected in a dose-dependent manner and selectively 
responded to nuclear factors. 
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A-20. Standard curve of IL-2 secretion measurements 
 
Objective: To confirm the sensitivity of IL-2 detection ELISA kit (R&D Sytems, cat# M2000). 
Methods: IL-2 standard solution was serially diluted and measured by linear regression of 
spectrophotometry readouts according to the manufacturer’s manual. 
Results: The IL-2 detection kit responded in dose-dependent manner. 
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A-21. Propidium iodide uptake of APC as determined by flow cytometry 
 
(A) Hybridoma (B) CD4
+
 T cell (C) CD4
+
 T cell + hybridoma 
co-cumture 
   
 
 
 
 
Objective: To gate viable CD4
+
 T cells from non-viable cells and APC. 
Results: Hybridoma exhibited propodium iodide (PI, 1mg/ml) uptake in red channer (A) 
and a subpopulation of CD4
+
 T cells were PI
+
 (B). Overall, viable CD4
+
 T cells were 
gated by drawing a polygon (C). 
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A-22. Gating of viable lymphocytes by side scatter properties using flow cytometry 
 
 
(A) FSC vs SSC (B) Propidium iodide uptake 
 
 
 
 
 
Objective: To gate viable lymphocytes by flow cytometry. 
Results: Population 1 (P1) determined by FSC vs SSC property exhibited higher 
propidium iodide uptake properties, indicating that P1 is non- or less viable. Therefore, 
we decided to use P2 for further analyses. 
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P1 
  
 
134
A-23. Images of CD4
+
 T cell culture 
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Methods: Purified CD4
+
 T cells were labeled with 5 M CFSE (Appendix B-10) to 
trace cell division in PBS with 5% FBS. 1x10
5
 cells were cultured in total 200 L 
complete medium in 96-well plates with or without stimuli. Representative images were 
captured at 2 h, 48 h and 68 h (10x objective). 
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APPENDIX B 
EXPERIMENTAL PROTOCOLS  
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B-1. DO11.10 Genotyping  
(From Ping Zhang) 
 
Primers: 
#0786  CAG GAG GGA TCC AGT GCC AGC 
#0787 TGG  CTC  TAC AGT GAG TTT GGT 
 
 
Reaction Mix: 
PCR Platinum supermix    45 µl 
#0786 (10pmol/ul each)  0.5 µl 
#0787 (10pmol/ul each)   0.5 µl 
~75 to 100 ng DNA   ~75-100 ng 
Water     To 50 µl total volume 
 
 
PCR Parameters: 
 
94
o
C 6 min 
 
30 cycles of: 
94
 o
C 1 min 
 64
 o
C 1 min 30 sec 
 72
 o
C 2 min 
 
72
 o
C 10 min 
4
 o
C ∞ 
 
 
DNA Gel 
10 µl PCR product  
1.1 µl 10x sample dye,  
quick mix.  Heat at 65°C for 5 min.  Run at 4% EtBr-agarose gel (Reliant Gel System, 
Cambrex, #54927) (with 0.5X TAE running buffer) at 200V in cold room for 1 to 1.5 hr.  
Also, include 5 µl MW marker (Hyperladder IV, Bioline#BIO-33029) 
 
Band is approx. 300 bp 
Refer to Appendix A-1 for a representative image.  
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B-2. Protocol for Adoptive Transfer Study  
 
 
 
 
I. Isolate splenocytes and CD4+ T cells  
1. Spleen and Lymph nodes Isolation 
A. Materials 
i) DO11.10 mice. 
ii) Sterile tools (scissors and forceps). 
iii) 70% EtOH. 
iv) Labeled 15 ml conical tube filled with 3 ml complete RPMI. 
B. Methods 
i) Sacrifice mice by CO2. 
ii) Place a mouse with abdomen facing up. 
iii) Apply 70% alcohol to the abdomen area. 
iv) Grab the skin of the abdomen with forceps and make a small incision. 
v) Peel the skin to expose the membrane underneath. 
vi) Find the lymph nodes under the arms. Pinch the lymph nodes off and 
tease off the connect fat, put them in a tube containing complete 
RPMI.  
vii) Make an incision in the membrane at abdomen and find the 
mesenteric node. Get it and put in the above tube.  
viii) Turn the mice around and find the spleen. 
ix) Remove the spleen with forceps while cutting the fat tissue with 
scissors. 
x) Carefully remove as much fat as possible. 
DO11.10
Washout diet Exp diet Kill
CD4+ T cell
CFSE label
B10.D2
Washout diet Exp diet
Adoptive transfer
Immunize (OVA) Kill
KJ1-26 label
Flow
1wk 2wk
1wk 2wk 1d 3d
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xi) Place the spleens in a conical tube containing complete RPMI. 
 
2. Spleen and lymph node cells preparation 
A. Materials 
i) Sterile glass-in-glass homogenizers. 
ii) Sterile wire filters. 
iii) 5 ml syringes. 
iv) 20 gauge needles. 
v) 15 ml conical tubes. 
B. Methods 
i) Transfer spleen and lymph nodes into corresponding glass-in-glass 
homogenizers. 
ii) Homogenize spleens until completely broken up (5-7 strokes) and 
homogenize the lymph nodes in the same way (only 3-4 strokes will 
be enough). 
iii) Assemble a 5 ml syringe, wire filter and 20 gauge needle unit and 
place on top of a newly labeled 15 ml conical tube. 
iv) Remove the syringe plungers and transfer the appropriate spleen and 
lymph node suspension into the assembled units. 
v) Slowly reinsert the plunger to filtrate the suspension into the 
corresponding tube (be gentle with this step). 
vi) Fill each tube with RPMI for washing and centrifuge at 200x g 
(acc/bcc=6) for 5 min at RT. 
vii) After the spinning, carefully aspirate the RPMI. 
viii) Resuspend cells in 3 ml complete medium. 
 
3. Isolation of lymphocytes by Lympholyte-M  
A. Materials 
i) Lympholyte-M (Cedarlane Laboratories, Cat# CL5030) warmed to 
RT . 
ii) 1x column buffer (Provided in column kit). 
iii) Monoclonal antibody (Provided in column kit). 
iv)  PBS/5% FBS (regular, not heat-inactivated). 
B. Methods 
i) Add 3 ml of Lympholyte-M by layering it beneath the suspended cells 
(insert the pipet tip into the bottom of the conical tube then dispense 
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the Lympholyte-M slowly and carefully in order to see 2 distinct 
layers). 
ii) Centrifuge the cells at 500x g for 15 min (deactivate centrifuge break 
by setting acc/dcc=0) at RT. 
iii) After spinning, 2 distinct layers (white on top and pink on bottom) 
and an interface band should be seen. 
iv) Carefully remove the interface band with a pipette and dispense into a 
new conical tube. 
v) Fill the conical tube with RPMI, mix and centrifuge at 200x g for 5 
min at RT. 
vi) Aspirate off the RPMI. 
vii) Combine all lymph node cells with 1 ml PBS/5% FBS. Lymph node 
cells are ready for CFSE staining (previous studies confirmed that 
more than 90% of lymph node cells are CD4
+
 T-cells). 
viii) Mix 1 vial (0.5 ml) of antibody cocktail to every splenocyte tube, and 
incubate at RT for 15min. (At this point, begin column washing). 
ix) Wash cells with 10 ml of 1x column buffer at 200x g for 5 min. 
x) Resuspend in 1ml of 1x column buffer. 
 
4. CD4+ T cell purification 
A. Materials: 
i) R&D CD4+ columns-small (Cat# MCD4C-1000) at RT. 
ii) R&D column rack. 
iii) 70% EtOH. 
iv) Waste receptacle. 
v) Timers. 
vi) Sterile 15 ml conical tubes. 
B. Methods: 
i) Place the T cell columns in the R&D column rack and place a waste 
receptacle beneath the columns. 
ii) To prepare the columns, remove the top cap first, and then remove the 
bottom cap. 
iii) Allow the fluid within the column to drain until dripping stops; 
meanwhile rinse the outside of the column tip with 70% EtOH. 
iv) Wash the column with 6 ml of 1x column buffer. 
v) Replace the waste receptacle with a newly labeled sterile 15 ml 
conical tube. 
vi) Apply 1 ml cell suspension to the top of the column. 
  
 
140
vii) Allow the cells to sit in the column for 10 min at RT. 
viii) Apply 8 ml of 1x column wash buffer to the column to elute the CD4+ 
T cells. 
ix) Once all the T cells have been collected, centrifuge at 200x g for 5 
min at RT. 
x) Aspirate the supernatant, and combine purified splenocytes with 
lymph node cells in 1 ml PBS/5% FBS.  
xi) Now cells are ready to be counted (lymph node cells are thought as 
CD4
+
 T cells). 
 
5. Cell counting by hemacytometer 
A. Materials: 
i) Trypan blue (Sigma, cat# T8154). 
ii) Eppendorf tubes. 
iii) Hemacytometer. 
B. Methods: 
i) Add 180 L H2O and 10 L Trypan blue to an epi-tube. 
ii) Mix the T cells and remove 10 L to add to a sample tube with 
Trypan blue. 
iii) Mix by pipetting up and down several times. 
iv) Remove about 20 L from the suspension and put in a hemacytometer. 
v) Count the viable white cells by microscope at 10x magnification 
(count at least 200 cells) 
                Cell concentration (cells/ml) =  (cell count)/(squares)  104   20 
                          
 
II. CFSE labeling of CD4+ T cells 
A. Materials 
i) BSA: IgG free, Boehringer Mannheim Laboratory Reagents, 100018 
(non-sterile). 
ii) PBS/0.1% BSA : filter thorough 0.2 µm filter to sterilize. 
iii) Carboxyfluorescein succinimidyl ester (CFSE, Molecular probes V-
12883). 
- To prepare 10 mM CFSE, dissolve one vial (50 µg) in 90 µl 
DMSO. 
- Aliquot 10 µl in epi-tubes. 
- Store at -20 oC up to a month. 
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iv) RPMI 1640/10% FBS (regular). 
B. Methods; 
i) Add 1µl of 10mM CFSE in the tube containing cells. Vortex 
IMMEDIATELY. 
ii) Incubate at 37 oC. (in water bath) for 10 min . 
iii) Add 5 ml of ice-cold RPMI 1640/10% FBS and incubate for 5 min on 
ice. 
iv) Fill the tube with sterile PBS, spin down (200x g, 5min) and aspirate 
supernatant. 
v) Resuspend cells at 3x107 cells/ml in PBS and load 100 µl into 30 
gauge insulin syringes (BD, cat# 328438). 
vi) Put syringes on ice and bring over to LARR for tail injection. 
 
III. Immunization (D+1) 
A. Materials 
i) Sterile PBS. 
ii) OVA323-339 peptide (ISQAVHAAHAEINEAGR, synthesized by 
Biosource, Inc) needs to be warmed to RT before use. 
iii) Complete Freund’s adjuvant (CFA), Sigma #F-5881. 
iv) Micro-emulsifying needles 73mm, Popper & Sous, Inc., New Hyde 
Park, N.Y., #7973. 
v) 1 ml BD Luer-Lok syringe, #309585. 
vi) 3 ml BD Luer-Lok syringe, #309628. 
vii) 25 5/8 G needle BD #305122. 
B. Methods 
i) One day after tail injection, dissolve OVA peptide in PBS. (We want 
final concentration 6 mg/ml, 1mg in a bottle, thus dissolve 6 bottles in 
1 ml PBS). 
ii) Emulsify with 1 ml CFA (Add OVA peptide in a syringe at one end 
of the mixing tube, then add 1 ml of CFA to another syringe attached 
to the other end of the mixing tube, push through the mixing tubes 
until it is really hard to push, which means it is ready). 
 OVA peptide conc. is diluted half (3 mg/ml). 
iii) Inject subcutaneously in a total volume of 0.1 ml (300 µg OVA 
peptide per mouse) distributed between two dorsal sites on the back 
with 25 5/8 needle. 
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IV. Flow detection of antigen-specific cells 
A. Materials 
i) 0.2um Nylon membrane filter, Gelman Laboratory, #4433. 
ii) Staining buffer. 
- Sterile PBS. 
- 1% heat-inactivated FBS. 
- 0.09% sodium azide. 
- adjust pH to 7.4-7.6, filter, store at 4 oC. 
iii) Fc Block (5 µg/ml). 
: diluted from Fc Block stock (0.5 mg/ml, Pharmingen, cat# 553142) 
(4 µl Fc Block + 396 µl staining buffer). 
iv) KJ1-26 anti-TcR-Cy5.5 (0.2 mg/ml), Caltag Laboratories #MM7506. 
v) 1.5 ml microtubes. 
vi) 12x75 mm Polystyrene tubes (BD, cat# 352054). 
B. Methods 
i) Sacrifice B10.D2 recipient mice and get draining lymph nodes in 3 ml 
complete RPMI (15 ml conical tube). 
ii) Sacrifice 2 B10.D2 control mice (without donor cells), and get 
draining lymph nodes (for KJ1-26 negative control). 
iii) Sacrifice 2 DO11.10 mice, and get draining lymph nodes (for KJ1-26 
positive control) 
iv) Homogenize lymph nodes and wash with complete RPMI medium. 
v) Count viable cells by Trypan blue exclusion. 
vi) Resuspend cells in 100 µl of 5 µg/ml Fc Block and incubate at 4 oC. 
for 15min. 
vii) Add 5 ml staining buffer, centrifuge (200x g, 5 min, RT) and aspirate 
supernatant. 
viii) Resuspend cells in 100 µl KJ1-26 antibody diluted in staining buffer 
(KJ1-26 dilute to 2 µg/ml: 4 µl KJ1-26 + 396 µl staining buffer) and 
incubate in dark at 4 
o
C for 30 min. 
ix) Add 5 ml staining buffer into the tube, spin down (200x g, 5 min, RT) 
and aspirate. 
x) Resuspend cells in 500 µl staining buffer and transfer to FACS tubes. 
xi) Promptly take samples for flow cytometer analysis in ice. 
 
 
  
  
 
143
B-3. Fat-1 phenotyping 
(modified from Yang-Yi Fan’s protocol) 
 
*Always keep the samples in ice. 
I. Prepare leak proof tubes (D-1) 
1. Put 1 ml acetone in 12 ml glass tubes with black Teflon caps. 
2. Evaporate for 1hr in 80 oC oven. 
3. Check if acetone has evaporated. 
 
II. Extract total lipid (D-0) 
1. Preset centrifuge at 4 oC. 
2. Clean 12 ml tubes. 
A. Work in hood. 
B. Pour out acetone (into brown waste bottle). 
C. Put upside down on the rack (don’t mix the caps). 
D. Clean the tubes with 1 ml methanol (GC grade) using glass pipette. 
E. Dry down the tube. 
3. Put 1 ml 0.1 M KCl (in walk-in refrigerator) with plastic pipette into 2 ml epi-
tubes. 
4. Cut the mouse tail to small pieces using glass plate and blade, into the tube from 
#3. 
5. Homogenize the sample with Polytron blade (Ultra-Turrax T8, IKA 
Labortechnik) at speed 5 for 15 sec. (Put the sample tube on ice during the 
homogenization). The tail mixture will turn brownish color. 
6. Add 5 ml of Folch (CHCl3/MeOH, 2:1, v/v) into 12 ml glass tube, then transfer 
the sample to the tube. 
7. Vortex the sample for 1min. 
8. Centrifuge the sample at 3000rpm for 5min at 4 oC. (Put the glass tube inside 
plastic tube wrapper to avoid breaking during the centrifugation). After 
centrifugation, set centrifuge temp. at 20 
o
C. 
9. Transfer lower phase to a leak-proof 12 ml glass vial with Pasteur glass pipette. 
Push the bulb to make bubbling during passing the upper phase to avoid 
contamination. After getting out the pipette, throw away 1-2 drops. 
10. Wipe the needles of N2 dryer with MeOH in the hood. 
11. Dry sample under N2 
12. Mix 6% HCl-MeOH under the hood near walk in freezer. (HCl is under the hood, 
and GC-grade MeOH is near the balance). Use mass cylinder to measure. 
13. Add 3 ml 6% HCl-MeOH to the tube. 
14. Flush sample with N2, close cap tight. 
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15. Vortex and incubate at 76 oC oven for ~15 hrs. 
16. Prepare 4 ml tubes with labels. (Recap with green Teflon caps). 
 
III. Extract FAME (D+1) 
1. At this time, turn on GC 
2. Set centrifuge at 4 oC. 
3. Extract FAME by adding 1 ml cold 0.1M KCl and 2 ml Hexane to the 
methylated sample. Vortex for 1min, centrifuge at 3000rpm for 5min at 4 
o
C. 
4. Transfer upper phase to 4 ml glass vial. 
5. Dry FAME under N2. 
6. Redissolve the sample in 25ul methylene chloride (CH2Cl2) using wiretrol. 
7. Vortex the tubes in order to dissolve all the FAME on the wall. 
8. Ready for running on GC. 
 
IV. GC analysis 
1. Turn on GC, stabilize for 15min. 
2. Turn on computer, open 32 Karat 7.0 
3. Click on GC, then OK. 
4. Click on single run icon (Blue single arrow), the screen shows “waiting for 
trigger” 
5. Then, inject std (68A std, Nuchek) 
A. Find the tube with yellow tag in -20 oC. freezer 
B. Vortex. 
C. Rinse the inject needle with CH2Cl2. 
D. Load 0.5 µl std in the needle: avoid any bubble. 
E. Push the needle into injector inlet, the push the plunger. 
F. Pull back the needle, then press “start” button on GC machine. 
G. After injection, flush the tube with N2. 
H. Put back in -20 oC. freezer. 
6. Vortex the sample and inject in the same way. 
7. For the report, 
A. Click “3.2 Karat”, then “offline GC”. 
B. Data  Open (D\GC\GCdata\wooki). 
C. Method  integration events  minimum area  adjust  green (analyze). 
D. Ctrl+z : escape highlight. 
E. Method  custom report. 
F. Double click on graph to change the Y axis range. 
  
 
145
B-4. Fat-1 genotyping 
(modified from Yang-Yi Fan and Evelyn Callaway’s protocols) 
 
 
I. Isolation of total DNA from mouse tail. 
1. Material. 
A. Mouse tail (~1cm), frozen in liquid nitrogen. 
B. DNeasy Tissue Kit (Qiagen, cat# 69504). 
C. Other buffers are provided in the kit. 
 
2. Preparation of reagent. 
A. For the first time use, add appropriate amounts of 100% EtOH to Buffers 
AW1 and AW2 as indicated on the bottles. 
B. Prewarm 55 oC shaking water bath (set at 75 rpm). 
 
3. Procedure (It is better to do this in the late afternoon). 
A. Perform all steps in RT, vortex for 5-10 sec. unless specified. 
B. Allow the frozen tail to warm to RT. Put the tail on a new glass slide. 
C. Cut the tail into smaller pieces using brand new or DNA away-zapped razor 
blade. 
D. Transfer the tail pieces to a new 2 ml sterile epi-tube. 
E. Add 180 uL Buffer ATL to the tube. 
F. Add 20 uL proteinase K to the tube and vortex (make sure all pieces are 
down) 
G. Incubate the tube (on a floating platform) in 55 oC. shaking water bath (75 
rpm) overnight (~16-18 hr). 
 
------------------------ Overnight---------------------------- 
H. Mix 200 uL Buffer AL and 200 uL 100% EtOH to make Buffer ALE for each 
sample, using DNase free pipette-tips. (Make fresh) 
I. Remove the tube from the water bath. Vortex for 15 sec. 
J. Add 400 uL Buffer ALE to the sample, and mix vigorously by vortexing 
(make sure it mixes thoroughly) 
K. Pipette the mixture into DNeasy Mini spin column placed in a 2ml collection 
tube (kit provided). 
L. Centrifuge at >6000 x g (8000 rpm) for 1 min. (Eppendorf centrifuge 5414D) 
M. Discard flow-through and collection tube. 
N. Place the DNeasy Mini spin column in a new 2 ml collection tube (provided). 
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O. Add 500 uL Buffer AW1, and centrifuge for 1 min at >6000 x g (8000 rpm). 
P. Discard flow-through and collection tube. 
Q. Place the DNeasy Mini spin column in a new 2 ml collection tube (provided). 
R. Add 500uL Buffer AW2, and centrifuge for 3 min at 20,000 x g (14,000 rpm) 
to dry the DNeasy membrane. (Centrifuge 5417R) It is important to 
completely dry the membrane, since EtOH will interfere with subsequent 
reactions. 
S. Discard flow-through and collection tube. 
T. Place the DNeasy Mini spin column in a new sterile 2 ml collection tube with 
lid (not provided). Pipette 200 uL of Buffer AE directly onto the DNeasy 
membrane. 
U. Incubate at RT for 1 min, then centrifuge for 1 min at >6000 x g (8000 rpm) 
to elute the DNA 
V. Pipette 200 uL of Buffer AE directly onto the DNeasy membrane, in the 
same 2 ml tube. 
W. Incubate at RT for 1 min, then centrifuge for 1 min at >6000 x g (8000 rpm) 
to elute the DNA in the same tube. 
 
II. DNA quantification 
1. Handle Quartz plate with lens cleaner, ALWAYS!!  Avoid “any” scratch !! 
2. Turn on Spectra Max and the Mac computer connected. (Prewarm 10-15 min) 
3. Find the “Spectra Max” icon on the Desktop, and double click it. 
4. Click “Set up”  Wavelength Lm1: 260 / Lm2: 280  Calibrate: On 
5. Place Quartz plate on the machine 
6. Find “Control” toolbar on menu  close tray 
7. Control  Run  Pre-read  OK 
8. The machine reads the plate, then the Quartz plate comes out. 
9. Save, and bring the plate to the bench table. 
10. Make 1X TE with 0.1% Tween 20  
11. Put 95 uL TE buffer into designated wells (duplicate is better) 
12. Make sure the first two wells are “Blank” 
13. Use DNA quantification control (~115 µg/ml, in Laurie’s freezer) 
14. Put 5 uL of DNA samples into appropriate wells. 
15. Bring the plate to the Spectra Max, and load the plate. 
16. Click Control  Close Tray  Read  Experiment  OK 
17. The machine reads the plate 
18. After the reading, click “Template” 
19. Drag wells which are used  Unknown 
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20. Group number: 2 
21. Drag first two wells  Blank 
22. Then, look into result part 
23. Delete any unnecessary columns 
24. Calculate “MeanValues” for duplicates 
25. Calculate “DNA quantity (µg/ml) by formulation: MeanValues*20 (dilution 
factor)*214 (Correction) 
Correction table 
Volumn in Quartz plate DNA RNA 
200 uL 93.6 83.0 
150 uL 131.0 115.8 
100 uL 214.0 191.3 
50 uL 597.0 523.8 
 
(1) Dilute DNA to make 10 uL of 15 µg/ml DNA with ddH2O. 
 
III. RT-PCR (SYBR Green real time PCR, 7900HT) 
1. Per Reaction: 
2X SYBR Master Mix 6.25 uL 
Forward primer (300 nM) 1 uL 
Reverse primer (300 nM) 1 uL 
DNA (~15 µg/ml) 0.5 uL 
ddH2O 3.75 uL 
 
2. Make a cocktail with Maser Mix, both primers, and ddH2O. 
Master Mix 6.25 uL x = uL 
F primer 1 uL x = uL 
R primer 1 uL x = uL 
ddH2O 3.75 uL x = uL 
  Total cocktail volume uL 
 
A. Add 12 uL of cocktail to plate and 0.5uL diluted DNA (Do in the hood for 
PCR, plate part# 4346906) 
B. Cover the plate with plastic cover. 
C. Squeeze with a rubber to ensure all wells are completely sealed. (If any well 
is not sealed, the material evaporates during PCR cycle). 
D. Centrifuge the plate several seconds. (when the centrifuge reaches up to 1000 
rpm, turn off). 
E. Run RT-PCR  
3. RT-PCR running 
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F. Turn on machine and computer 
G. Click SDS 2.2.2 on desktop 
H. File  new 
 Assay: Absolute quantification 
 Container: 96 well 
 Template: Blank  OK 
I. Designate sample-containing wells by clicking and dragging on plate map 
J. (Use CTRL key if you need to add/drop wells) 
K. Setup  add detector  SYBR  copy to plate documents  done 
L. Mark “X” on detector SYBR 
M. (Make sure that all sample-containing wells are designated and marked as 
SYBR) 
N. Instrument  Mode  Standard  Sample volume (µl)  13 
O. Connect  open  load plate  close  start 
 
4. After RT-PCR is done 
A. Designate wells  analysis  analyze 
B. Open  take out sample  done 
  
 
149
B-5. CD4
+ 
T cell Positive Isolation by Miltenyi®  Beads and Column 
(Modified from Qian Jia’s protocol) 
 
I. Preparation (D-1) 
1. Prepare media/tubes 
A. Fill conical tubes with 3 ml MACS buffer (cat# 130-091-221). 
B. Prepare scissors, forceps, 70% EtOH squeeze bottle, 5 ml syringes. 
 
II. Kill/Co-culture (D-0) 
1. Isolate CD4+ T cells from spleens  
A. Sacrifice mice by CO2. 
B. Place mice on their right side so that the left side faces you. 
C. Apply alcohol to the abdomen area. 
D. Grab the skin of the abdomen with forceps and make a small incision. 
E. Peel back the skin/fur with fingers to expose the membrane underneath. 
F. Grab the membrane with forceps and cut the membrane to expose the organs. 
G. Remove the spleen (dark red organ) with forceps. 
H. Carefully remove as much fat from the exterior of the spleen as possible. 
I. Place a spleen in a 15 ml conical tube containing 3 ml MACS buffer, transfer 
to cell culture room. 
2. Preparing single-cell suspension 
A. Place a Falcon cell strainer (70 m mesh, BD, # 35-2350), on the 100mm 
petri dish, and pre-wet with 5 ml MACS®  buffer. 
B. Transfer spleens into cell strainer. 
C. Gently press spleen against the bottom of the strainer with a plunger from a 5 
ml syringe. Use up and down motion (not grinding), being careful not to 
damage cells. 
D. When only the spleen connective tissue remains in the strainer, remove the 
plunger.  
E. Transfer the cell suspension from the dish to the original 15ml conical tube. 
F. Wash strainer with 5 ml MACS buffer, and transfer to the same tube to 
collect the remaining cells. 
G. Spin down at 300x g for 10 min. 
H. Aspirate the supernatant. 
I. Take 10 ml MACS buffer and pre-wet the 30 m filter (Miltenyi, cat# 130-
041-407, on a 15 ml conical tube) with 2 ml buffer. 
J. Resuspend cells in 8 ml buffer and pass the cells through the filter. 
K. Remove 10 µl to a Coulter Counter tube for counting.  
L. Centrifuge the cells at 300x g for 10 min. 
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M. Remove the supernatant and resuspend the pellet by flicking the tube or 
ratcheting the tube over a tube rack. 
N. Count the cell number during waiting for centrifuge by Coulter Counter with 
4 m cut-off. 
 
3. Mixing with magnetic bead/column separation 
A. Resuspend cells with 90 µl cold MACS buffer per 107 total cells. 
B. Add 10 µl of CD4 (L3T4) Microbeads (Miltenyl Biotec, cat# 130-049-201) 
per 10
7
 total cells. 
C. Mix well and incubate for 15 min at 4-8 °C (refrigerator, not ice!!) (No 
shaking needed) 
D. Wash cells by adding MACS buffer up to 12 ml, and centrifuge at 300x g 
rpm for 10 min.   
E. Aspirate the supernatant. Flick the tube to loosen the pellet. 
F. Resuspend up to 108 cells in 500 µl cold MACS buffer. If cell number 
exceeds 10
8
, multiply the volume by cell number. 
G. Place MS** column at Octo MACS Separator. 
 
(**The following buffer volume is for MS column only.) 
H. Rinse MS column with 500 µl MACS buffer.  Let the buffer slowly drip to 
drop, wait until dry (very quick, less than 1 min). 
I. Apply cell suspension to the column. 
J. Let unlabeled cells pass through, and wash MS column with 500 µl MACS 
buffer 3 times.  
K. Let the column drip completely dry between washes.  
L. Remove total column from the separator, and place it on a collection 15 ml 
conical tube. 
M. Pipette 1 ml of sterile MACS buffer onto the column. Immediately flush out 
fraction with the magnetically labeled cells by firmly applying the plunger 
supplied with the column. 
N. Now, CD4+ T cells are ready in 1ml buffer. 
O. Count CD4+ T cells by Coulter Counter with 4 µm cut-off. 
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B-6. Counting Cells with Coulter Counter 
(modified from Evelyn Callaway’s) 
 
I. Prepare sample cups 24-48 hrs ahead: De-gas Isotone: turn red lever to the left and 
lift dispensing pump twice. Turn red lever so it is parallel to the arm. Fill 
Coulter vials with 10 ml per vial (one pump of Isotone). 
 
II. On the counting day, 
1. Turn power on, open door, lower stage. 
2. Remove vial of Coulter Clenz, replace with Isotone/Isoflow, raise stage. 
3. Readout: Setup #1 (S1). Scroll down to last line and set cell size. This 
measurement is to be set for the smallest cell of acceptable range. Our laboratory 
usually sets 4 µm for CD4
+
 T-cells. 
4. Select: FUNCTIONS on keypad. Scroll to Flush Asperature. Hit: START/STOP 
to flush. Repeat flush, then replace Isotone. Flush twice more. 
5. Select: OUTPUT on keypad. Scroll to Count/Concentration and select one., If 
“concentration” is selected, readout will be in #cells/ml. Scroll to Dilution and 
enter dilution factor. Leave units on um. 
6. Add 10 µl sample to Coulter vial (for 1:1,000 dilution) Place vial on stage, raise, 
and press START/STOP on keypad to count. Count each sample 2-3 times and 
average. 
7. To shut down machine, replace vial of blue Coulter Clenz and flush aperature 
(under FUNCTIONS) 2-3 times. When flush is complete, turn off power. 
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B-7. Laurdan study protocol 
 
 
I. Poly-L-Lysine precoating (D-1) 
1. Dilute 0.1%(w/v) Poly-L-Lysine solution (Sigma, cat# P8920) to 0.01% with 
sterile water. 
2. Fill the chambered coverglass (Nunc, cat# 155380) wells with 0.01% Poly-L-
Lysine solution (1 ml), allow it to sit for 30 min, then aspirate excess solution 
and allow the coverglass wells to air dry. Sterilize the coverglass slides under UV 
light for 1 hr. 
 
II.  Isolate CD4+ T cells from spleens (D-0) 
1. After CD4+ T cell isolation (Appendix B-5), centrifuge cells at 300x g for 5 min, 
RT. 
2. Resuspend cells in 1 ml complete medium and count cells using Coulter counter 
(4 µm). 
3. Adjust cell concentration at 1x106 cells/ml in the complete medium. 
4. Keep cells in 37 oC., 5% CO2 incubator with the cap loosen. 
 
III. Hybridoma (anti-CD3 expressing, clone 145-2C11) cell preparation. 
1. Pipette cell suspension up/down several times to detach cells from bottom of 
flask. 
2. Transfer cell suspension to a 50 ml conical tube. 
3. Wash the flask with 10 ml RPMI twice and transfer to the 50ml conical tube 
containing cells. 
4. Centrifuge at 200x g for 5 min at RT. 
5. Aspirate supernatant and resuspend cells in 1 ml Leibovitz’s media (Gibco cat# 
21083-02). 
6. Count cells by Coulter counter with 4 µm cut-off. 
7. Adjust cell concentration at 0.2x106 cells/ml. 
8. In optional experiments, anti-DNP expressing hybridoma (clone UC8-1B9) can 
serve as a negative control. 
9. Now cells are ready. 
 
IV. Cell Tracker CMTPX Invitrogen, (M.W. 686.25, 50 µg/vial) stock solution 
preparation (optional) 
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1. In some experiments, hybridoma cells are stained with CMTPX to be 
distinguished from CD4
+
 T cells under microscope 
2. Dissolve one vial in 728.6 µl DMSO  
 50 µg / 728.6 uL * 1 umole / 686.25 µg = 100 µM 
3. Aliquot 20 µl and keep in -20 oC. 
4. Transfer 10 ml hybridoma cells (0.2x106 cells/ml) into a 15 ml conical tube. 
5. Spin down cells at 200x g for 5 min, RT. 
6. Resuspend cells in 2 ml serum-free RPMI medium. 
7. Add 1 µl of [100 µM] CMTPX stock solution  [0.05 µM]. 
8. Incubate at 37 oC for 15 min (water bath). 
9. Following incubation, add 10 ml serum-free RPMI and spin down cells at 200x g 
for 10 min, aspirate supernatant. 
10. Resuspend cells in 1 ml Leibovitz medium. 
11. Count cells using Coulter counter (4 µm). 
12. Adjust cell concentration at 0.2x106 cells/ml 
 
V. Material to bring to Image lab: 
1. Poly-L-Lysine coated plates 
2. CD4+ T cells in 15 ml conical tubes (1x106 cells/ml) 
3. Hybridoma cells in 15 ml conical tubes (0.2x106 cells/ml) 
4. Laurdan stock (Invitrogen, cat# D250, 10 mM in EtOH) on ice covered by 
aluminum foil 
5. 1000p pipette + tips 
6. 200p pipette + tips 
7. 10p pipette + tips 
8. Timer 
9. Empty glass vials. 
10. Aluminum foil 
11. Empty 15 ml conical tubes 
12. Sterile 2 ml epi-tubes 
13. FBS 
 
VI.  Lipid-raft specific cholesterol depletion by Methyl-β-cyclodextrin treatment 
(optional). 
1. Prepare [10 mM] methyl-beta-cyclodextrin (MβCD, Sigma cat# C4555). 
A. Take 10 mg in (1000x10)/(1320x10) ml serum-free RPMI medium. 
B. Dissolve (1000x10)/(1320x10) mg FA-free BSA (Boeringer 
Mannheim) 
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2. Transfer 2 ml of CD4+ T-cells to a 15 ml conical tube. 
3. Spin down at setting 5 of centrifuge in Dr. Berghardt Lab for 5 min, then 
resuspend cells in 2 ml [10 mM] MβCD. 
4. Incubate at 37 oC for 3 min, and wash with 10 ml serum-free RPMI (centrifuge at 
setting 5 for 5 min). 
5. Resuspend cells in 2 ml serum-free RPMI. 
 
VII. T cell labeling of Laurdan  
1. Trasnfer 2 ml CD4+ T cells (1x106 cells/ml) into a 15 ml conical tube. 
2. Add 2 µl of [10 mM] Laurdan solution into 2 ml CD4+ T-cell suspension. 
3. Vortex at dial setting 7 for 2 sec. 
4. Incubate at 37 oC for 10 min. 
5. Spin down at the speed 5 by the centrifuge at Imaging Lab for 5 min. 
6. Resuspend cells in 2 ml Leibovitz’s medium. 
 
VIII. Mix cells (T cell:hybridoma = 5:1) 
7. Mix 0.4 ml hybridoma into 2 ml T-cell suspension. 
8. Incubate the tube on ice for 1 min. 
9. Rinse Poly-L-Lysine pre-coated chambered coverglass slides with 1 ml warm 
Leibovitz’s medium once. 
10. Transfer 1.2 ml of cell suspension from the tube to each of 2 chambered slide 
wells. 
11. Capture images after 30 min incubation at 37 oC., 5% CO2. 
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B-8. GP-value calculation 
 
1. Capture Laurdan images and save the image files as 8-bit TIFF format. 
2. Open the image file in Adobe Photoshop®  CS (v.8.0). 
3. Using a marquee tool, make a circle to select cell-cell contact region.  
4. In “Histogram” panel, we can choose each channel of RGB. 
5. Once blue channel is selected, the panel displays “mean intensity” of marquee-se
lected region. 
6. Histogram also shows the pixels chosen by marquee tool. We generally choose 8
00-1200 pixels for contact region. 
7. If you change the channel to green, mean intensity is changed, while pixel is not. 
8. For non-contact control cells, select whole cell by marquee tool. 
9. Histogram shows green/blue mean intensities. 
10. Record green and blue intensities to calculate GP-values by fomula GP= (IBlue-
IGreen)/(IBlue+IGreen). Example calculation is shown in Appendix A-5). 
  
 
156
B-9. Immunofluoresence protocol 
(modified from Dr. Yang-Yi Fan’s protocol) 
 
Materials: 
1. FITC-CTx (Sigma, cat# C1655), make [250 µg/ml stock in dd-H2O], store at 4°C  
2. Rabbit anti-LAT (Millipore, cat# 06-807, Lot# 22622, 1,000 µg/ml)  
*Ref: Fan et al., J Immunol. 2004 Nov 15;173(10):6151-60 
3. Rabbit anti-phospho-LAT (Tyr 191) (Millipore, cat# 04-467, Lot# JBC1371310, 
100-500 µg/ml) 
4. Alexa 568 goat anti-rabbit IgG(H+L), [2 mg/ml] (Molecular Probe, cat# A-11036)  
5. ProLong Antifade Kit (Molecular Probe, cat# P-36931)  
6. 0.1%(w/v) Poly-L-Lysine solution (Sigma, cat#P8920) 
7. Coverglass (No. 1, 22 x 50 mm, Corning) 
8. Fresh 4% PFA in PBS (dilute from 20% PFA, EMS#15713-S) 
9. Lab-Tek II 2-well glass chamber slide (Nalge, cat# 154461) 
 
Procedure:  
1. Precoat Lab-Tek II 2-well glass chamber slides with 0.01% poly-L-Lysine (10x 
diluted from 0.1%(w/v) Poly-L-Lysine solution with sterile H2O) (2 wells/slide) the 
day before assay: Add 2 ml of 0.01% poly-L-Lysine/well for 30 min, then aspirate 
excess solution and allow the chamber slides to air dry.  Sterile the coverglasses 
under UV light for 1 hr.  
2. Prewarm the coated chamber slides at 37°C for 30 min before use. 
3. Prepare T cells resuspend in complete RPMI at 2x106 cells/ml (See Appendix B-5) 
4. Prepare hybridoma cells resuspend in complete DMEM at 2x106 cells/ml (See 
Appendix B-10) 
5. For each well, we want 2 x 106 T cells + 0.4 x 106 Hybridoma 
 
(For each 2-well samples) 
6. Wash the coated chamber slides with warm medium 3 times. 
7. For each sample (2 wells), mix 2 ml T cells with 0.4 ml Hybridoma in 15 ml conical 
tube. 
8. Mix 4 ml T cells/mouse with 0.8 ml Hybridoma 
9. Mix 2 ml WT T cells with 0.4 ml Hybridoma for Ctrl 
10. Centrifuge at 300 g for 5 min. 
11. Resuspend the cell mix pellet in 4 ml complete RPMI. 
12. Seed 1 ml/well section (dropwisely add cell suspension onto the well).   
13. Incubate at 37°C for 30 min. 
14. While incubation, make 4% PFA. (4 ml of 20X PFA + 16 ml PBS => 4% PFA) 
15. Wash cells (on the chamber slide) with PBS 3x, then immediately fix in Fresh 4% 
paraformaldehyde in PBS for 20 min at RT.   
16. Rinse samples with PBS 2x, incubate cells with 10 mM glycine in PBS for 10 min at 
RT to quench the aldehyde groups.   
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17. Wash chamber slides with PBS 2x, permeabilize cells in PBS/0.2% Triton X-100 for 
5 min at RT, followed by PBS wash 3x.  
18. Incubate cells in Blocking solution (1% BSA/0.1% NaN3 in PBS) at 4°C overnight 
19. Wash chamber slides with PBS 3x. 
20. Dilute all Ab in Blocking solution 
For 1 well: 
A. (anti-LAT) 1°Ab mix:  8 µl of GM1 [stock 250 µg/ml] (25x dil) +  5 µl of anti-
LAT [stock 1,000 µg/ml] (40x dil) +  187 µl buffer 
 80 L GM1 + 50 L a-LAT + 1870 L buffer 
B. (anti-phospho-LAT) 1°Ab mix: 8 µl of GM1 [stock 250 µg/ml] (25x dil) + 5 µl 
of anti-phospho-LAT [stock 100-500 µg/ml] (40x) +  187 µl buffer 
 80 L GM1 + 50 L a-p-LAT + 1870 L buffer 
21. Incubate all cells with 200 µl AB/well, incubate at room temp for 1 hr (Protect from 
light)   
22. After 1 hr incubation, wash slide chamber with PBS 3x, and the last wash with 
blocking solution. 
23. For 1 well:  2° Ab 1 µl of Alexa 568 goat anti-rabbit IgG [stock 2 mg/ml] (1:200 dil) 
+ 199 µl buffer 
24. 20 L Alexa 568 + 3980 L Buffer 
25. Incubate cells with 200 µl/well 2° Ab (Alexa 568 goat anti-rabbit IgG [10µg/ml] at 
RT for 1 hr at a humidity chamber.   
 
** Prepare the ProLong medium and labeling slides during the 1 hr incubation 
- Mix 2 ml of ProLong mounting medium (Component B) to two brown vials of 
 Prolong antifade reagent (Component A).  (Mix well by pipetting or vortexing, 
 remove bubbles that have formed during the mixing procedure by sonication) 
 
26. Use the slide separator to remove the chamber.  Put the slides on the metal slide 
holder for the following wash. 
27. Wash coverglass with PBS 3x.   
28. Incubate coverglass in 70% ethanol 1x. 
29. Incubate coverglass in 95% ethanol 1x. 
30. Incubate coverglass in 100% ethanol 1x. 
31. Incubate coverglass in fresh xylene 1x. 
32. Apply a small amount of antifade reagent/mounting medium mixture to the 
coverglass, cover the slide while it is still wet.  (Use glass rod to put a line of 
medium on the side of the coverglass, then cover the slide at 45° angle to avoid 
bubbles) use razor blade to help coverslipping. 
33. Place the coverglass/slide on a flat surface in the dark to dry overnight at RT. 
34. Once dry, seal the coverglass to the slide with fingernail polish, to prevent shrinkage 
of the mounting medium and subsequent sample distortion.   
35. After sealing, store the coverglass/slide upright in a covered slide box at -20 °C. 
Desiccant may be added to the box to ensure that the slide remains dry. 
36. Examine sample under Fluorescence microscopy. 
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B-10. Curcumin/Limonin study protocol 
 
 
 
I. D-1: Reagents preparation 
1. OVA stock preparation 
1) Prepare 0.5% acetic acid solution: 500 µl HPLC grade acetic acid in 100 
ml sterile water, then split into two 50 ml conical tube. 
2) Dissolve 1 mg lyophilized OVA peptide in 0.5 ml sterile water. 
3) To a low retention eppi tube, add 360 µl sterile water and 90 µl 0.5% 
acetic acid. 
DO11.10 
1 wk 
2 wks 
CO, CC, CL,  
FO, FC, FL 
Basal, OVA+APC, 
aCD3/28 
Lympholyte-M 
CO wash-out diet 
Experimental diet 
Kill 
Balb/C per day 
Kill / Spleens 
Lymphocytes 
Mitomycin C 
Mix w/ OVA 
Should be 
done in 4 hrs 
 CD4+ T-cells 
Miltenyi®  column 
Aliquot/freeze 
Media 
IL-2 analysis 
~5x10
6
 cells 
Culture 
1.0x10
6
 cells/well 
72hrs 
Nuclear extract 
NF-kB/NFAT/AP-1 
72hrs 
Culture 
[
3
H]thymidien 
uptake 
0.1x10
6
 cells/well 
Spleen 
CFSE labeling 
72hrs 
Culture 
CFSE profile 
0.1x10
6
 cells/well 
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4) To the same tube, add 450 µl dissolved peptide. 
5) Aliquote to 20 µl and store < -70 oC. 
Stock concentration: (OVA M.W. 1774 g/mole) 
1 mg/500 µl x 1/2 x mole/1774 g = 563.698 µM 
 
2. 25 µg/ml Mitomycin preparation 
1) Mitomicyn C (Sigma, MW 334.3, cat# M4287) contains total 50 mg of 
2mg mitomycin C and 48mg sodium chloride. 
2) Measure 10 mg  2*10/50 mg mitomycin C 
3) Dissolve in 16 ml sterile PBS  25 µg/ml 
 
II. D-0: Kill/Co-culture 
1. APC preparation 
1) Sacrifice Balb/C mouse by CO2. 
2) Place the mouse on their right side so that the left side is facing up. 
3) Apply 70% EtOH to the abdomen area. 
4) Grab the skin of the abdomen with forceps and make a small incision. 
5) Peel the skin to expose the membrane underneath. 
6) Grab the membrane with forceps and cut the membrane to expose the 
organs. 
7) Remove the spleen with forceps while cutting the fat tissue with scissors. 
8) Carefully remove as much fat as possible. 
9) Place the spleen in a conical tube containing MACS buffer. 
10) Bring the tube into cell culture room. 
 
-----Do the below in the HOOD---- 
1) Place a Falcon cell strainer (70 m mesh, BD, # 35-2350) on the 100mm 
petri dish, and pre-wet with 5 ml MACS buffer. 
2) Transfer spleens into cell strainer. 
3) Gently press spleen against the bottom of the strainer with a plunger 
from a 5 ml syringe. Use up and down motion (not grinding), being 
careful not to damage cells. 
4) When only the spleen connective tissue remains in the strainer, remove 
the strainer.  
5) Place a 30 m filter on the top of a new 15 ml conical tube, and pre-wet 
with 2 ml Miltenyi buffer. 
6) Transfer the cell suspension from the dish to the filter. 
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7) Wash strainer with 5 ml MACS buffer to collect the remaining cells. 
Transfer to the filter 
8) Spin down at 300x g for 10 min. 
9) Aspirate supernatant, and resuspend the pellet in 3 ml complete RPMI 
(w/o 2-ME). 
10) Shake-mix Lympholyte-M before use. Lay 3 ml Lympholyte-M down 
by putting pipette tip into the bottom of tube. 
11) Centrifuge at 500x g for 15 min, RT with acc/brake=0. 
12) Transfer the interface band by pipetting up into a 15 ml conical tube. 
13) Wash with 10 ml RPMI (300x g for 10 min, RT), then aspirate the 
supernatant. 
14) Resuspend cells in 1 ml of 25 µg/ml mitomycin C solution. 
15) Incubate at 37 oC. (water bath) for 20 min. 
16) Add 10 ml complete media, and transfer 2 ml to a new conical tube for 
APC control. (no OVA) 
17) Wash with complete RPMI (300x g for 10 min, RT). 
2. OVA preparation with APC 
--- for OVA stimulation --- 
1) Dilute OVA stock into 0.1 µM 
: 4.43 µl OVA stock into 25 ml complete RPMI with 2-ME. 
2) Resuspnd cells in 5 ml complete RPMI with OVA. 
--- for APC control --- 
3) Resuspedn cells in 1 ml complete media (w/o OVA) 
4) Count cells by Coulter Counter. 
5) Adjust cell concentrations at 2.5x106 cells/ml. 
6) Now APC are ready for co-culture, keep cells at 37 oC in 5% CO2 
chamber. 
 
III. Isolate CD4+ T cells from spleens of DO11.10 mice following Appendix B-5. 
IV. Culture for with stimuli 
7) Count CD4+ T-cell by Coulter counter. 
8) Adjust cell concentration to 1x106 cells/ml. 
9) Transfer 1 ml cell suspension into each well of 24-well plate for 
cytokine/nuclear extration. 
10) Transfer 100 L cell suspension into each well of 96-well plate for cell 
proliferation assays. 
11) Tape the plate then place into 37 oC in 5% CO2 incubator for 72 hr. 
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B-11. Hybridoma Handling (145-2C11, UC8-1B9) 
(modified from Dr. L. Davidson’s protocol and Product Info Sheet from ATCC) 
 
1. Reagents 
A. Complete medium 
 Vol(ml) % Stock Conc Final Conc Vendor Cat# 
DMEM 500.00  86.03    Gibco 11960-44 
FBS 58.00  9.98    Invitrogen 16000 
Glutamax 11.60  2.00  200mM 4mM Gibco 35050-061 
Na pyruvate 5.80  1.00  100mM 1mM Cellgro 25-000-CI 
Pen-Strep 5.80  1.00  
10,000U/ml P 
10,000µg/ml S 
100U/ml P 
100µg/ml S 
Gibco 15140-148 
Total 581.20  100.00      
 
B. During critical period (ie. After thawing), add 80u/ml hrIL-6  
hrIL-6 stock is 200,000U/ml. Mix 50 ml complete media with 20 µl hrIL-6. 
    (Roche, Cat# 11-138-600-001, Lot# 93320322) 
C. Cryoprotectant medium 
: complete medium with 5% (v/v) sterile DMSO 
D. Hybridoma 
i) 145-2C11: ATCC Cat# CRL-1975, Lot# 3048198 
ii) UC8-1B9: ATCC Cat# CRL-1968, Lot# 1375980 
 
2. Handling frozen cells 
A. Prepare 45 ml and 14 ml complete media (with IL-6, see reagents) for 145-2C11 
and UC8-1B9, respectively, in T-75 flask (the volumes differ to each batch. 
Confirm to Specific Batch Info) 
B. Place the flask into 5% CO2 inculbator at 37 oC for at least 15min. 
C. Thaw the vial by gentle agitation in a 37 oC water bath. To reduce the possibility 
of contamination, keep the O-ring and cap out of the water. Thawing should be 
rapid (approx. 30 sec). 
D. Move the vial to sterile hood, and spray 70% EtOH to the vial. 
E. Transfer the vial contents to a 15 ml conical tube. 
F. Wash with 10 ml complete medium by centrifuge at 200x g for 5 min. 
G. Aspirate supernatant and resuspend cell in 1 ml complete medium. 
H. Transfer cell suspension to the pre-warmed T-75 flask. 
I. Incubate in 5% CO2 inculbator at 37
o
C. 
J. After thawing, cells generally become confluent in 5 days (UC8-1B9) or 7 days 
(145-2C11). 
K. Renew the medium 2-3 times weekly (If media look yellow-it means acidic-, 
replace media immediately) 
L. A number of cells are adherent to the flask bottom. The viability was 93.66% 
(suspending cells) and 77.77% (adherent cells) determined by trypan blue 
exclusion method. Therefore, use only suspending cells by pipetting up the media, 
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not touching the flask bottom. 
 
2. Passaging 
A. Prepare 18 ml complete media in a T-75 flask and keep the flask in the 37 oC 
incubator for ~15 min. 
B. Harvest suspending cells by pipette into a 50 ml conical tube. (Try to avoid 
mixing adherent cells by shaking flask or touching the flask bottom). Centrifuge 
cells at 200x g for 5 min. Aspirate the supernatant and resuspend cells in 5 ml 
complete DMEM media.  
C. Count cell concentration by Coulter Counter. Adjust conc. to 1x106 cells/ml by 
adding complete DMEM.  
D. Transfer 2 ml cell suspension into the pre-warmed T-75 flask. 
E. Place the flask in the 37 oC 5% CO2 incubator. 
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B-12. PMA/Ionomycin preparation 
 
 
PMA (Sigma #P8139-1MG, Light sensitive) 
1. Inject 1 ml sterile filtered DMSO into container using 1 ml syringe. 
2. Wait until all powder dissolves 
 This is 1 mg/ml solution (too concentrated) 
3. Take 2 µl of [1 mg/ml] soln, and add to 1 ml sterile DMSO 
 This is 2 µg/ml soln. 
4. Aliquot 15 µl, and store at -20 oC. 
5. Save remaining [1 mg/ml] at -20 oC. 
 
 
Ionomycin (Calbiochem #407952) 
1. Add 1.33 ml sterile filtered DMSO to 1mg powder 
0.001 g x 1 mole/747.1 g x 1000 mM/1 mole = 1.33 x 10
-3
 mM 
1.33 x 10
-3
 mMole/1.33 ml = 1mM 
2. Mix and let sit for 5 min. 
3. Aliquot 15 µl, and store at -20 oC. 
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